DOCKET NO.: **19603/10303 (CRF D-1043A)**
EXPRESS MAIL NO.: **EL 434571921US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE A + Bos Seq.

UTILITY PATENT APPLICATION TRANSMITTAL FORM
(only for new nonprovisional applications under 37 CFR 1.53(b)

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231
BOX: PATENT APPLICATION

SIR:

Transmitted herewith for filing is the patent application (including Cover Pages and PCT Publication documents, Specification, Claims, and Abstract (84 pages) of:

Inventors : **Dennis Gonsalves and Sheng-Zhi Pang**

For : **TOSPOVIRUS RESISTANCE IN PLANTS**

***If a CONTINUING APPLICATION, please mark where appropriate and supply the requisite information below and in a preliminary amendment:*

[X] *continuation* [ ] *divisional* [ ] *Continuation-In-Part (CIP) of prior application* ***Serial No. 08/495,484***

Prior application information: Examiner : E. McElwain
Art Unit : 1649

Enclosed are:

[X] 5 sheets of informal drawings.

[ ] **Signed** Combined Declaration and Power of Attorney (_____ pages).

[X] **Copy** of **signed** Combined Declaration and Power of Attorney (2 pages) from a prior application (1.63(d) (for continuation/divisional).

[ ] **Signed** statement deleting inventor(s) named in prior application (_____ pages) (1.63(d)(2) and 1.33(b)).

[X] **Incorporation By Reference**: The entire disclosure of the prior application, from which a **copy** of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the enclosed application and is hereby incorporated by reference therein.

[ ] Assignment (_____ pages) of the invention to _____.

[ ] Assignment Transmittal Letter.

[ ] Certified copy of a foreign priority document.

[ ] Associate power of attorney.

[ ] Verified statement to establish small entity status (_____ pages) (newly signed or copy filed in prior application).

[X] Preliminary Amendment (11 pages).

[X] Information Disclosure Statement, form PTO-1449 (5 pages) (in duplicate) and 39 references (not attached).

[X] Sequence Listing (21 pages).

[X] Statement in Accordance with 37 CFR §§ 1.821(f) and 1.825(b) and computer readable 3.5" Diskette.

[X] A self-addressed, prepaid postcard acknowledging receipt.

[ ] Other:

The Filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	SMALL ENTITY			LARGE ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE	OR	RATE	FEE
BASIC FEE	XXXXXXXX	XXXXXXXX	XXXX	$380	OR	XXXX	$760
TOTAL CLAIMS	15 - 20 =	0	x 9 =	$	OR	x 18 =	$
INDEP CLAIMS	5 - 3 =	2	x 39=	$	OR	X78 =	$156
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED			x130 =	$	OR	x260 =	$
			TOTAL	$	OR	TOTAL	$916

*If the Total Claims are less than 20 and Indep. Claims are less than 3, enter "0" in Col. 2

[ ] Please charge my Deposit Account No._____ in the amount of $_____. **A duplicate copy of this sheet is enclosed.**

[X] A check in the amount of **$916.00** to cover the filing fee is enclosed.

[X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1138. **A duplicate copy of this sheet is enclosed.**

[X] Address all future communications to:

Michael L. Goldman
NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603

Date: October 22, 1999

Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1128
Facsimile: (716) 263-1600

PATENT
Docket No.: **19603/10303 (CRF D-1043A)**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Gonsalves et al.	Examiner: To Be Assigned
Serial No.	:	Continuation of 08/495,484	
Filed	:	Herewith	Art Unit: To Be Assigned
For	:	TOSPOVIRUS RESISTANCE IN PLANTS	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

Please amend the above-identified application as follows:

In the Title:

Please change the title to read --TOSPOVIRUS RESISTANCE IN PLANTS--.

In the Specification:

On page 1, immediately below the Title of the Invention, please insert --This application is a continuation of U.S. Patent Application Serial No. 08/495,484 filed September 25, 1995, as a national stage application of PCT Application No. PCT/US94/01046 filed January 27, 1994, which claims the priority benefit of U.S. Patent Application Serial No. 08/010,410 filed January 29, 1993.--

On page 3, line 18, change "in vivo" to --*in vivo*--.

On page 4, line 25 "change "viron" to --virion-- (each occurrence).

On page 4, line 27, change "viron" to --virion--.

On page 5, line 13, change "MK_2HPO_4" to --M K_2HPO_4--.

On page 5, lines 19-20, change “weight. The” to --weight, the--.

On page 6, line 23, before “complementary”, insert -- (SEQ. ID. No. 1) --.

On page 6, line 24, before “of”, insert -- (SEQ. ID. No. 2) --.

On page 6, line 27, change “clones” to --clone--.

On page 6, line 32, before “(also”, insert -- (SEQ. ID. No. 3) --.

On page 7, line 9, before “(also”, insert -- (SEQ. ID. No. 4) --.

On page 9, line 7, after the word “sequence” but before the “:”, please insert --(SEQ. ID. No. 5)--.

Please delete lines 8-35 on page 9 and lines 1-17 on page 10, and insert the following:

```
-- CAAGTTGAAA GCAACAACAG AACTGTAAAT TCTCTTGCAG TGAAATCTCT GCTCATGTCA     60
   GCAGAAAACA ACATCATGCC TAACTCTCAA GCTTCCACTG ATTCTCATTT CAAGCTGAGC    120
   CTCTGGCTAA GGGTTCCAAA GGTTTTGAAG CAGGTTTCCA TTCAGAAATT GTTCAAGGTT    180
   GCAGGAGATG AAACAAACAA AACATTTTAT TTATCTATTG CCTGCATTCC AAACCATAAC    240
   AGTGTTGAGA CAGCTTTAAA CATTACTGTT ATTTGCAAGC ATCAGCTCCC AATTCGCAAA    300
   TGCAAAGCTC CTTTTGAATT ATCAATGATG TTTTCTGATT TAAAGGAGCC TTACAACATT    360
   GTTCATGACC CTTCATACCC CAAAGGATCG GTTCCAATGC TCTGGCTCGA AACTCACACA    420
   TCTTTGCACA AGTTCTTTGC AACTAACTTG CAAGAAGATG TAATCATCTA CACTTTGAAC    480
   AACCTTGAGC TAACTCCTGG AAAGTTAGAT TTAGGTGAAA GAACCTTGAA TTACAGTGAA    540
   GATGCCTACA AAAGGAAATA TTTCCTTTCA AAAACACTTG AATGTCTTCC ATCTAACACA    600
   CAAACTATGT CTTACTTAGA CAGCATCCAA ATCCCTTCAT GGAAGATAGA CTTTGCCAGA    660
   GGAGAAATTA AAATTTCTCC ACAATCTATT TCAGTTGCAA AATCTTTGTT AAAGCTTGAT    720
   TTAAGCGGGA TCAAAAAGAA AGAATCTAAG GTTAAGGAAG CGTATGCTTC AGGATCAAAA    780
   TAATCTTGCT TTGTCCAGCT TTTTCTAATT ATGTTATGTT TATTTTCTTT CTTTACTTAT    840
   AATTATTTCT CTGTTTGTCA TCTCTTTCAA ATTCCTCCTG TCTAGTAGAA ACCATAAAAA    900
   CAAAAAATAA AAATGAAAAT AAAATTAAAA TAAAATAAAA TCAAAAAATG AAATAAAAAC    960
   AACAAAAAAT TAAAAAACGA AAAACCAAAA AGACCCGAAA GGGACCAATT TGGCCAAATT   1020
   TGGGTTTTGT TTTTGTTTTT TGTTTTTTGT TTTTTATTTT TTATTTTATT TTTATTTTAT   1080
   TTTATTTTTA TTTTATTTTT ATTTTATTTA TTTTTTGTTT TCGTTGTTTT TGTTATTTTA   1140
   TTATTTATTA AGCACAACAC ACAGAAAGCA AACTTTAATT AAACACACTT ATTTAAAATT   1200
   TAACACACTA AGCAAGCACA AGCAATAAAG ATAAAGAAAG CTTTATATAT TTATAGGCTT   1260
```

```
TTTTATAATT TAACTTACAG CTGCTTTCAA GCAAGTTCTG CGAGTTTTGC CTGCTTTTTA    1320

ACCCCGAACA TTTCATAGAA CTTGTTAAGA GTTTCACTGT AATGTTCCAT AGCAACACTC    1380

CCTTTAGCAT TAGGATTGCT GGAGCTAAGT ATAGCAGCAT ACTCTTTCCC CTTCTTCACC    1440

TGATCTTCAT TCATTTCAAA TGCTTTGCTT TTCAGCACAG TGCAAACTTT TCCTAAGGCT    1500

TCCTTGGTGT CATACTTCTT TGGGTCGATC CCGAGGTCCT TGTATTTTGC ATCCTGATAT    1560

ATAGCCAAGA CAACACTGAT CATCTCAAAG CTATCAACTG AAGCAATAAG AGGTAAGCTA    1620

CCTCCCAGCA TTATGGCAAG TCTCACAGAC TTTGCATCAT CGAGAGGTAA TCCATAGGCT    1680

TGAATCAAAG GATGGGAAGC AATCTTAGAT TTGATAGTAT TGAGATTCTC AGAATTCCCA    1740

GTTTCTTCAA CAAGCCTGAC CCTGATCAAG CTATCAAGCC TTCTGAAGGT CATGTCAGTG    1800

CCTCCAATCC TGTCTGAAGT TTTCTTTATG GTAATTTTAC CAAAAGTAAA ATCGCTTTGC    1860

TTAATAACCT TCATTATGCT CTGACGATTC TTTAGGAATG TCAGACATGA AATAACGCTC    1920

ATCTTCTTGA TCTGGTCGAT GTTTTCCAGA CAAAAAGTCT TGAAGTTGAA TGCTACCAGA    1980

TTCTGATCTT CCTCAAACTC AAGGTCTTTG CCTTGTGTCA ACAAAGCAAC AATGCTTTCC    2040

TTAGTGAGCT TAACCTTAGA CATGATGATC GTAAAAGTTG TTATATGCTT TGACCGTATG    2100

TAACTCAAGG TGCGAAAGTG CAACTCTGTA TCCCGCAGTC GTTTCTTAGG TTCTTAATGT    2160

GATGATTTGT AAGACTGAGT GTTAAGGTAT GAACACAAAA TTGACACGAT TGCTCT        2216 --
```

On page 10, line 21, after "783" but before the ":", please insert --(SEQ. ID. No. 7)--.

Please delete lines 22-39 on page 10 and lines 1-18 on page 11, and insert the following:

```
-- Gln Val Glu Ser Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys Ser
   1               5                  10                  15

   Leu Leu Met Ser Ala Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Ser
               20                  25                  30

   Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Val Pro Lys Val
           35                  40                  45

   Leu Lys Gln Val Ser Ile Gln Lys Leu Phe Lys Val Ala Gly Asp Glu
       50                  55                  60

   Thr Asn Lys Thr Phe Tyr Leu Ser Ile Ala Cys Ile Pro Asn His Asn
   65                  70                  75                  80

   Ser Val Glu Thr Ala Leu Asn Ile Thr Val Ile Cys Lys His Gln Leu
                   85                  90                  95
```

```
Pro Ile Arg Lys Cys Lys Ala Pro Phe Glu Leu Ser Met Met Phe Ser
            100                 105                 110

Asp Leu Lys Glu Pro Tyr Asn Ile Val His Asp Pro Ser Tyr Pro Lys
        115                 120                 125

Gly Ser Val Pro Met Leu Trp Leu Glu Thr His Thr Ser Leu His Lys
    130                 135                 140

Phe Phe Ala Thr Asn Leu Gln Glu Asp Val Ile Ile Tyr Thr Leu Asn
145                 150                 155                 160

Asn Leu Glu Leu Thr Pro Gly Lys Leu Asp Leu Gly Glu Arg Thr Leu
                165                 170                 175

Asn Tyr Ser Glu Asp Ala Tyr Lys Arg Lys Tyr Phe Leu Ser Lys Thr
            180                 185                 190

Leu Glu Cys Leu Pro Ser Asn Thr Gln Thr Met Ser Tyr Leu Asp Ser
        195                 200                 205

Ile Gln Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Lys
    210                 215                 220

Ile Ser Pro Gln Ser Ile Ser Val Ala Lys Ser Leu Leu Lys Leu Asp
225                 230                 235                 240

Leu Ser Gly Ile Lys Lys Lys Glu Ser Lys Val Lys Glu Ala Tyr Ala
                245                 250                 255

Ser Gly Ser Lys
            260 --
```

On page 11, line 21, after the word "gene" (second occurrence) but before the ".", please insert --(SEQ. ID. No. 6)--.

On page 12, line 20, after the word "gene" but before the ".", please insert --(SEQ. ID. No. 8)--.

On page 13, line 9, after the word "is" and before ":", please insert --(SEQ. ID. No. 9)--.

On page 16, line 23, change "in vitro" to --*in vitro*--.

On page 16, line 33, change "a nd" to --and--.

On page 18, line 31, change "teh" to --the--.

On page 19, line 26, change "TSWV-BI" to --TSWV-BL--.

On page 21, line 32, change "viron" to --virion--.

On page 22, line 7, change "viron" to --virion--.

On page 22, line 28, change "symptomless" to --Symptomless--.

On page 22, line 33, change "cold" to --could--.

On page 23, line 18, change "viron" to --virion--.

On page 24, line 8, change "symptom less" to --symptomless--.

On page 26, line 22, before the ",", insert -- (SEQ. ID. No. 10) --.

On page 26, line 33, before "complementary", insert -- (SEQ. ID. No. 11) --.

On page 27, line 1, change "anshor" to --anchor--.

On page 27, line 2, before "that", insert -- (SEQ. ID. No. 17) --.

On page 27, line 4, change "ampllified fragement" to --amplified fragment--.

On page 27, line 7, before "close", insert -- (SEQ. ID. No. 16) --.

On page 27, line 28, after the word "is" but before the ":", please insert -- (SEQ. ID. No. 14)--.

On page 29, line 22, after the word "are" but before the ":", please insert -- (SEQ. ID. No. 12)--.

Please delete lines 23-38 on page 29, lines 1-44 on page 30, and lines 1-3 on page 31, and insert the following:

```
-- Met Ser Ser Gly Val Tyr Glu Ser Ile Ile Gln Thr Lys Ala Ser Val
   1               5                  10                  15

   Trp Gly Ser Thr Ala Ser Gly Lys Ser Ile Val Asp Ser Tyr Trp Ile
               20                  25                  30

   Tyr Glu Phe Pro Thr Gly Ser Pro Leu Val Gln Thr Gln Leu Tyr Ser
           35                  40                  45

   Asp Ser Arg Ser Lys Ser Ser Phe Gly Tyr Thr Ser Lys Ile Gly Asp
       50                  55                  60

   Ile Pro Ala Val Glu Glu Glu Ile Leu Ser Gln Asn Val His Ile Pro
   65                  70                  75                  80

   Val Phe Asp Asp Ile Asp Phe Ser Ile Asn Ile Asn Asp Ser Phe Leu
                   85                  90                  95

   Ala Ile Ser Val Cys Ser Asn Thr Val Asn Thr Asn Gly Val Lys His
               100                 105                 110

   Gln Gly His Leu Lys Val Leu Ser Leu Ala Gln Leu His Pro Phe Glu
           115                 120                 125

   Pro Val Met Ser Arg Ser Glu Ile Ala Ser Arg Phe Arg Leu Gln Glu
       130                 135                 140

   Glu Asp Ile Ile Pro Asp Asp Lys Tyr Ile Ser Ala Ala Asn Lys Gly
   145                 150                 155                 160

   Ser Leu Ser Cys Val Lys Glu His Thr Tyr Lys Val Glu Met Ser His
                   165                 170                 175
```

```
Asn Gln Ala Leu Gly Lys Val Asn Val Leu Ser Pro Asn Arg Asn Val
            180                 185                 190

His Glu Trp Leu Tyr Ser Phe Lys Pro Asn Phe Asn Gln Ile Glu Ser
        195                 200                 205

Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys Ser Leu Leu Met Ala
    210                 215                 220

Thr Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Phe Val Lys Ala Ser
225                 230                 235                 240

Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Ile Pro Lys Val
                245                 250                 255

Leu Lys Gln Ile Ala Ile Gln Lys Leu Phe Lys Phe Ala Gly Asp Glu
            260                 265                 270

Thr Gly Lys Ser Phe Tyr Leu Ser Ile Ala Cys Ile Pro Asn His Asn
        275                 280                 285

Ser Val Glu Thr Ala Leu Asn Val Thr Val Ile Cys Arg His Gln Leu
    290                 295                 300

Pro Ile Pro Lys Ser Lys Ala Pro Phe Glu Leu Ser Met Ile Phe Ser
305                 310                 315                 320

Asp Leu Lys Glu Pro Tyr Asn Thr Val His Asp Pro Ser Tyr Pro Gln
                325                 330                 335

Arg Ile Val His Ala Leu Leu Glu Thr His Thr Ser Phe Ala Gln Val
            340                 345                 350

Leu Cys Asn Lys Leu Gln Glu Asp Val Ile Ile Tyr Thr Ile Asn Ser
        355                 360                 365

Pro Glu Leu Thr Pro Ala Lys Leu Asp Leu Gly Glu Arg Thr Leu Asn
    370                 375                 380

Tyr Ser Glu Asp Ala Ser Lys Lys Lys Tyr Phe Leu Ser Lys Thr Leu
385                 390                 395                 400

Glu Cys Leu Pro Val Asn Val Gln Thr Met Ser Tyr Leu Asp Ser Ile
                405                 410                 415

Gln Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Arg Ile
            420                 425                 430

Ser Pro Gln Ser Thr Pro Ile Ala Arg Ser Leu Leu Lys Leu Asp Leu
        435                 440                 445

Ser Lys Ile Lys Glu Lys Lys Ser Leu Thr Trp Glu Thr Ser Ser Tyr
    450                 455                 460

Asp Leu Glu
465         --
```

On page 31, line 4, after the word "and", please insert --(SEQ. ID. No. 13)--.

On page 31, line 41, after the word "is" but before the ":", please insert --(SEQ. ID. No. 15)--.

Please delete lines 42-43 on page 31 and lines 1-16 on page 32, and replace with the following:

```
-- TTATGCAACA CCAGCAATCT TGGCCTCTTT CTTAACTCCA AACATTTCAT AGAATTTGTC      60

   AAGATTATCA CTGTAATAGT CCATAGCAAT GCTTCCCTTA GCATTGGGAT TGCAAGAACT     120

   AAGTATCTTG GCATATTCTT TCCCTTTGTT TATCTGTGCA TCATCCATTG TAAATCCTTT     180

   GCTTTTAAGC ACTGTGCAAA CCTTCCCCAG AGCTTCCTTA GTGTTGTACT TAGTTGGTTC     240

   AATCCCTAAC TCCTTGTACT TTGCATCTTG ATATATGGCA AGAACAACAC TGATCATCTC     300

   GAAGCTGTCA ACAGAAGCAA TGAGAGGGAT ACTACCTCCA AGCATTATAG CAAGTCTCAC     360

   AGATTTTGCA TCTGCCAGAG GCAGCCCGTA AGCTTGGACC AAAGGGTGGG AGGCAATTTT     420

   TGCTTTGATA ATAGCAAGAT TCTCATTGTT TGCAGTCTCT TCTATGAGCT TCACTCTTAT     480

   CATGCTATCA AGCCTCCTGA AAGTCATATC CTTAGCTCCA ACTCTTTCAG AATTTTTCTT     540

   TATCGTGACC TTACCAAAAG TAAAATCACT TTGGTTCACA ACTTTCATAA TGCCTTGGCG     600

   ATTCTTCAAG AAAGTCAAAC ATGAAGTGAT ACTCATTTTC TTAATCAGGT CAAGATTTTC     660

   CTGACAGAAA GTCTTAAAGT TGAATGCGAC CTGGTTCTGG TCTTCTTCAA ACTCAACATC     720

   TGCAGATTGA GTTAAAAGAG AGACAATGTT TTCTTTTGTG AGCTTGACCT TAGACAT        777
```

The complementary nucleic acid molecule has a nucleotide sequence as shown in SEQ. ID. No. 19.--.

On page 32, line 24, change "vial" to --viral--.

On page 33, line 29, change "the" to --The--.

On page 33, line 32, change "differs" to --differ--.

On page 34, line 17, change "exactly same positions" to --exact same position--.

On page 35, line 12, change "event." to --event,--.

On page 35, line 13, change "Tospovirus" to --*Tospovirus*--.

On page 36, line 10, change "generated" to --generate--.

On page 36, line 27, change "Np" to --NP--.

On page 39, line 16, after "virus" insert --was--.

On page 39, line 17, change ", and is" to --and was--.

On page 40, line 25, change "resistant" to --resistance--.

On page 41, line 3, before "and", insert -- (SEQ. ID. No. 20) --.

On page 41, line 4, before ",", insert -- (SEQ. ID. No. 21) --.

On page 41, line 10, after "plants" insert --that--.

On page 41, line 11, change "greenhouse. All" to --greenhouse, all--.

On page 43, line 9, after "appearance" insert --.--

On page 43, line 15, change "pants" to --plants--.

On page 45, line 19, change "vecor" to -- vector --.

On page 45, line 33, before ",", insert -- (SEQ. ID. No. 22) --.

On page 45, line 35, before ",", insert -- (SEQ. ID. No. 23) --.

On page 46, line 31, before "was", insert -- (SEQ. ID. No. 24) --.

On page 47, line 11, change "Hewlet Scanjet" to --Hewlett Scanjet™--.

On page 51, line 2, change "Tospoviruses" to --*Tospoviruses*--.

On page 53, line 11, change "Tospovirus" to --*Tospovirus*--.

On page 53, line 14, change "realated" to --related--.

On page 53, line 16, change "RNE" to -- RNA --.

On page 53, line 28, change "generqated" to --generated--.

On page 54, line 2, before ",", insert -- (SEQ. ID. No. 25) --.

On page 54, line 4, before "for", insert -- (SEQ. ID. No. 26) --.

On page 54, line 6, before "for", insert -- (SEQ. ID. No. 27) --.

On page 54, line 10, before "which", insert -- (SEQ. ID. No. 28) --.

On page 54, line 12, before "for", insert -- (SEQ. ID. No. 29) --.

On page 54, line 15, before "for", insert -- (SEQ. ID. No. 30) -- and change "untranslatablesecond" to -- untranslatable second --.

On page 54, line 33, change "expressin" to --expression--.

On page 55, line 23, change "fragemnts" to --fragments--.

On page 55, line 32, change "fragements" to --fragments--.

On page 55, line 30, change "prodcing" to -- producing --.

On page 55, line 34, change "expressin" to -- expression --.

On page 56, line 4, change "trnscription" to --transcription--.

On page 56, line 6, change "pant" to -- plant -- and change "resluting" to -- resulting --.

On page 56, line 32, change "variojs" to -- various --.

On page 57, line 23, change "portin" to -- portion --.

Please delete the sequence listing from the specification, page 57, line 26 to page 75, line 9 and insert the new sequence listing (attached hereto) as a separately paginated document which is part of the present application.

In the Claims:

Please delete claims 1-3 and add new claims 4-18 as follows:

--4. An isolated DNA molecule capable of transcription to a messenger RNA which is modified from a form encoding a nucleocapsid protein of an L serogroup *Tospovirus* so that it does not translate to the nucleocapsid protein, wherein, when the DNA molecule is transformed into a plant cell, it is capable of being transcribed into messenger RNA which exists at low level density readings of 15-50 as measured using a Hewlett ScanJet and Image Analysis Program.--

--5. A DNA molecule according to claim 4, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--6. A recombinant DNA expression system comprising an expression vector into which is inserted a heterologous DNA molecule according to claim 4.--

--7. A plant cell transformed with a heterologous DNA molecule according to claim 4.--

--8. A transgenic plant containing the DNA molecule according to claim 4.--

--9. A method of treating a plant cell comprising:

transforming a plant cell with a DNA molecule according to claim 4 and

transcribing the DNA molecule under conditions effective to maintain the messenger RNA in the plant cell at low level density readings of 15-50, as measured

using the Hewlett ScanJet and Image Analysis Program, wherein the plant cell acquires resistance to an L serogroup *Tospovirus*.--

--10. A method of imparting to a plant cell resistance to infection by an I serogroup *Tospovirus*, said method comprising:

transforming a plant cell with a DNA molecule encoding a nucleocapsid protein of an L serogroup *Tospovirus*, wherein the DNA molecule is expressed to produce an ELISA level of OD405nm = 0.50 to 1.00 of the nucleocapsid protein in the plant cell, as measured using an antibody raised against the nucleocapsid protein of *Tospovirus* isolate TSWV-BL, and the plant cell acquires resistance to an I serogroup *Tospovirus*.--

--11. A method according to claim 10, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--12. A method according to claim 10, wherein the I serogroup *Tospovirus* is selected from the group consisting of INSV-Beg and INSV-LI.--

--13. A method of imparting to a plant cell resistance to infection by L serogroup *Tospoviruses*, said method comprising:

transforming a plant cell with a DNA molecule encoding a nucleocapsid protein of an L serogroup *Tospovirus*, wherein the DNA molecule is expressed to produce an ELISA level of OD 405nm = 0.02 to 0.20 of the nucleocapsid protein in the plant cell, as measured using an antibody raised against the nucleocapsid protein of *Tospovirus* isolate TSWV-BL, and the plant cell acquires resistance to the L serogroup *Tospovirus* and a second L serogroup *Tospovirus*.--

--14. A method according to claim 13, wherein the L serogroup *Tospovirus* is selected from the group consisting of TSWV-10W and TSWV-BL.--

--15. A method of imparting to a plant cell resistance to infection to a *Tospovirus* comprising:

transforming a plant cell with a DNA molecule encoding a nucleocapsid protein or polypeptide of a serogroup L *Tospovirus* under conditions effective to render the plant cell resistant to infection by serogroup L *Tospovirus* isolates and a serogroup 2 *Tospovirus* isolate.--

--16. A method according to claim 15, wherein the serogroup 2 *Tospovirus* isolate is a TSWV-B *Tospovirus* isolate.--

--17. A transgenic plant containing a heterologous DNA molecule encoding a nucleocapsid protein or polypeptide of a serogroup L *Tospovirus*, wherein the transgenic plant, upon challenge with both a *Tospovirus* isolate belonging to serogroup L and a *Tospovirus* isolate belonging to serogroup 2, exhibits resistance to both the L serogroup *Tospovirus* isolate and the serogroup 2 *Tospovirus* isolate.--

--18. A transgenic plant according to claim 17, wherein the serogroup 2 *Tospovirus* isolate is a TSWV-B *Tospovirus* isolate.--

Date: October 22, 1999



Edwin V. Merkel
Registration No. 40,087
Attorney for Applicants

Nixon Peabody LLP
Clinton Square, P.O. Box 1051
Rochester, New York 14603
Telephone: (716) 263-1128
Facsimile: (716) 263-1600

TOMATO SPOTTED WILT VIRUS

Viruses in the *Tospovirus* genus infect a wide variety of plant species, particularly tobacco, peanut, vegetables and ornamental plants. Two virus species, tomato spotted wilt virus (TSWV) and impatiens necrotic spot virus (INSV) are recognized within the Tospovirus genus.

Tomato Spotted Wilt Virus (TSWV) is unique among plant viruses in that the nucleic acid-protein complex is covered by a lipoprotein envelope and it is the only thrip transmitted virus. This virus has recently been classified as the Tospovirus genus of the *Bunyaviridae* family. TSWV virions contain a 29K nucleocapsid protein ("NP" or "N"), two membrane-associated glycoproteins (58K and 78K) and a large 200K protein presumably for the viral transcriptase [see J. Gen. Virol. 71:2207 (1991); Virol. 56:12 (1973); and J. Gen. Virol. 36:267 (1977)]. The virus genome consists of three negative-strand (-) RNAs designated L RNA (8900 nucleotides), M RNA (5400 nucleotides) and S RNA (2900 nucleotides) [see J. Gen. Virol. 36:81 (1977); J. Gen. Virol. 53:12 (1981); and J. Gen. Virol. 70:3469 (1989)], each of which is encapsulated by the NP. The partial or full-length sequences of S RNAs from three TSWV isolates reveals the presence of two open reading frames (ORF) with an ambisense gene arrangement [see J. Gen Virol. 71:1 (1990) and J. Gen. Virol. 72:461 (1991)]. The larger open reading frame is located on the viral RNA strand and has the capacity to encode a 52K nonstructural protein. The smaller ORF is located on the viral complementary RNA strand and is translated through a subgenomic RNA into the 29K NP.

The ambisense coding strategy is also characteristic of the TSWV M RNA, with the open reading frames encoding the 58K and 78K membrane-associated glycoproteins. The TSWV L RNA has been sequenced to encode a large 200K protein presumably for the viral transcriptase.

Two TSWV serogroups, "L" and "I", have been identified and characterized based on serological analysis of the structural proteins and morphology of cytopathic structures [see J. Gen Virol. 71:933 (1990) and Phytopathology 81:525 (1991)]. They have serologically conserved G1 and G2 glycoproteins, but the NP of the "I" serogroup is

serologically distinct from that of the "L" serogroup. Comparison of the NP between the "L" and "I" serogroups has shown 62% and 67% identities at nucleotide and amino acid levels, respectively [see J. Gen. Virol. 72:2597 (1991)].

TSWV has a wide host range, infecting more than 360 plant species of 50 families and causes significant economic losses to vegetables and ornamental plants worldwide. The "L" serogroup has been found extensively in field crops such as vegetables and weeds, while the "I" serogroup has been largely confined to ornamental crops. A cucurbit isolate has recently been identified [see Plant Disease 68:1006 (1984)] as a distinct isolate because it systemically infects watermelon and other curcurbits and its NP is serologically unrelated to that of either serogroup. Although the spread of the TSWV disease can sometimes be reduced by breeding resistant plants or using non-genetic approaches, complete control of the disease by these conventional methods has generally proven to be difficult [see Plant Disease 73:375 (1989)].

Since 1986, numerous reports have shown that transgenic plants with the coat protein (CP) gene of a virus are often resistant to infection by that virus. This phenomenon is commonly referred to as coat protein-mediated protection (CPMP). The degree of protection ranges from delay in symptom expression to the absence of disease symptoms and virus accumulation. Two recent independent reports [see Biol. Technology 9:1363(1991) and Mol. Plant-Microbe Interact. 5:34 (1992)] showed that transgenic tobacco plants expressing the nucleocapsid protein (NP) gene of TSWV are resistant to infection by the homologous isolate. However, since TSWV is widespread with many biologically diverse isolates, it is very important to test the effectiveness of the transgenic plants to resist infections by different TSWV isolates. The findings of the present invention expand on those of the previous reports by demonstrating that transgenic plants according to the present invention showed resistance to two heterologous isolates of the "L" serogroup and an isolate of the "I" serogroup. We also show that resistance to the two heterologous isolates of the "L" serogroup was mainly found in plants accumulating very low, if any,

levels of NP, while transgenic plants that accumulated high levels of NP were resistant to the isolate of the "I" serogroup.

However, no resistance was observed to a Brazilian isolate, although the plants that accumulated high levels of the N protein did display a delay in symptom expression. This Brazilian isolate, designated TSWV-B has the N protein that was serologically distinct from the "L" and "I" serogroups and biologically differs from a curcurbit isolate in that the TSWV-B does not systemically infect melons or squash . Therefore, one aspect of the present invention is to characterize the TSWV-B by cloning and sequencing of its S RNA and comparisons with the published sequences of other TSWV isolates.

Various aspects of the present invention will become readily apparent from the detailed description of the present invention including the following example, figures and data.

In the Figures;

Fig. 1 depicts the strategy for cloning the NP gene from viral RNA according to the present invention;

Fig. 2 depicts the In vivo transient expression of the nucleocapsid protein (NP) gene of tomato spotted wilt virus according to the present invention in tobacco protoplasts;

Fig. 3 depicts the location of the sequenced cDNA clones in the TSWV-B S RNA according to the present invention;

Fig. 4 depicts a dendogram showing relationships among TSWV isolates according to the present invention;

Fig. 5 depicts the serological relationship of TSWV isolates described herein;

Fig. 6 depicts the correlation of the level of nucleocapsid protein (NP) accumulation in transgenic plants with the degree of resistance to TSWV isolates;

Fig. 7 depicts the TSWV-BL N coding sequences introduced into transgenic plants in accordance with one aspect of the present invention; and

Fig. 8 depicts the TSWV-BL half N gene fragments introduced into plants in accordance with one aspect of the present invention.

More specifically, figure 2 depicts transient expression of the NP gene in which the constructs were transferred into tobacco mesophyll protoplasts using polyethylene glycol (PEG). The transformed protoplasts were subsequently incubated for two days for the expression of the NP gene. Proteins were extracted from the protoplasts and tested for the NP by double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) using antibodies against the TSWV NP. NP^- and NP^+ represent the protoplasts transformed with plasmids pBI525-NP^- and pBI525-NP^+, respectively. Concentration of the antibodies for coating: 5 µg/ml: dilution of the enzyme conjugate: 1:250. Data were taken 30, 60 and 90 min. after addition of substrate.

In figure 3, the five overlapping cDNA clones are shown to scale below a S RNA map of TSWV-B. These clones were synthesized with random primers from double-stranded RNA isolated from *N. benthamiana* plants infected with TSWV-B.

In figure 4, the sequences were compared using the pileup program of the GCG Sequence analysis software package. Horizontal lines are proportional to the genetic distance while vertical lines are of arbitrary length and have no significance.

More specifically, in figure 5, *N. benthamiana* Domin. were infected with TSWV isolates [TSWV-BL (a lettuce isolate), Arkansas, 10W pakchoy (TSWV-10W), Begonia, and Brazil (TSWV-B)). An infected leaf disc (0.05 gram) was ground in 12 ml of the enzyme conjugate buffer and analyzed by DAS-ELISA using antibodies raised against TSWV-BL viron (BL viron), or the NP of TSWV-BL (BL-NP), or TSWV-I (I-NP). Concentration of antibodies for coating were 1µg/ml; dilution of conjugates were 1:2000 for BL viron, 1:250 for BL-NP, and 1:1000 for I-NP. The results were taken after 10 minutes (BL), 50 minutes (BL-NP), or 30 minutes after adding substrate.

With regard to figure 6, transgenic plants were assayed in DAS-ELISA for NP accumulation with antibodies raised against the NP of TSWV-BL. Plants were read 150 min. after adding substrate and the transgenic plants were grouped into four categories: OD_{405nm} smaller than 0.050, OD_{405nm} between 0.050 to 0.200, OD_{405nm} between 0.200 to 0.400, and OD_{405nm} greater than 0.400. The OD_{405nm} readings of

control NP (-) plants were from zero to 0.05. The same plants were challenged with either the Arkansas (Ark) and 10W pakchoy (10W) isolates or the Begonia isolate and the susceptibility of each plant was recorded about 12 days after inoculation. The results were pooled from fifty-one R_1 NP (+) plants inoculated with the Arkansas and 10W pakchoy isolates and one hundred thirty-nine R_1 NP(+) plants inoculated with the Begonia isolate. Numbers above bars represent total numbers of R_1 NP(+) plants tested.

EXAMPLE I

Isolation of TSWV-BL RNAs:

The TSWV-BL isolate was purified from *Datura stramonium* L. as follows: the infected tissues were ground in a Waring Blender for 45 sec with three volumes of a buffer (0.033 M KH_2PO_4, 0.067 MK_2HPO_4, 0.01 M Na_2SO_3). The homogenate was filtered through 4 layers of cheesecloth moistened with the above buffer and centrifuged at 7,000 rpm for 15 min. The pellet was resuspended in an amount of 0.01 M Na_2SO_3 equal to the original weight of tissue and centrifuged again at 8,000 rpm for 15 min. After the supernatant was resuspended in an amount of 0.01 M Na_2SO_3 equal to 1/10 of the original tissue weight. The virus extract was centrifuged at 9,000 rpm for 15 min. and the supernatant was carefully loaded on a 10-40% sucrose step gradient made up in 0.01 M Na_2SO_3. After centrifugation at 23,000 rpm for 35 min., the virus zone (about 3 cm below meniscus) was collected and diluted with two volumes of 0.01 M Na_2SO_3. The semi-purified virus was pelleted at 27,000 rpm for 55 min.

EXAMPLE II

Purification of TSWV and viral RNAs:

The TSWV-BL isolate [see Plant Disease 74:154 (1990)] was purified from *Datura stramonium* L, as described in Example I. The purified virus was resuspended in a solution of 0.04% of bentonite, 10 µg/ml of proteinase K, 0.1 M ammonium carbonate, 0.1% (w/v) of sodium diethyldithiocarbanate, 1 mM EDTA, and 1% (w/v) of sodium dodecyl sulfate (SDS), incubated at 65°C for 5 min., and immediately extracted from H_2O-saturated phenol, followed by another extraction

with chloroform/isoamyl alcohol (24:1). Viral RNAs were precipitated in 2.5 volumes of ethanol and dissolved in distilled H_2O.

EXAMPLE III

cDNA and PCR-based NP gene cloning:

The first strand cDNA was synthesized from purified TSWV-BL RNAs using random primers as described by Gubler and Hoffman [see Gene 25:263 (1983)]. The second strand was produced by treatment of the sample with RNase H/DNA polymerase. The resulting double-stranded cDNA sample was size-fractionated by sucrose gradient centrifugation, methylated by EcoRI methylase, and EcoRI linkers were added. After digestion with EcoRI, the cDNA sample was ligated into the EcoRI site of pUC18, whose 5'-terminal phosphate groups were removed by treatment with calf intestinal alkaline phosphotase. *E. coli* DH5 α competent cells (Bethesda Research Laboratories) were transformed and clones containing TSWV cDNA inserts were first selected by plating on agar plates containing 50 µg/ml of ampicillin, IPTG, and X-gal. Plasmid DNAs from selected clones were isolated using an alkaline lysis procedure [see BRL Focus 11:7 (1989)], and the insert sizes were determined by EcoRI restriction enzyme digestion followed by DNA transfer onto GeneScreen Plus nylon filters (DuPont). Plasmid clones that contained a TSWV-BL S RNA cDNA insert were identified as described below by hybridizing against a ^{32}P-labelled oligomer (AGCAGGCAAAACTCGCAGAACTTGC) complementary to the nucleotide sequence (GCAAGTTCTGCGAGTTTTGCCTGCT) of the TSWV-CPNH1 S RNA [see J. Gen. Virol. 71:001 (1990)]. Several clones were identified and analyzed on agarose gels to determine the insert sizes. The clones pTSWVS-23 was found to contain the largest cDNA insert, about 1.7 kb in length.

The full-length NP gene was obtained by the use of polymerase chain reaction (PCR). First-strand cDNA synthesis was carried out at 37°C for 30 min. in a 20 µl reaction mixture using oligomer primer JLS90-46 (5'-> 3') AGCTAACCATGGTTAAGCTCACTAAGGAAAGC (also used to synthesize the nucleocapsid gene of TSWV-10W) which is complementary to the S RNA in the 5' terminus of TSWV NP gene (nucleotide positions 2751 to 2773 of the TSWV-CPNH1). The reaction

mixture contained 1.5 µg of viral RNAs,1 µg of the oligomer primer, 0.2 mM of each dNTP, 1X PCR buffer (the GeneAmp kit, Perkin-Elmer-Cetus), 20U of RNAs in Ribonuclease inhibitor (Promega), 2.5 mM of $MgCl_2$, and 25U of AMV reverse transcriptase (Promega Corporation). The reaction was terminated by heating at 95°C for 5 min. and cooled on ice. Then 10 µl of the cDNA/RNA hybrid was used to PCR-amplify the NP gene according to manufacturer's instructions (Perkin-Elmer-Cetus) using 1 µg each of oligomer primers JLS90-46 and JLS90-47 (5'->3'), AGCATTCCATGGTTAACACACTAAGCAAGCAC (also used to synthesize the nucleotide gene of TSWV-10W), the latter oligomer being identical to the S RNA in the 3' noncoding region of the gene (nucleotide positions 1919 to 1938 of the TSWV-CPNH1). A typical PCR cycle was 1 min. at 92°C (denaturing), 1 min. at 50°C (annealing), and 2 min. at 72°C (polymerizing). The sample was directly loaded and separated on a 1.2% agarose gel. The separated NP gene fragment was extracted from the agarose gel, ethanol-precipitated and dissolved in 20 µl of distilled H_2O.

EXAMPLE IV

Construction of plant expression and transformation vectors.

The gel-isolated NP gene fragment from Example III was digested with the restriction enzyme *NcoI* in 50 µl of a reaction buffer [50 mM Tris-HCl (pH 8.0), 10 mM $MgCl_2$, 0.1 M NaCl] at 37°C for 3 hours, and directly cloned into *NcoI*-digested plant expression vector pB1525. The resulting plasmids were identified and designated as pB1525-NP+ in the sense orientation relative to the cauliflower mosaic virus (CaMV) 35S promoter, and as pB1525-NP- in the reverse orientation. The ability of this expression cassette to produce the NP was determined by transient expression of the NP gene in *Nicotiana tobacum* protoplasts, as described by Pang et al [see Gene 112:229 (1992)]. The expression cassette containing the NP gene was then excised from pB1525-NP+ by a partial digestion with *Hind*III/*Eco*RI (since the NP gene contains internal *Hind*III and *Eco*RI sites), and ligated into the plant transformation vector pBIN19 (Clontech Laboratories, Inc.) that had been cut with the same enzymes. The resulting vector, pBIN19-NP+ and the control plasmid pBIN19 were transferred to *A. tumefaciens* strain

LBA4404, using the procedure described by Holsters et al [see Mol. Gen. Genet. 163:181 (1978)].

Nucleotide sequence analyses of the inserts in clones pTSWV-23 and Pb1525-NP+were determined using the dideoxyribonucleotide method, T7 polymerase (U.S. Biochemicals, Sequenase™), and the double-stranded sequencing procedure described by Siemieniak et al [see Analyt. Biochem. 192:441 (1991)]. Nucleotide sequences were determined from both DNA strands and this information was compared with the published sequences of TSWV isolates CPNH1 using computer programs available from the Genetics Computer Group (GCG, Madison, WI).

Transient expression of the NP gene in tobacco protoplasts were also prepared. Plasmid DNAs for clones pTSWVS-23 and pUC18cpphas TSWV-NP (containing the PCR-engineered NP gene insert) were isolated using the large scale alkaline method. The PCR-engineered NP gene insert was excised from clone pBIS25-NP+ by NcoI digestion to take advantage of the available flanking oligomer primers for sequencing. The expression cassette pUC18cpphas is similar to pUC18cpexp except that it utilizes the poly(A) addition signal derived from the *Phaseolus vulgaris* seed storage gene phaseolin. These plasmid DNAs were subjected to two CsCl-ethidium bromide gradient bandings, using a Beckman Ti 70.1 fixed angle rotor. DNA sequences were obtained using dideoxyribonucleotides and the double-stranded plasmid DNA sequencing procedure described above. Nucleotide sequence reactions were electrophoresed on one-meter long thermostated (55°C) sequencing gels and nucleotide sequence readings averaging about 750 bp were obtained. Nucleotide sequences were determined from both DNA strands of both cloned inserts to ensure accuracy. Nucleotide sequence information from the TSWV-BL S RNA isolate was compared as discussed below, with TSWV isolates CPNH1 and L3 using computer programs (GCG, Madison, WI).

The nucleotide and deduced amino acid sequences of cloned cDNA and PCR-engineered insert of TSWV-BL S RNA and their comparison with the nucleotide sequence of TSWV-CPHN1 S RNA are shown below. The nucleotide sequence of the TSWV-BL S RNA clones pTSWVS-23

(TSWV-23) and pBI525-NP+ (TSWV-PCR) were obtained using the double-stranded dideoxynucleotide sequencing procedure of Siemieniak, and their sequences are compared with the relevant regions of the nucleotide sequence of the TSWV-CPNH1 S RNA reported in GeneBank Accession No. D00645. The nucleotide sequence of TSWV-CPNH1 S RNA has been reported by De Haan (1990) and is represented by the following sequence:

CAAGTTGAAA GCAACAACAG AACTGTAAAT TCTCTTGCAG TGAAATCTCT , 50
GCTCATGTCA GCAGAAAACA ACATCATGCC TAACTCTCAA GCTTCCACTG 100
ATTCTCATTT CAAGCTGAGC CTCTGGCTAA GGGTTCCAAA GGTTTTGAAG 150
CAGGTTTCCA TTCAGAAATT GTTCAAGGTT GCAGGAGATG AAACAAACAA 200
AACATTTTAT TTATCTATTG CCTGCATTCC AAACCATAAC AGTGTTGAGA 250
CAGCTTTAAA CATTACTGTT ATTTGCAAGC ATCAGCTCCC AATTCGCAAA 300
TGCAAAGCTC CTTTTGAATT ATCAATGATG TTTTCTGATT TAAAGGAGCC 350
TTACAACATT GTTCATGACC CTTCATACCC CAAAGGATCG GTTCCAATGC 400
TCTGGCTCGA AACTCACACA TCTTTGCACA AGTTCTTTGC AACTAACTTG 450
CAAGAAGATG TAATCATCTA CACTTTGAAC AACCTTGAGC TAACTCCTGG 500
AAAGTTAGAT TTAGGTGAAA GAACCTTGAA TTACAGTGAA GATGCCTACA 550
AAAGGAAATA TTTCCTTTCA AAAACACTTG AATGTCTTCC ATCTAACACA 600
CAAACTATGT CTTACTTAGA CAGCATCCAA ATCCCTTCAT GGAAGATAGA 650
CTTTGCCAGA GGAGAAATTA AAATTTCTCC ACAATCTATT TCAGTTGCAA 700
AATCTTTGTT AAAGCTTGAT TTAAGCGGGA TCAAAAAGAA AGAATCTAAG 750
GTTAAGGAAG CGTATGCTTC AGGATCAAAA TAATCTTGCT TTGTCCAGCT 800
TTTTCTAATT ATGTTATGTT TATTTTCTTT CTTTACTTAT AATTATTTCT 850
CTGTTTGTCA TCTCTTTCAA ATTCCTCCTG TCTAGTAGAA ACCATAAAAA 900
CAAAAAATAA AAATGAAAAT AAAATTAAAA TAAAATAAAA TCAAAAAATG 1000
AAATAAAAAC AACAAAAAAT TAAAAAACGA AAAACCAAAA AGACCCGAAA 1050
GGGACCAATT TGGCCAAATT TGGGTTTTGT TTTTGTTTTT TGTTTTTTGT 1100
TTTTTATTTT TTATTTTATT TTTATTTTAT TTTATTTTTA TTTTATTTTT 1150
ATTTTATTTA TTTTTTGTTT TCGTTGTTTT TGTTATTTTA TTATTTATTA 1200
AGCACAACAC ACAGAAAGCA AACTTTAATT AAACACACTT ATTTAAAATT 1250
TAACACACTA AGCAAGCACA AGCAATAAAG ATAAAGAAAG CTTTATATAT 1300
TTATAGGCTT TTTTATAATT TAACTTACAG CTGCTTTCAA GCAAGTTCTG 1350
CGAGTTTTGC CTGCTTTTTA ACCCCGAACA TTTCATAGAA CTTGTTAAGA 1400
GTTTCACTGT AATGTTCCAT AGCAACACTC CCTTTAGCAT TAGGATTGCT 1450

GGAGCTAAGT ATAGCAGCAT ACTCTTTCCC CTTCTTCACC TGATCTTCAT 1500
TCATTTCAAA TGCTTTGCTT TTCAGCACAG TGCAAACTTT TCCTAAGGCT 1550
TCCTTGGTGT CATACTTCTT TGGGTCGATC CCGAGGTCCT TGTATTTTGC 1600
ATCCTGATAT ATAGCCAAGA CAACACTGAT CATCTCAAAG CTATCAACTG 1650
AAGCAATAAG AGGTAAGCTA CCTCCCAGCA TTATGGCAAG TCTCACAGAC 1700
TTTGCATCAT CGAGAGGTAA TCCATAGGCT TGAATCAAAG GATGGGAAGC 1750
AATCTTAGAT TTGATAGTAT TGAGATTCTC AGAATTCCCA GTTTCTTCAA 1800
CAAGCCTGAC CCTGATCAAG CTATCAAGCC TTCTGAAGGT CATGTCAGTG 1850
CCTCCAATCC TGTCTGAAGT TTTCTTTATG GTAATTTTAC CAAAAGTAAA 1900
ATCGCTTTGC TTAATAACCT TCATTATGCT CTGACGATTC TTTAGGAATG 1950
TCAGACATGA AATAACGCTC ATCTTCTTGA TCTGGTCGAT GTTTTCCAGA 2000
CAAAAAGTCT TGAAGTTGAA TGCTACCAGA TTCTGATCTT CCTCAAACTC 2050
AAGGTCTTTG CCTTGTGTCA ACAAAGCAAC AATGCTTTCC TTAGTGAGCT 2100
TAACCTTAGA CATGATGATC GTAAAAGTTG TTATAGCTTT GACCGTATGT 2150
AACTCAAGGT GCGAAAGTGC AACTCTGTAT CCCGCAGTCG TTTCTTAGGT 2200
TCTTAATGTG ATGATTTGTA AGACTGAGTG TTAACGTATG AACACAAAAT 2250
TGACACGATT GCTCT 2265

The incomplete deduced amino acid sequence of the nonstructural protein gene on TSWV-CPNH1 S RNA is provided below beginning with nucleic acid at position 1 and ending with the nucleic acid codon ending at position 783:

Gln Val Glu Ser Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys
5 10 15
Ser Leu Leu Met Ser Ala Glu Asn Asn Ile Met Pro Asn Ser Gln
20 25 30
Ala Ser Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Val
35 40 45
Pro Lys Val Leu Lys Gln Val Ser Ile Gln Lys Leu Phe Lys Val
50 55 60
Ala Gly Asp Glu Thr Asn Lys Thr Phe Tyr Leu Ser Ile Ala Cys
65 70 75
Ile Pro Asn His Asn Ser Val Glu Thr Ala Leu Asn Ile Thr Val
80 85 90
Ile Cys Lys His Gln Leu Pro Ile Arg Lys Cys Lys Ala Pro Phe
95 100 105
Glu Leu Ser Met Met Phe Ser Asp Leu Lys Glu Pro Tyr Asn Ile
110 115 120
Val His Asp Pro Ser Tyr Pro Lys Gly Ser Val Pro Met Leu Trp
125 130 135

Leu Glu Thr His Thr Ser Leu His Lys Phe Phe Ala Thr Asn Leu
140 145 150
Gln Glu Asp Val Ile Ile Tyr Thr Leu Asn Asn Leu Glu Leu Thr
155 160 165
Pro Gly Lys Leu Asp Leu Gly Glu Arg Thr Leu Asn Tyr Ser Glu
170 175 180
Asp Ala Tyr Lys Arg Asp Tyr Phe Leu Ser Lys Thr Leu Glu Cys
185 190 195
Leu Pro Ser Asn Thr Gln Thr Met Ser Tyr Leu Asp Ser Ile Gln
200 205 210
Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Lys Ile
215 220 225
Ser Pro Gln Ser Ile Ser Val Ala Lys Ser Leu Leu Lys Leu Asp
230 235 240
Leu Ser Gly Ile Lys Lys Lys Glu Ser Lys Val Lys Glu Ala Tyr
245 250 255
Ala Ser Gly Ser Lys
260

The nucleotide sequence for TSWV-23 depicted below compares closely with the TWSV sequence given above, and contains one-half of the nonstructural gene and one half of the nucleocapsid protein gene.

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGCAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATCCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTACACCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900

TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050
TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGCA AACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCACA AACAATAAA 1200
GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300
ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCCTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650
TTGAATCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCC 1709

The nucleic acid sequence for TSWV-PCR according to the present invention as depicted below also compares closely with the TSWV sequence given above and covers the whole nucleocapsid protein gene.

TTAACACACT AAGCAAGCAC AAACAATAAA GATAAAGAAA GCTTTATATA 50
TTTATAGGCT TTTTTATAAT TTAACTTACA GCTGCTTTTA AGCAAGTTCT 100
GTGAGTTTTG CCTGTTTTTT AACCCCAAAC ATTTCATAGA ACTTGTTAAG 150
GGTTTCACTG TAATGTTCCA TAGCAATACT TCCTTTAGCA TTAGGATTGC 200
TGGAGCTAAG TATAGCAGCA TACTCTTTCC CCTTCTTCAC CTGATCTTCA 250
TTCATTTCAA ATGCTTTTCT TTTCAGCACA GTGCAAACTT TTCCTAAGGC 300
TTCCCTGGTG TCATACTTCT TTGGGTCGAT CCCGAGATCC TTGTATTTTG 350
CATCCTGATA TATAGCCAAG ACAACACTGA TCATCTCAAA GCTATCAACT 400
GAAGCAATAA GAGGTAAGCT ACCTCCCAGC ATTATGGCAA GCCTCACAGA 450
CTTTGCATCA TCAAGAGGTA ATCCATAGGC TTGACTCAAA GGGTGGGAAG 500
CAATCTTAGA TTTGATAGTA TTGAGATTCT CAGAATTCCC AGTTTCCTCA 550
ACAAGCCTGA CCCTGATCAA GCTATCAAGC CTTCTGAAGG TCATGTCAGT 600
GGCTCCAATC CTGTCTGAAG TTTTCTTTAT GGTAATTTTA CCAAAAGTAA 650
AATCGCTTTG CTTAATAACC TTCATTATGC TCTGACGATT CTTCAGGAAT 700
GTCAGACATG AAATAATGCT CATCTTTTTG ATCTGGTCAA GGTTTTCCAG 750

ACAAAAAGTC TTGAAGTTGA ATGCTACCAG ATTCTGATCT TCCTCAAACT 800
CAAGGTCTTT GCCTTGTGTC AACAAAGCAA CAATGCTTTC CTTAGTGAGC 850
TTAACCAT 858

Together the cloned TSWV-23 insert overlaps the TSWV-PCR insert, and together they represent the 2028 nucleotides of the TSWV-BL S RNA according to the present invention. This 2028 nucleotide sequence according to the present invention contains a part of the nonstructural gene and whole nucleocapsid protein gene. The combined sequence is:

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGCAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATCCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTACACCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900
TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050
TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGC AAACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCAC AAACAATAAA 1200
GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300

ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCCTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAC 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650
TTGACTCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCCC AGTTTCCTCA ACAAGCCTGA CCCTGATCAA GCTATCAAGC 1750
CTTCTGAAGG TCATGTCAGT GGCTCCAATC CTGTCTGAAG TTTTCTTTAT 1800
GGTAATTTTA CCAAAAGTAA AATCGCTTTG CTTAATAACC TTCATTATGC 1850
TCTGACGATT CTTCAGGAAT GTCAGACATG AAATAATGCT CATCTTTTTG 1900
ATCTGGTCAA GGTTTTCCAG ACAAAAAGTC TTGAAGTTGA ATGCTACCAG 1950
ATTCTGATCT TCCTCAAACT CAAGGTCTTT GCCTTGTGTC AACAAAGCAA 2000
CAATGCTTTC CTTAGTGAGC TTAACCAT 2028

This comparison showed that cDNA insert of clone pTSWVS-23 included about 760 bp of the 52 K protein viral component gene, the complete intergenic region (492 bp), and 450 bp of the NP gene (about half of the NP gene). This cloned insert had its 3'-end located exactly at an EcoRI recognition site, which suggested incomplete EcoRI methylation during the cDNA cloning procedure. Although this clone did not contain the complete TSWV-BL NP gene, its sequence was of considerable importance since it had a 450 bp overlap with the sequence of the PCR-engineered NP gene (a total of 2028 bp of the TSWV-BL S RNA is presented in the nucleotide sequence for TSWV). The sequence comparison between this TSWV-BL PCR-engineered and TSWV-CPNH1 NP genes revealed a total of 21 nucleotide differences (2.7%), eight of which encode amino acid replacements (3.1%). Since this PCR engineered NP gene was obtained using Taq polymerase, which is known to incorporate mutations, it is possible that some of these differences were introduced during PCR amplification. However, 15 of these nucleotide differences were located within the overlapping region between the TSWV-BL cDNA and PCR clones, and all but one of these nucleotide differences (position 1702 of TSWV; position 485 of TSWV-PCR)) are shared by both TSWV-BL S RNA derived clones. This

comparison clearly showed that the PCR amplification did not contribute greatly, if at all, to the difference between the nucleotide sequences of these two cloned NP gene regions. The nucleotide difference at position 1702 resulted in the amino acid replacement of Ile with Ser, and even this difference could be due to the lack of homogeneity within the TSWV-BL isolate.

EXAMPLE V

Agrobacterium-mediated transformation:

Leaf discs of *Nicotiana tabacum* var *Havana* cv 423 were inoculated with the *Agrobacterium* strain LBA4404 (ClonTech) containing the vector pBIN19-NP+ or the control plasmid pBIN19, by soaking overnight in a liquid culture of the *Agobacterium*, and the inoculated leaf discs were incubated on non-selective MS medium for 3 days. [see Science 227:1229 (1985)]. Transformed cells were selected and regenerated in MS medium containing 300 µg/ml kanamycin and 500 µg/ml carbenicillin for shoot regeneration. Roots were induced after transfer of plantlets to hormone-free medium. Rooted transformants were transferred to soil and grown under greenhouse conditions. The MS medium contains full strength MS salt (Sigma), 30 g/l sucrose, 1 mg/l BA and 1 ml of B_5 vitamins [1 mg/ml Nicotinic acid, 10 mg/ml Thiamine (HCl), 1 mg/ml Pyridoxine (HCl), 100 mg/ml Myo-Inositol]. Transgenic plants were self-pollinated and seeds were selectively germinated on kanamycin medium.

EXAMPLE VI

Serological detection of proteins:

Double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) was used to detect the expression of NP gene in transgenic plants with polyclonal antibodies against the TSWV-BL NP. Each sample was prepared by grinding a leaf disc (about 0.05 g) from the top second leaf of the plant in 3 ml of an enzyme conjugate buffer [phosphate-buffered saline, 0.05% Tween 20, 2% polyvinylpyrrolidone 40, and 0.2% ovalbumin]. For tobacco protoplasts, the cell extracts after centrifugation were directly used for the assay. A ten- and three-fold dilutions of the samples from both transgenic plants and tobacco protoplasts were made just before DAS-ELISA.

For Western blots, a leaf disc (about 0.05 g) was ground in 0.25 ml of 2X SDS/sample buffer (0.126 M Tris buffer, 20% glycerol, 2% SDS, 2% 2-mercaptoethanol, and 0.01 mg/ml bromphenol blue). The homogenates were centrifuged and the supernatants were boiled before loading. Proteins (10-20 µl sample/lane) were separated and blotted onto a membrane. The membrane was then processed following the manufacturer's immunoselect kit instruction manual (Gibco BRL Life Technologies Inc.). Antibodies to the whole virion were preabsorbed with cell extracts from health tobacco plants [See Plant Disease 70:501 (1986)], and were used in Western blot at a concentration of 2 µg/ml.

Serological reactions of TSWV isolates (TSWV-BL, Arkansas, 10W pakchoy, Begonia or Brazil) were assayed in DAS-ELISA using antibodies raised against TSWV-BL virion, or the NP of TSWV-BL or TSWV-I.

EXAMPLE VII

Inoculation of transgenic plants with TSWV isolates.

Inocula were prepared by infecting *Nicotiana benthamiana* Domin. with different TSWV isolates and grinding infected leaves (0.5 g) of *N. benthamiana* plants (1 to 2 weeks after inoculation) in 15 ml. of a buffer (0.033 M KH_2PO_4, 0.067 M K_2HPO_4 and 0.01 M Na_2SO_3). The inoculum extracts were immediately rubbed on corundum-dusted leaves of transgenic plants and the inoculated leaves were subsequently rinsed with H_2O. Because TSWV is highly unstable in vitro after grinding, each batch of inoculum was used to first inoculate NP(+) plants containing the NP gene; the last inoculated plants of each inoculum were always control NP(-) plants containing the vector sequence alone to assure that a particular virus inoculum was still infective at the end of inoculation.

Data on local lesions and systemic infections were taken 7-15 days after inoculation and expressed in the following table as the number of plants systemically infected over the number of plants inoculated, except where indicated. In this table, the data collected under "ELISA" is the data of R_0 lines from which the R_1 plants were derived; the Begonia isolate induced local lesions on the R_1 plants, an d the resistance was expressed as the number of plants producing local

lesions over the number of plants inoculated; and NT indicates that there was no test.

Reactions of R1 plants expressing the nucleocapsid protein (NP) gene of tomato spotted wilt virus (TSWV) to inoculation with TSWV isolates.

		Reactions to TSWV isolates					
		ELISA: (R0 pl.)	BL	Arkansas	10W Pakchoy	Begonia	Brazil
	R0 line						
	NP(+)2	0.015	0/20	4/25	3/24	29/40	36/36
	NP(+)4	0.386	6/30	21/23	18/21	9/48	42/42
	NP(+)9	0.327	0/20	NT	20/20	_	_
	NP(+)14	0.040	0/20	_	9/20	8/18	18/18
	NP(+)21	0.042	0/15	5/15	3/15	2/4	6/6
	NP(+)22	0.142	0/20	_	15/20	31/36	36/36
	NP(+)23	0.317	0/20	_	16/20	_	_
	NP(-)	-	42/42	24/24	62/62	66/66	54/54

As described above, the isolation of the TSWV-BL NP gene, which resides in the S RNA component of TSWV, was approached using two strategies. The cDNA cloning strategy yielded several clones containing cDNA inserts derived from TSWV-BL S RNA, as identified by hybridization against an oligomer probe complementary to the TSWV-CPNH1 S RNA. Clone pTSWVS-23 contained the longest insert, which mapped at about 1.7 kb in length . The second strategy utilized the published sequence of TSWV-CPNH1 S RNA and PCR to amplify and engineer the NP gene for expression directly from total TSWV-BL RNA. Oligomer primers JLS90-46 and -47 were synthesized, with JLS90-46 being complementary to the S RNA in the 5'-coding region of the NP gene (positions 2051-2073 of the TSWV-CPNH1) while JLS90-47 being of the 3'-noncoding region of the NP gene (positions 1218 to 1237 of the TSWV-CPNH1) . Both of the primers contain the recognition site for the restriction enzyme *Nco*I for subsequent cloning, and the primer JLS90-46 has a plant consensus translation initiation codon sequence (AAXXATGG), which upon amplification was expected to fuse the translation initiation codon to the third codon (GTT) of the NP gene . Fusion of the translation initiation codon to the third codon of the

TSWV-BL NP gene was done to preserve the *Nco*I recognition site while not incorporating any amino acid codons. Thus, expression of the PCR-engineered TSWV NP gene would yield a TSWV-BL NP that was two amino acids (Ser-Lys) shorter at the N-terminus than the native NP.

This specifically-amplified DNA fragment, of about 850 bp, was digested with NcoI and cloned into the plant expression vector pB1525. The orientation of the TSWV-BL NP gene with respect to the CaMV 35S promoter was determined by restriction enzyme site mapping (EcoRI, HindIII, AvaI and AlwNI). Several clones were isolated that contain the insert in the proper orientation (pB1525-NP$^+$) and others that contain the insert in the opposite orientation (pB1525-NP$^-$). This restriction enzyme site mapping data also showed that the inserts of clones pB1525-NP$^+$ contained restriction enzyme sites that were identical to those found in the TSWV-CPNH1 NP gene. The expression of TSWV-BL NP gene was thus controlled by a double CaMV 35S promoter fused to the 5'-untranslated leader sequence of alfalfa mosaic virus (ALMV) of the expression vector pB1525. Expression vectors that utilize the stacked double CaMV 35S promoter elements yield higher levels of mRNA transcription than similar vectors that utilize a single 35S promoter element.

Three pB1525-NP$^+$clones were translently expressed in tobacco protoplasts to confirm that the amplified DNA fragment encoded the NP. To achieve this, the clones were transferred into tobacco protoplasts by the PEG method, and after two days of incubation the expressed NP was detected by DAS-ELISA using antibodies against the whole TSWV-BL virion . High levels of NP were produced in tobacco protoplasts harboring the NP gene in plasmid pB1525-NP$^+$; while no NP was detected in tobacco protoplasts transformed with the antisense NP sequence (pB1525-NP$^-$).

As described previously, the PCR-engineered insert of clone pBI525-NP$^+$ and teh cDNA insert of the clone pTSWV-23 were subjected to double stranded sequencing. The sequence analysis of the cDNA and the PCR clones revealed inserts of 1.71 kb and 865 bp, respectively which, when compared with the sequence TSWV-CPNH1 S RNA, shows that cDNA insert of clone pTSWV-23 includes about 760 bp of the 52 K

protein viral component gene, the complete intergenic region (492 bp), and 450 bp of the NP gene (about one-half of the gene). This cloned insert has its 3'-end located exactly at an *Eco*RI recognition site suggesting incomplete *Eco*RI methylation during the cDNA cloning procedure. Although this clone does not contain the complete TSWV-BL NP gene, its sequence is of considerable importance since it has a 450 bp overlap with the sequence of the PCR-engineered NP gene. The sequence comparison between this TSWV-BL PCR-engineered and TSWV-CPNH1 NP genes reveals a total of 21 nucleotide differences (2.7%), eight of which encode amino acid replacements (3.1%). Since this PCR-engineered NP gene was obtained using *Taq* polymerase, which is known to incorporate mutations, it is possible that some of these differences were introduced during PCR amplification. However, 15 of these nucleotide differences are located within the overlapping region between the TSWV-BL cDNA and PCR clones, and all but one of these differences (position 1702) are present in both TSWV-BL S RNA derived clones. This comparison clearly shows that the PCR amplification did not contribute greatly, if at all, to the difference between the nucleotide sequences of these two NP genes. The nucleotide difference at position 1702 results in the amino acid replacement of Ile with Ser, and even this difference could be due to the lack of homogeneity within the TSWV-BL isolate.

The possibility that the nucleotide differences can be attributed to divergence among the TSWV isolates is also supported by comparisons with other sequenced regions among TSWV-CPNH1, TSWV-L3, and TSWV-Bl S RNAs. These comparisons are tabulated below:

Percent nucleotide and amino acid sequence differences for the comparison of TSWV S RNA component from isolates CPNH1, L3 and BL[a]

	52 K Protein Gene		Intergenic	NP Gene	
Comparison	Nucleotide	Amino Acid	Nucleotide	Nucleotide	Amino Acid
CPNH1/L3	68/1396[b](4.9)[c]	49/464(10.6)	46/511(9.0)	24/777(3.1)	4/258(1.6)
CPNH1/BL	21/758(4.1)	23/251(9.2)	26/496(5.2)	19/765(2.5)	8/255(3.1)
L3/BL	38/765(5.0)	20/254(7.9)	38/498(7.6)	19/767(2.5)	4/255(1.6)

[a] Comparisons are made using the sequence information available from the particular component region of TSWV-BL. The comparison for the TSWV-BL NP gene includes the combined sequence information from the cDNA clone, pTSWVS-23 and PCR-engineered insert.

[b] Comparison numbers are total differences (nucleotides or amino acids) divided by total number of positions (nucleotides or amino acids) compared. For both nucleotide and amino acid calculation gaps, regardless of length, were counted as one mismatch.

[c] Numbers in parentheses are percentages.

The nucleotide sequence of the NP genes from the CPNH1 and L3 isolates differ from each other by 3.1% and from the BL isolate by nearly a similar degree (2.5%). However, the NP amino acid sequences between CPNH1 and BL isolates differ by a considerably larger amount than they differ between the L3 and BL or CPNH1 and L3 isolates. The results tabulated above also reveal that the NP gene region of these TSWV isolates is subject to a higher degree of selective pressure than the 52 K protein as the differences among the amino acid sequences of the 52 K protein range between 7.9 to 10.6%, more than twice that found for the amino acid sequence of the NPs. Nucleotide sequence divergence is highest among the intergenic regions, indicating that this region is subject to less selective pressure than either genetic region.

The presence of NP gene sequences in transgenic plants was first confirmed by PCR analysis. A NP DNA fragment of about 800 bp was specifically amplified from the total DNAs of transgenic NP(+) plants using the primers homologous to sequences flanking the NP gene, whereas no corresponding fragment was detected in control NP(-) plants. Expression of the NP gene was assayed in each R_0 transgenic plant by DAS-ELISA, and the results are presented in the following table:

Reactions of R0 transgenic plants expressing the nucleocapsid protein (NP) gene of tomato spotted wilt virus (TSWV) to inoculation with TSWV-BL isolate

plant age	R0 clone	ELISA[a]	Lesions/leaf[b]	NP(+):NP(-)[c]
7-8 leaves:				
	NP(+)1	0.374	7 (199)	1:28
	NP(+)2	0.015	0 (199)	0:199
	NP(+)3	0.407	23 (102)	1:4
	NP(+)4	0.386	2 (102)	1:51
	NP(+)5	0.023	0 (124)	0:124
	NP(+)6	0.197	35 (325)	1:9
	NP(+)7	0.124	1 (325)	1:325
9-10 leaves:				
	NP(+)8	0.344	36 (36)	1:1
	NP(+)9	0.327	2 (20)	1:10
	NP(+)10	0.406	34 (33)	1:1
	NP(+)11	0.156	5 (20)	1:4
	NP(+)12	0.133	9 (57)	1:6
	NP(+)13	0.144	2 (7)	1:4
	NP(+)14	0.040	0 (19)	0:19
	NP(+)16	0.053	0 (10)	0:10
5-6 leaves:				
	NP(+)20	0.487	203 (117)	2:1
	NP(+)21	0.042	0 (117)	0:117
	NP(+)22	0.142	0 (208)	0:208
	NP(+)23	0.317	223 (208)	1:1
	NP(+)24	0.051	0 (35)	0:35
	NP(+)25	0.286	13 (35)	1:3
	NP(+)26	0.037	0 (22)	0:22
	NP(+)27	0.425	305 (22)	14:1

[a]production of the NP in transgenic plants was assayed by double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA); concentration of antibodies against viron for coating: 1 µg/ml; dilution of conjugate to the NP of TSWV-BL: 1:250; results taken 150 min. after adding substrate; readings at 405 nm.

[b]local lesions that developed on inoculated leaves were counted 7 days after inoculation. Data represent the average of three inoculated leaves. Data in parentheses are the number of lesions produced from control NP(-) plants inoculated with the same inoculum.

[c]the ratio of local lesions that developed on NP(+) plants transformed with pBIN19-

NP+ versus local lesions that developed on the control NP(-) plant when inoculated with the same inoculum.

Of the 23 NP(+) clones, 10 produced high levels of NP, 5 accumulated intermediate levels of NP, and the remaining 8 produced low levels of NP. The size of the NP expressed in transgenic plants was analyzed using Western blot. Many polypeptides from tobacco extracts were reactive to the antibodies against the whole viron even though the antibodies were pre-absorbed with extracts from healthy tobacco plants. Of those, only one band was unique to the pattern of polypeptides from tobacco plants transformed with the NP gene. This polypeptide was estimated to be around 29 kDa, which is near the expected size of the native NP. No antibody reactive-protein band of similar size was found in extracts from transgenic plants containing the vector pBIN19.

Inoculation of tobacco leaves with TSWV-BL isolate could result in either systemic infection or necrotic local lesions, depending upon weather conditions and physiological stages of plants. When R_0 plants were tested with TSWV-BL for viral resistance, TSWV-BL induced typical necrotic lesions on the inoculated leaves of control NP(-) plants 6-8 days after inoculation. However, transgenic NP(+) plants showed a spectrum of resistance to the virus when compared to control NP(-) plants. Eleven of the 23 NP(+) plants did not develop any local lesion or the number of lesions that developed was at least 20-fold less than that on the corresponding inoculated NP(-) plants. Three NP(+) plants had intermediate reactions (5- to 19-fold less lesions than controls) while the remaining 9 plants had low or no resistance. None of the inoculated NP(+) or NP(-) plants showed systemic infection. symptomless R_0 plants were monitored until the end of their life cycle, and no symptom was observed throughout their life cycles. The inoculated leaves of the symptomless NP(+) plants were checked for the presence of the virus on the leaves of *C. quinoa* plants. No virus was recovered from TSWV-BL-challenged leaves of highly resistant NP(+) plants, suggesting that the virus cold not replicate or spread in these NP(+) plants.

Leaf discs from selected R_0 plants were subcloned, and the regenerated plantlets were challenged by the virus. All subcloned R_0 plants displayed levels of resistance similar to their corresponding original R_0 plants.

Since TSWV is widespread and many biologically distant strains exist, the effectiveness of the transgenic plants to resist infections by different TSWV isolates were also tested. Five TSWV isolates were chosen in this study to challenge R1 plants germinated on kanamycin-containing medium: TSWV-BL, Arkansas, 10W pakchoy, Begonia and Brazil. The first three isolates were reactive to the antibodies against the whole virion and the NP of TSWV-BL (the common TSWV "L" serogroup) (see figure 5). Begonia isolate reacted strongly to the antibodies against the NP of TSWV-I (the "I" serogroup) but not to those raised against the TSWV-BL NP, and therefore belonged to the "I" serogroup. No detectable reaction of Brazil isolate was found to the antibodies against either the NP of the TSWV-BL or the TSWV-I serogroup, and it was weakly reactive to the antibodies against the whole viron of TSWV-BL. Moreover, this isolate caused systemic mottle and crinkle on the leaves of infected tobacco and *N. benthamiana*, but did not infect squash or cucumbers indicating that it is a distinct isolate from the cucurbit isolate. These results indicate that this isolate may be considered to be a third serogroup.

Seedlings derived from seven R_0 lines were germinated on kanamycin medium and inoculated with the above TSWV isolates. Infectivity data were recorded daily starting seven days after inoculation. Plants inoculated with TSWV-BL, Arkansas, 10W pakchoy or Brazil isolates were rated susceptible if virus symptoms were observed on uninoculated leaves. Plants inoculated with the Begonia isolate were rated susceptible if local lesions were observed on inoculated leaves, since this isolate does not cause systemic infection in tobacco. All inoculated control NP(-) R_1 plants were susceptible to infection by these five isolates. They were systemically infected 12 days after inoculation except that transgenic R_1 plants inoculated with Begonia produced only local lesions on the inoculated leaves. However, almost all NP(+) R_1 plants were highly resistant to the homologous

isolate TSWV-BL, while much lower percentages of NP(+) R_1 plants were resistant to heterologous isolates Arkansas, 10W pakchoy and Begonia. On the other hand, all NP(+) R_1 plants from the seven transgenic lines were susceptible to the Brazil isolate, even though a slight delay (1 to 2 days) in symptom expression was observed in some of the high NP-expressing NP(+) R_1 plants from line NP(+)4.

Resistant R_1 plants remained symptomless throughout their life cycles. The inoculated leaves of seventeen symptom less NP(+) plants were checked for the presence of the virus by back inoculation on leaves of *Chenopodium quinoa* plants. No virus was recovered from the inoculated leaves of symptomless NP(+) plants, suggesting that the virus could not replicate or spread in these NP(+) plants.

The relationship between the level of NP accumulation in transgenic plants and the degree of resistance to heterologous TSWV isolates was also studied. Analysis of the data described above suggested that R_1 plants derived from R_0 lines with low levels of NP offered the best resistance to the heterologous isolates of the "L" serogroup (Arkansas and 10W pakchoy) while R_1 from a R_0 line with high level of NP were resistant to the Begonia isolate, which belongs to the "I" serogroup. For example, an average 76% of inoculated R_1 plants from low NP expressing lines NP(+) 2, 14, and 21 were resistant to infections by the Arkansas and 10W pakchoy isolates, while resistance to these isolates was observed in only 11% of similarly inoculated plants from high NP expressing lines NP(+)4, 9, and 23. On the other hand, the Begonia isolate infected 79% of R_1 plants from the low NP expressing line NP(+)2, 14, and 21 but only 19% from high NP expressing line NP(+)4.

Therefore, it was concluded that the transgenic R_1 plants expressing low levels of the NP gene were highly resistant to infection with the isolate 10W pakchoy (the "L" serogroup), but not to Begonia isolate (the "I" serogroup). In contrast, the highly NP-expressing R_1 plants were very resistant to infection by Begonia isolate but not to infection by the isolate from 10W pakchoy.

Thus, it was of interest to accurately quantitate the relation of NP expression in individual plants with resistance to the heterologous

isolates. In a number of inoculation experiments reported herein, leaf samples of transgenic plants were taken before inoculating with the Arkansas and 10W pakchoy isolates. Samples were also taken from non-inoculated leaves of plants inoculated with the Begonia isolate after observations of the apparent relation between NP expression levels and resistance were made. The latter method of sampling could be done without interference from infection by the Begonia isolate because this isolate does not cause systemic infection in tobacco nor reacts with antibodies to the TSWV-BL NP. All samples were assayed for relative NP levels by DAS-ELISA using antibodies raised to isolated NP of TSWV-BL. Figures 5 and 6 show the relation between NP levels in transgenic R_1 plants (irrespective of the R_0 lines they came from) and their resistance to the Arkansas and 10W pakchoy isolates or to the Begonia isolate. Nearly all transgenic R_1 plants with very low or undetectable ELISA reactions (0-0.05 OD_{405nm}) were resistant to infections by the Arkansas and 10W pakchoy isolates (the "L" serogroup) but susceptible to the Begonia isolate (the "I" serogroup). In contrast, almost all R_1 plants that gave high ELISA reactions (0.4-1.0 OD_{405nm}) were resistant to the Begonia isolate but susceptible to the Arkansas and 10W pakchoy isolates.

The double-stranded (ds) RNA was isolated from the *N. benthamiana* plants infected with TSWV-B using a combination of methods [See Acta Horticulturae 186:51 (1986), and Can. Plant Dis Surv 68:93(1988)] which have been successfully used for isolation of dsRNA from tissue infected with grapevine leafroll virus. The dsRNA was chosen for the cDNA synthesis since isolation of the virus particle from this isolate has not been possible [see Plant Disease 74:154 (1990)]. In order to make a cDNA library specific to the S RNA of TSWV-B, the double stranded S RNA was gel-purified, denatured by methyl-mercury treatment, and subjected to cDNA synthesis procedure provided by Promega using random primers. The synthesized cDNA fragments were cloned via an EcoRI adaptor into the *Eco*RI digested λ ZAPII (Stratégene), and positive clones were identified by colony hybridization using the cDNA probes prepared by reverse transcription of gel-purified S RNA. Dozens of positive clones were analyzed on

agarose gels and only three overlapping clones containing the largest inserts (L1, L22 and L30) were selected (see figure 3), covering nearly entire TSWV-B S RNA.

The nucleotide sequences of the inserts in clones L1, L22 and L30 were determined from both DNA strands, first by the universal and reverse primers and then by the internal primers designed for sequencing the S RNA of TSWV-B. Sequencing was done using the Sanger dideoxyribonucleotide method, T7 polymerase (U.S. Biochemicals, Sequenase TM), and the double-stranded sequencing procedure described by Siemieniak [see Analyt. Biochem. 192:441 (1991)]. The sequence analyses of these clones revealed inserts of 1.994 kb, 2.368 kb and 1.576 kb, respectively, and these sequences represented 93% of the S RNA genome (see figure 3). The assembled sequence was analyzed by comparisons with sequences of TSWV isolates CONH1, L3, I, and BL using computer programs available from the Genetics Computer Group (GCG, Madison, WI).

Computer analysis showed that the assembled sequence of 2.842 kb covered the complete 52 K nonstructural protein gene, the complete intergenic region (629 bp), and 737 bp of the NP gene (only 39 N-terminal nucleotides of the N gene were not represented). In order to obtain this missing region of the N gene, a primer TTCTGGTCTTCTTCAAACTCA, identical to a sequence 62 nucleotides from the initiation codon of the N gene, was end-labeled with polynucleotide kinase to screen the cDNA library described above. Five putative clones were obtained. Sequence analysis of the five clones showed that only clones S6 and S7 contain these 39 missing nucleotides of the N gene. The latter clone also included the extreme 3' end of the S RNA.

The 5' extreme end of the S RNA was obtained using the 5' RACE System (GIBCO). Both ssRNA of TSWV-B and total RNAs isolated from tobacco plants infected with TSWV-B were used to synthesize first strand cDNA with an oligonucleotide (5'-CTGTAGCCATGAGCAAAG) complementary to the nucleotide positons 746-763 of te TSWV-B S RNA. The 3'-end of the first strand cDNA was tailed with dCTP using terminal deoxynucleotidyl transferase. Tailed cDNA was then amplified

by PCR using an anshor primer that anneals to the homopolymeric tail, and an oligonucleotide (5'-TTATATCTTCTTCTTGGA) that anneals to the nucleotide positions 512-529 of the TSWV-B S RNA. The PCR-amplified fragement was gel-purified and directly cloned into the T-vector pT7Blue (Novagen) for sequence analysis. Eight independent clones were sequenced with an oligomer primer (5'-GTTCTGAGATTTGCTAGT) close to the 5' region of the S RNA (nucleotide positions 40-57 of the TSWV-B S RNA). Six of the resulting clones contained the 5' extreme end of the S RNA and the 5'-terminal nucloetide sequence from these clones was identical. Thus, the complete nucleotide sequence of the TSWB-B S RNA is 3049 nucleotides in length.

Thus these two clones together with the three clones previously sequenced (L1, L22, L30, S6 and S7) covered a total of 3032 nucleotides depicted above. Comparisons with the terminal sequences of TSWV-CPNH1 and TSWV-I revealed that although the extreme 5' end of 18 nucleotides was not represented in the assembled sequence, the extreme 3'-terminus of the TSWV-B S RNA is identical to the extreme 3' end of the TSWV-I S RNA and is only one out of fifteen nucleotides different from the extreme 3' end of TSWV-CPNH1. The conservation of the terminal sequence among TSWV isolates is consistent with observations of the other members of *Bunyaviridae* genera, and supports the hypothesis that the terminal sequences might form stable base-paired structure, which could be involved in its replication and encapsulation.

The complete nucleotide sequence of the S RNA genome of TSWV-B (the Brazilian isolate discussed above) according to the present invention is:

AGAGCAATTG GGTCATTTTT TATTCTAAAT CGAACCTCAA CTAGCAAATC 50
TCAGAACTGT AATAAGCACA AGAGCACAAG AGCCACAATG TCATCAGGTG 100
TTTATGAATC GATCATTCAG ACAAAGGCTT CAGTTTGGGG ATCGACAGCA 150
TCTGGTAAGT CCATCGTGGA TTCTTACTGG ATTTATGAGT TTCCAACTGG 200
TTCTCCACTG GTTCAAACTC AGTTGTACTC TGATTCGAGG AGCAAAAGTA 250
GCTTCGGCTA CACTTCAAAA ATTGGTGATA TTCCTGCTGT AGAGGAGGAA 300
ATTTTATCTC AGAACGTTCA TATCCCAGTG TTTGATGATA TTGATTTCAG 350

CATCAATATC AATGATTCTT TCTTGGCAAT TTCTGTTTGT TCCAACACAG 400
TTAACACCAA TGGAGTGAAG GATCAGGGTC ATCTTAAAGT TCTTTCTCTT 450
GCCCAATTGC ATCCCTTTGA ACCTGTGATG AGCAGGTCAG AGATTGCTAG 500
CAGATTCCGG CTCCAAGAAG AAGATATAAT TCCTGATGAC AAATATATAT 550
CTGCTGGTAA CAAGGGATGT CTGTCCTGTG TCAAAGAACA TACTTACAAA 600
GTCGAAATGA GCCACAATCA GGGTTTAGGC AAAGTGAATG TTCTTTCTCC 650
TAACAGAAAT GTTCATGAGT GGCTGTATAG TTTCAAACCA AATTTCAACC 700
AGATCGAAAG TAATAACAGA ACTGTAAATT CTCTTGCAGT CAAATCTTTG 750
CTCATGGCTA CAGAAAACAA CATTATGCCT AACTCTCAAG CTTTTGTTAA 800
AGCTTGTACT GATTCTCATT TTAAGTTGAG CCTTTGGCTG AGAATTCCAA 850
AAGTTTTGAA GCAAATAGCC ATACAGAAGC TCTTCAAGTT TGCAGGAGAC 900
GAAACCGGTA AAAGTTTGTA TTTGTCTATT GCATGCATCC CAAATCACAA 950
CAGTGTGGAA ACAGCTTTAA ATGTCACTGT TATATGTAGA CATCAGCTTC 1000
CAATGCCTAA GTCCAAAGCT CCTTTTGAAT TATCAATGAT TTTCTCCGAT 1050
CTGAAAGAGC CTTACAACAC TGTGCATGAT CCTTCATATC CTCAAAGGAT 1100
TGTTCATGCT TTGCTTGAGA CTCACACTTC CTTTGCACAA GTTCTCTGCA 1150
ACAAGCTGCA AGAAGATGTG ATCATATATA CTATAAACAG CCCTGAACTA 1200
ACCCCAGCTA AGCTGGATCT AGGTGAAAGA ACCTTGAACT ACAGTGAAGA 1250
TGCTTCGAAG AAGAAGTATT TTCTTTCAAA AACACTCGAA TGCTTGCCAG 1300
TAAATGTGCA GACTATGTCT TATTTGGATA GCATCCAGAT TCCTTCATGG 1350
AAGATAGACT TTGCCAGAGG AGAGATCAGA ATCTCCCCTC AATCTACTCC 1400
TATTGCAAGA TCTTTGCTCA AGCTGGATTT GAGCAAGATC AAGGAAAAGA 1450
AGTCCTTGAC TTGGGAAACA TCCAGCTATG ATCTAGAATA AAAGTGGCTC 1500
ATACTACTCT AAGTAGTATT TGTCAACTTG CTTATCCTTT ATGTTGTTTA 1550
TTTCTTTTAA ATCTAAAGTA AGTTAGATTC AAGTAGTTTA GTATGCTATA 1600
GCATTATTAC AAAAAATACA AAAAAATACA AAAAAATACA AAAATATAA 1650
AAAACCCAAA AAGATCCCAA AAGGGACGAT TTGGTTGATT TACTCTGTTT 1700
TAGGCTTATC TAAGCTGCTT TTGTTTGAGC AAAATAACAT TGTAACATGC 1750
AATAACTGGA ATTTAAAGTC CTAAAAGAAG TTTCAAAGGA CAGCTTAGCC 1800
AAAATTGGTT TTTGTTTTTG TTTTTTTGTT TTTGTTTTT TTGTTTTATT 1850
TTTATTTTTA GTTTATTTTT TGTTTTTGTT ATTTTTATTT TTATTTTATT 1900
TTCTTTTATT TTATTTATAT ATATATCAAA CACAATCCAC ACAAATAATT 1950
TTAATTTCAA ACATTCTACT GATTTAACAC ACTTAGCCTG ACTTTATCAC 2000
ACTTAACACG CTTAGTTAGG CTTTAACACA CTGAACTGAA TTAAAACACA 2050
CTTAGTATTA TGCATCTCTT AATTAACACA CTTTAATAAT ATGCATCTCT 2100

GAATCAGCCT TAAAGAAGCT TTTATGCAAC ACCAGCAATC TTGGCCTCTT 2150
TCTTAACTCC AAACATTTCA TAGAATTTGT CAAGATTATC ACTGTAATAG 2200
TCCATAGCAA TGCTTCCCTT AGCATTGGGA TTGCAAGAAC TAAGTATCTT 2250
GGCATATTCT TTCCCTTTGT TTATCTGTGC ATCATCCATT GTAAATCCTT 2300
TGCTTTTAAG CACTGTGCAA ACCTTCCCCA GAGCTTCCTT AGTGTTGTAC 2350
TTAGTTGGTT CAATCCCTAA CTCCTTGTAC TTTGCATCTT GATATATGGC 2400
AAGAACAACA CTGATCATCT CGAAGCTGTC AACAGAAGCA ATGAGAGGGA 2450
TACTACCTCC AAGCATTATA GCAAGTCTCA CAGATTTTGC ATCTGCCAGA 2500
GGCAGCCCGT AAGCTTGGAC CAAAGGGTGG GAGGCAATTT TTGCTTTGAT 2550
AATAGCAAGA TTCTCATTGT TTGCAGTCTC TTCTATGAGC TTCACTCTTA 2600
TCATGCTATC AAGCCTCCTG AAAGTCATAT CCTTAGCTCC AACTCTTTCA 2650
GAATTTTTCT TTATCGTGAC CTTACCAAAA GTAAAATCAC TTTGGTTCAC 2700
AACTTTCATA ATGCCTTGGC GATTCTTCAA GAAAGTCAAA CATGAAGTGA 2750
TACTCATTTT CTTAATCAGG TCAAGATTTT CCTGACAGAA AGTCTTAAAG 2800
TTGAATGCGA CCTGGTTCTG GTCTTCTTCA AACTCAACAT CTGCAGATTG 2850
AGTTAAAAGA GAGACAATGT TTTCTTTTGT GAGCTTGACC TTAGACATGG 2900
TGGCAGTTTA GATCTAGACC TTTCTCGAGA GATAAGATTC AAGGTGAGAA 2950
AGTGCAACAC TGTAGACCGC GGTCGTTACT TATCCTGTTA ATGTGATGAT 3000
TTGTATTGCT GAGTATTAGG TTTTTGAATA AAATTGACAC AATTGCTCT 3049

The deduced amino acid sequences of the nonstructural (single underlined above) and nucleocapsid proteins according to the present invention are:

Met Ser Ser Gly Val Tyr Glu Ser Ile Ile Gln Thr Lys Ala Ser
5 10 15
Val Trp Gly Ser Thr Ala Ser Gly Lys Ser Ile Val Asp Ser Tyr
20 25 30
Trp Ile Tyr Glu Phe Pro Thr Gly Ser Pro Leu Val Gln Thr Gln
35 40 45
Leu Tyr Ser Asp Ser Arg Ser Lys Ser Ser Phe Gly Tyr Thr Ser
50 55 60
Lys Ile Gly Asp Ile Pro Ala Val Glu Glu Ile Leu Ser Gln
65 70 75
Asn Val His Ile Pro Val Phe Asp Asp Ile Asp Phe Ser Ile Asn
80 85 90
Ile Asn Asp Ser Phe Leu Ala Ile Ser Val Cys Ser Asn Thr Val
95 100 105
Asn Thr Asn Gly Val Lys His Gln Gly His Leu Lys Val Leu Ser
110 115 120

Leu Ala Gln Leu His Pro Phe Glu Pro Val Met Ser Arg Ser Glu
125 130 135
Ile Ala Ser Arg Phe Arg Leu Gln Glu Glu Asp Ile Ile Pro Asp
140 145 150
Asp Lys Tyr Ile Ser Ala Ala Asn Lys Gly Ser Leu Ser Cys Val
155 160 165
Lys Glu His Thr Tyr Lys Val Glu Met Ser His Asn Gln Ala Leu
170 175 180
Gly Lys Val Asn Val Leu Ser Pro Asn Arg Asn Val His Glu Trp
185 190 195
Leu Tyr Ser Phe Lys Pro Asn Glu Asn Gln Ile Glu Ser Asn Asn
200 205 210
Arg Thr Val Asn Ser Leu Ala Val Lys Ser Leu Leu Met Ala Thr
215 220 225
Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Phe Val Lys Ala Ser
230 235 240
Thr Asp Ser His Phe Lys Leu Ser Leu Gln Leu Arg Ile Pro Lys
245 250 255
Val Leu Lys Gln Ile Ala Ile Gln Lys Leu Phe Lys Phe Ala Gly
260 265 270
Asp Glu Thr Gly Lys Ser Phe Tyr Leu Ser Ile Ala Cys Ile Pro
275 280 285
Asn His Asn Ser Val Glu Thr Ala Leu Asn Val Thr Val Ile Cys
290 295 300
Arg His Gln Leu Pro Ile Pro Lys Ser Lys Ala Pro Phe Glu Leu
305 310 315
Ser Met Ile Phe Ser Asp Leu Lys Glu Pro Tyr Asn Thr Val His
320 325 330
Asp Pro Ser Tyr Pro Gln Arg Ile Val His Ala Leu Leu Glu Thr
335 340 345
His Thr Ser Phe Ala Gln Val Leu Cys Asn Lys Leu Gln Glu Asp
350 355 360
Val Ile Ile Tyr Thr Ile Asn Ser Pro Glu Leu Thr Pro Ala Lys
365 370 375
Leu Asp Leu Gly Glu Arg Thr Leu Asn Tyr Ser Glu Asp Ala Ser
380 385 390
Lys Lys Lys Tyr Phe Leu Ser Lys Thr Leu Glu Cys Leu Pro Val
395 400 405
Asn Val Gln Thr Met Ser Tyr Leu Asp Ser Ile Gln Ile Pro Ser
410 415 420
Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Arg Ile Ser Pro Gln
425 430 435
Ser Thr Pro Ile Ala Arg Ser Leu Leu Lys Leu Asp Leu Ser Lys
440 445 450

Ile Lys Glu Lys Lys Ser Leu Thr Trp Glu Thr Ser Ser Tyr Asp
455 460 465
Leu Glu;

and

Met Ser Lys Val Lys Leu Thr Lys Glu Asn Ile Val Ser Leu Leu
5 10 15
Thr Gln Ser Ala Asp Val Glu Phe Glu Glu Asp Gln Asn Gln Val
20 25 30
Ala Phe Asn Phe Lys Thr Phe Cys Gln Glu Asn Leu Asp Leu Ile
35 40 45
Lys Lys Met Ser Ile Thr Ser Cys Leu Thr Phe Leu Lys Asn Arg
50 55 60
Gln Gly Ile Met Lys Val Val Asn Gln Ser Asp Phe Thr Phe Gly
65 70 75
Lys Val Thr Ile Lys Lys Asn Ser Glu Arg Val Gly Ala Lys Asp
80 85 90
Met Thr Phe Arg Arg Leu Asp Ser Met Ile Arg Val Lys Leu Ile
95 100 105
Glu Glu Thr Ala Asn Asn Glu Asn Leu Ala Ile Ile Lys Ala Lys
110 115 120
Ile Ala Ser His Pro Leu Val Gln Ala Tyr Gly Leu Pro Leu Ala
125 130 135
Asp Ala Lys Ser Val Arg Leu Ala Ile Met Leu Gly Gly Ser Ile
140 145 150
Pro Leu Ile Ala Ser Val Asp Ser Phe Glu Met Ile Ser Val Val
155 160 165
Leu Ala Ile Tyr Gln Asp Ala Lys Tyr Lys Glu Leu Gly Ile Glu
170 175 180
Pro Thr Lys Tyr Asn Thr Lys Glu Ala Leu Gly Lys Val Cys Thr
185 190 195
Val Leu Lys Ser Lys Gly Phe Thr Met Asp Asp Ala Gln Ile Asn
200 205 210
Lys Gly Lys Glu Tyr Ala Lys Ile Leu Ser Ser Cys Asn Pro Asn
215 220 225
Ala Lys Gly Ser Ile Ala Met Asp Tyr Tyr Ser Asp Asn Leu Asp
230 235 240
Lys Phe Tyr Glu Met Phe Gly Val Lys Lys Glu Ala Lys Ile Ala
245 250 255
Gly Val Ala

As the nucleocapsid protein gene depicted above is on the viral complementary strand, the nucleocapsid protein gene of TSWV-B is:

ATG TCT AAG GTC AAG CTC ACA AAA GAA AAC ATT GTC TCT CTT TTA 45
ACT CAA TCT GCA GAT GTT GAG TTT GAA GAA GAC CAG AAC CAG GTC 90

GCA TTC AAC TTT AAG ACT TTC TGT CAG GAA AAT CTT GAC CTG ATT 135
AAG AAA ATG AGT ATC ACT TCA TGT TTG ACT TTC TTG AAG AAT CGC 180
CAA GGC ATT ATG AAA GTT GTG AAC CAA AGT GAT TTT ACT TTT GGT 225
AAG GTC ACG ATA AAG AAA AAT TCT GAA AGA GTT GGA GCT AAG GAT 270
ATG ACT TTC AGG AGG CTT GAT AGC ATG ATA AGA GTG AAG CTC ATA 315
GAA GAG ACT GCA AAC AAT GAG AAT CTT GCT ATT ATC AAA GCA AAA 360
ATT GCC TCC CAC CCT TTG GTC CAA GCT TAC GGG CTG CCT CTG GCA 405
GAT GCA AAA TCT GTG AGA CTT GCT ATA ATG CTT GGA GGT AGT ATC 450
CCT CTC ATT GCT TCT GTT GAC AGC TTC GAG ATG ATC AGT GTT GTT 495
CTT GCC ATA TAT CAA GAT GCA AAG TAC AAG GAG TTA GGG ATT GAA 540
CCA ACT AAG TAC AAC ACT AAG GAA GCT CTG GGG AAG GTT TGC ACA 585
GTG CTT AAA AGC AAA GGA TTT ACA ATG GAT GAT GCA CAG ATA AAC 630
AAA GGG AAA GAA TAT GCC AAG ATA CTT AGT TCT TGC AAT CCC AAT 675
GCT AAG GGA AGC ATT GCT ATG GAC TAT TAC AGT GAT AAT CTT GAC 720
AAA TTC TAT GAA ATG TTT GGA GTT AAG AAA GAG GCC AAG ATT GCT 765
GGT GTT GCA TAA 777

The compete S RNA of TSWV-B should be 3049 nucleotides in length, 134 nucleotides longer than S RNA of TSWV-CPNH1. This difference was mainly attributed to the elongated intergenic region of the TSWV-B S RNA. Analysis of the sequenced region of TSWV-B S RNA revealed two open reading frames as depicted above, which is similar to other TSWV isolates. The larger one was localized on the viral RNA strand originating at nucleotide 88 and terminating at nucleotide 1491. The smaller one on the vial complementary strand was defined by an initiation codon at nucleotide 2898 and a termination codon at nucleotide 2122. The two open reading frames were separated by an intergenic region of 629 nucleotides. Comparisons of the entire sequenced TSWV-B S RNA with S RNA regions of other isolates in the following table which depicts the percent homology comparison of aligned nucleotide and amino acid sequences of the TSWV-B S RNA with those of the other isolates:

	Overall	53 K protein gene		Intergenic	29 K protein gene	
Comparisons[a]	nt	nt	aa	nt	nt	aa
B/CPNH1	76.4[b]	80.0	86.1(78.3)[c]	72.4	77.5	91.5(79.1)
B/L3	75.8	79.0	89.0(82.0)	76.4	78.0	91.1(79.9)
B/BL	76.3	-	-	72.8	77.6	90.3(79.5)
B/I	63.0	-	-	-	63.1	69.7(55.3)
CPNH1/L3	94.8	95.6	92.0(89.4)	89.2	96.8	99.6(98.5)
CPNH1/BL	96.4	-	-	95.9	97.2	98.8(96.9)
CPNH1/I	62.7	-	-	-	60.8	69.5(55.1)
L3/BL	95.1	-	-	92.6	97.3	99.2(98.5)
L3/I	60.9	-	-	-	60.9	69.5(55.1)
I/BL	61.7	-	-	-	60.9	68.8(53.9)

a The partial or complete S RNA sequences of isolates TSWV-CPNH1 (2.916 kb), TSWV-L3 (2.837 kb), TSWV-BL (2.037 kb) and TSWV-I (1.144 kb) were used for comparisons with the S RNA sequence of the TSWV-B (3.049 kb).

b Percent similarities were calculated by Comparison of their nucleotide or predicted amino acid sequence using the program BESTFIT of the GCG Sequence analysis software package.

c Percent identity is in parenthesis.

As depicted, the greatest nucleotide sequence similarity (75.8%-76.4%) was shown with the L-type isolates (CHNH1, L3 and BL). To the lesser extent, there was nucleotide sequence similarity (63%) between the TSWV-B S RNA and the S RNA of TSWV-I assigned to I serogroup. For comparison, the sequenced S RNA regions of the L-type isolates (CHPN1, L3 and BL) shared 94.8%-96.4% nucleotide sequence similarities.

The open reading frame of 777 nucleotides encodes the N protein of 258 amino acids with a predicted molecular weight of 28700 Da. the sequence comparisons of the N open reading frame from TSWV isolates revealed that nucleotide sequences of the N genes from the isolates CPNH1, L3 and BL differs from TSWV-B by a considerably larger amount (22%-22.5%) than they differ from each other (2.7%-3.2%). Consistent to the results of the immunological analysis, the N amino acid sequences among CPNH1, L3 and BL isolates are more closely related to each other (98.8%-99.6% similarities or 96.9%-98.5% identities) than to

the TSWV-B (90.3%-91.5% similarities or 79.1%-79.9% identities). Much lower homology was observed to TSWV-I at both nucleotide (63.1%) and amino acid (69.7% similarity or 55.3% identity) levels. Except for the N open reading frame of TSWV-I that encodes 262 amino acids, the N open reading frames of the other isolates code for the 258 amino acids. Computer analysis suggested that the extra residues of TSWV-I N open reading frame resulted from the amino acid sequence insertions (residues 82 through 84 and residue 116). One potential N-glycosylation site is found at residue 68.

The second open reading frame of 1404 nucleotides encodes the nonstructural protein of 467 amino acids with a predicted molecular weight of 52566 Da. Comparisons with homologous open reading frames of TSWV-CPNH1 and TSWV-L3 showed 80% and 79% similarities at the nucleotide level, and 86.1% (or 78.3% identity) and 89% (or 82.0% identity) similarities at the amino acid level. This open reading frame contains four potential glycosylation sites, which are located in the exactly same positions as those of TSWV-CPNH1 and TSWV-L3.

The intergenic region of the TSWV-B S RNA was, due to several insertions, 126 and 41 nucleotide longer than the counterparts of TSWV-CPNH1 and TSWV-L3, respectively. The sequence analysis by the program FOLD indicated the intergenic region can form very complex and stable hairpin structure by internally base-pairing U-rich stretches with A-rich stretches of the intergenic region, which had similar stability to those produced from TSWV-CPNH1 and TSWV-L3 as indicated by minimum free energy values. This internal base-paired structure may act as a transcription termination signal.

The results tabulated above also revealed that the N protein of TSWV-B is subject to a higher degree of selective pressure than the 52 K protein; the similarities among the amino acid sequences of the 52 K protein are lower than that found for the amino acid sequence of the NPs. Nucleotide sequence divergence is highest among the intergenic regions, which indicates that this region is subject to less selective pressure than either genetic region.

The evolutionary relationships among the TSWV-B and other four TSWV isolates were analyzed and depicted in figure 4 in which the

evolutionary tree organization is consistent with the relatedness of serological data collected for these TSWV isolates. Thus, the TSWV-B, according to the present invention, is more closely related to the L-type isolates than to the I-type isolate TSWV-I, but is much less similar to the L-type isolates than the L-type isolates are to each other.

Despite a slight delay of symptom expression, transgenic plants did not show resistance to the Brazil isolate of TSWV; Serological results show that this isolate is distinct from the "L" and "I" type isolates, and biologically different from the curcurbit isolate. The Brazil isolate may thus belong to still another serogroup of TSWV. In any event. infectivity results show that it is unlikely that a single NP gene will provide resistance to all isolates in the Tospovirus genus.

Transgenic plants according to the present invention that gave low or undetectable ELISA reactions (0-0.05 OD_{405nm}) were resistant to infection by the heterologous isolates (Arkansas and 10W pakchoy) of the "L" serogroup, whereas no protection against these isolates was found in plants accumulating high levels of the NP. Compared to the ELISA readings of control NP(-) plants (0.05 OD_{405nm}), these transgenic plants may produce little, if any, TSWV-BL NP. Similar results have been observed in transgenic plants, in which the CP accumulation was not detected; these were highly resistant to virus infection. The mechanism underlying this phenomenon is presently unknown. It is likely that this type of resistance might be attributed to interference of CP RNA molecules produced in transgenic plants with viral replication, presumably by hybridizing to minus-sense replicating RNA of the attacking virus, binding to essential host factors (e.g., replicase) or interfering with virion assembly.

It should be noted, however, that the resistance to the homologous TSWV-BL isolate is apparently independent of the expression levels of the NP gene. Although the relative NP levels of the individual R_1 plants inoculated with TSWV-BL were not measured, it is reasonable to assume that the NP produced in these inoculated R_1 plants (a total of 145 plants tested) ranged from undetectable to high.

In contrast to the case for protection against the heterologous isolates of the "L" serogroup, protection against the Begonia isolate of the TSWV-I serogroup was found in the high NP-expressing R_1 plants. Comparison of NP nucleotide sequence of the "L" serogroup with that of the "I" serogroup revealed 62% and 67% identity at the nucleotide and amino acid levels, respectively. The difference of NP genes of the two serogroups might be so great that the NP (the "L" serogroup) produced in transgenic plants acted as a dysfunctional protein on the attacking Begonia isolate of the "I" serogroup. Incorporation of this "defective" coat protein into virions may generated defective virus which inhibit virus movement or its further replication. This type of interaction is expected to require high levels of the NP for the protection. Alternatively, resistance to the Begonia isolate may also involve interference of NP transcripts produced in R_1 plants with viral replication. If this is true, more NP transcripts (due to the heterologous nature of two NP gene) may be required to inhibit replication of heterologous virus.

Although there are no obvious explanations for the results showing the relation of NP levels in individual R_1 plants to resistance to the heterologous isolates of the "L" and "I" serogroups, it is believed these are definite trends since the data were derived from a large number (190) of plants. Thus, it is believed that a measurement of CP or NP levels in individual plants may provide a more accurate way to relate NP or CP levels to resistance. By this form of data analysis, the results show that the resistance was more closely related to NP levels in each test plant than to the NP level of the R_0 line from which they were derived. For TSWV-BL Np gene in tobacco, at least, it appears that integration sites of the NP gene in plant chromosome may not be important for viral resistance.

Studies have also been conducted to determine the reaction of transgenic R_1 and R_2 tomatoes containing the nucleocapsid protein gene of TSWV-BL according to the present invention to the following isolates: Brazil (a distantly related virus), T91 (a closely related virus) and BL (a homologous isolate). In these studies, transgenic tomatoes (*L. esculentum*) were produced by *A. tumefaciens*-mediated gene transfer

of the nucleocapsid protein (N) gene of the lettuce isolate of tomato spotted wilt virus BL into germinated cotyledons using modifications of published procedures [see Plant Cell Reports 5:81 (1986)]. The tomato line "Geneva 80" was selected for transformation because it contains the Tm-22 gene which imparts resistance to TMV, thus creating the possibility of producing a multiple virus-resistant line.

Transformants were selected on kanamycin media and rooted transgenic tomatoes were potted and transferred into the greenhouse. R_1 and R_2 tomato seedlings expressed the NPT II gene, suggesting multiple insertions of this gene in the plant genome. In contrast, only 18% of the seedlings produced detectable levels of the N protein.

Nine R_1 and three R_2 lines were tested for resistance to the following three *Tospovirus* described, specifically TSWV-BL, TSWV-T91, and TSWV-B. Infectivity was based upon visual inspection of test plants. In those cases where plants appeared healthy except for a few rust-colored rings or insect damage, extracts from these plants were inoculated to N. benthamiana to test for the presence of the virus. As depicted in the following table, nearly all control tomato plants exhibited typical symptoms consisting of plant stunting, leaf yellow mosaic and rugosity 3 to 4 weeks after inoculations with TSWV-BL, TSWV-T91 or TSWV-B. However, only 4% of the R_1 and R_2 transgenic plants became infected with TSWV-BL, 7% with TSWV-T91, and 45% with TSWV-B.

Viral resistance in transgenic R1 and R2 tomatoes expressing the nucleoprotein gene of the lettuce strain of tomato spotted wilt virus

Plant Line	Inoculating Isolates[a] TSWV-BL	TSWV-T91	TSWV-B
R1 Plants:			
T13-1	0/22	1/26	7/24
T13-2	6/20	NT[b]	NT
T13-3	2/42	0/20	12/18
T13-4	0/25	NT	NT
T13-9	0/20	NT	NT
T13-10	1/50	2/26	11/26
T13-11	0/22	NT	NT
T13-12	1/29	NT	NT
T13-13	0/22	NT	NT
TOTAL	10/252	3/72	30/68
R2 Plants:			
T13-1-7	0/8	2/8	5/8
T13-1-9	0/8	1/8	2/8
T13-1-11	0/8	1/9	5/9
TOTAL	0/24	4/25	12/25
CONTROLS	92/95	51/53	52/53

a plants were inoculated at the one- to two-leaf stage with 5-, 10-, or 20-fold diluted leaf extract of N. benthamiana, H423 tobacco or tomato; the same plants were re-inoculated 7 days later and symptoms were recorded after another 14 days; the reaction is expressed as number of plants with symptoms/number of plants tested

b not tested

Accordingly, the description above supports the finding that transgenic tomato plants that express the N gene of TSWV-BL show resistance to infection to TSWV-BL, to other TSWV isolates that are closely related to TSWV-BL, and to the more distantly related TSWV-B.

In further limited studies with an additional isolate, all transgenic plants were resistant to the 10W (pakchoy) isolate, whereas the controls were infected. These results show that transgenic tomatoes are better protected against closely related isolates than distantly related isolates. Unlike in transgenic tobacco and *N. benthamiana* expressing the TSWV-BL N gene, the level of N protein expression did not correlate with the observed protection in transgenic

tomatoes; 55% of the transgenic tomatoes were also resistant to a distantly related isolate of TSWV-B, which was not observed in transgenic tobacco and *N. benthamiana* plants. These discrepancies may reflect that tomato is inherently less susceptible to *Tospoviruses*.

In addition, studies were also conducted to determine virus distribution in a small number of plants at 5 and 7 weeks after inoculation. The distal halves from leaflets of all expanded leaves of each plant were ground and back-inoculated onto *N. benthamiana*. The results taken seven days after inoculation showed that virus cannot be recovered from any leaf tissue of asymptomatic transgenic plants inoculated with either TSWV-BL. -T91, or -B, confirming the visual findings reported above. In transgenic plants showing symptoms, the virus is not distributed throughout the plant. For example, a transgenic plant which could not be conclusively rated visually contained the virus in only two of the 8 leaves; the second leaves from the bottom and top of the plant. Conversely, virus present in all leaves of the infected control plant, and is absent in those of the healthy control plants.

Graft inoculations were attempted to test whether the resistant transgenic plants could become infected if virus is introduced into the vascular system. R_1 and R_2 plants that had been inoculated at 1:5, 1:10 or 1:20 dilutions of TSWV-BL, -T91, or -B were grafted onto control plants infected with the same isolates and dilutions. The 34 transgenic plants were asymptomatic after 31 days, although the non-transgenic controls were infected. After 23 days, the top 46 cm of transgenic plants had been trimmed away to induce new growth and more plant stress. Although the young, vigorously growing new shoots failed to show any symptoms on the 31st day post inoculation, 33%, 31% and 45% of TSWV-BL, -T91 and -B were showing leaf or stem symptoms, respectively at 45 days post inoculation. These results indicate that some transgenic plants are tolerant, and others are immune to infection.

Thus, according to one aspect of the present invention, transgenic plants expressing the NP gene of the TSWV-BL isolate are highly resistant to infections of both the homologous TSWV-BL isolate and heterologous isolates of the same serogroup (Arkansas and 10W

pakchoy). More significantly, the resistance is effective to Begonia isolate from other serogroups. In brief, the above clearly describes that transgenic tobacco plants expressing the nucleoprotein gene of TSWV-BL display resistance to both TSWV and INSV, and the protection appears to be mediated by the nucleoprotein against distantly related INSV and by the nucleoprotein gene ribonucleotide sequence against the homologous and closely related TSWV isolates. This is the first time broad spectrum resistance of the engineered plants to different isolates of TSWV has been shown.

While coat protein protection generally displays delay and/or reduction in infection and symptom expression, but no immunity, the present invention provided a significantly high percentage of transgenic plants which were symptom-free and free of the infective virus. Resistance of these plants under greenhouse conditions persisted throughout their life cycle, and more importantly was inherited to their progenies as shown above.

It was observed in the present invention that the transgenic plants producing little, if any, TWSV-BL NP were highly resistant to infection by the homologous isolate and other closely-related isolates within the same serogroup of TSWV, whereas no protection was found in those expressing high levels of the NP gene.

The biological diversity of TSWV is well documented and has been reported to overcome the genetic resistance in cultivated plants such as tomato. Thus, it is extremely important to develop transgenic plants that show resistant to many strains of TSWV. The present invention indicates that one method to do so would be to utilize the viral NP gene to confer this resistance, and that this resistance would be to diverse TSWV isolates. Thus, the finding of the present invention that the expression of TSWV NP gene is capable of conferring high levels of resistance to various TSWV isolates has a great deal of commercial importance.

In another series of studies, Plasmid BIN19-N$^+$ was constructed and transferred to *A. tumefaciens* strain LBA4404 in accordance with Example IV, and transferred to *Nicotiana benthamiana* in accordance

with Example V. The nucleocapsid genes of INSV-Beg and -LI were amplified with oligomer primers INSV-A (5'-TAGTTATCTAGAACCATGGACAAAGCAAAGATTACCAAGG) and INSV-B (5'-TAGAGTGGATCCATGGTTATTTCAAATAATTTATAAAAGCAC), hybridizing to the 5'-coding and 3'-noncoding regions of the nucleocapsid gene of an INSV isolate, respectively. The amplified nucleocapsid gene fragments were purified in accordance with Example III, and digested and sequenced in accordance with Example IV.

Of a total of 24 N+ (transformed with pBIN19-N+) and 18 N- (transformed with vector pBIN19) transgenic *N. benthamiana* plants were transferred to soil and grown in the greenhouse. All N+ lines were confirmed by PCR at leaf stages 4-5 to contain the N gene sequence. The relative level of N protein accumulation was estimated in each independent R_0 transgenic clonal line by DAS-ELISA using antibodies of the TSWV-BL N protein. Of the twenty-four N+ lines, two had OD_{405nm} readings of 0.50-1.00, seventeen between 0.02-0.10, and the remaining five less than 0.02. Healthy *N. benthamiana* or transgenic N- plants gave OD_{405nm} readings of 0.00-0/02. All the R_0 plants were self-pollinated and the seeds from the following transgenic lines were germinated on kanamycin (300 µg/ml) selection medium for inoculation tests: (1) N- -2 and -6, control transgenic lines containing vector pBIN19 alone; (2) N+-28, a transgenic line that produced an undetectable amount of the N protein (OD405nm = 0.005); (3) N+-21, a transgenic line producing a low level of the N protein (OD405nm = 0.085); and (4) N+-34 and -37, two transgenic lines accumulating high levels of the N protein (OD405nm = 0.50-1.00. These six lines were then analyzed by Northern hybridization; the intensity of N gene transcripts correlated well with the levels of ELISA reactions.

Transgenic seedlings from the six R_0 lines were selected by germinating seeds on kanamycin selection medium, and these seedlings were inoculated with the five *Tospoviruses*. The inoculated R1 plants were rated susceptible if virus symptoms were observed on uninoculated leaves. In order to exclude the possibilities of escapes, transgenic control N- plants were always used in each inoculation of transgenic N+ plants. In addition, each inoculum extract was always

used to first inoculate N+ plants followed by control N- plants. The results from this series of studies are depicted below:

Reactions of R_1 plants expressing the nucleocapsid (N) protein gene of *N. benthamiana* spotted wilt virus (TSWV) to inoculation with *Tospoviruses*

		No. plants infected/No. plants inoculated[b]				
		TSWV ISOLATE		INSV ISOLATE		
R0 Line	ELISA[a]	BL	10W	Beg	LI	TSWV-B
N--2/-6	<0.02	32/32	32/32	32/32	20/20	32/32
N+-28	0.005	16/16	16/16	15/16		16/16
N+-21	0.085	9/40	17/40	39/40	18/20	40/40
N+-34	0.715	25/28[c]	28/28	23/28[c]		28/28
N+-37	0.510	26/28[c]	22/22	21/28[c]	16/20[c]	22/22

[a]ELISA data of R_0 lines from which the R_1 plants were derived;

[b]30-fold diluted leaf extracts of infected N. benthamiana plants were applied to the three leaves of plants at the 3-5 leaf stages. Each extract was always used to inoculate N+ plants followed by control N- plants. Data were taken daily for at least two months after inoculation and expressed as number of plants systemically infected/number of plants inoculated;

[c]indicate that nearly all susceptible R1 plants displayed a significant delay of symptom appearance.

As depicted in the above table, all R1 plants from control lines N-2 and -6 showed systemic symptoms 5-8 days after inoculation with all the viruses tested. None of the R_1 plants from line N+-28 produced detectable levels of the N protein, and all were susceptible to these viruses except for one plant inoculated with INSV-Beg. ELISA assays of leaf discs from this N+-28 R_1 plant sampled before inoculation clearly showed that the plant identified to possess the INSV-Beg resistant phenotype did accumulate a high level of the N protein (OD_{405nm} = 0.78 as compared to OD_{405nm} <0.02 for all other N+-28 R_1 plants).

The low N gene expressing line N+-21 showed the best resistance against the homologous (78%) and closely related TSWV-10W (57%) isolates and very little resistance to the two INSV isolates (3% and 10%); only three N+-21 plants showed the resistant phenotype when inoculated with the INSV isolates. Leaf samples from these INSV-resistant N+-21 R_1 plants gave much higher ELISA reactions (OD_{405nm} 0.5 to 1.00) and thus higher amounts of the N protein than the

susceptible N^+-21 plants (OD_{405nm} 0.02 to 0.20). The high N gene expressing lines N^+-34 and -37 showed the highest resistance to INSV isolates (18%-25%) followed by the homologous TSWV-BL isolate (7% and 11%) while none of the plants showed resistance to TSWV-10W; however, the N^+-34 and -37 R_1 plants that became infected with INSV or TSWV-BL did show various lengths of delays in symptom expression. None of the R1 plants from these four transgenic N^+ lines were resistant to TSWV-B; some of the R1 plants from the N^+-34 and -37 lines showed a slight delay of symptom appearance

In studies to determine whether the level of N protein production in N^+ R_1 plants was associated with resistance to different *Tospoviruses*, the inoculated N^+ R_1 plants in the preceding table were re-organized into four groups based on the intensity of their ELISA reactions of tissues taken before inoculation irrespective of original R_0 pants. The N^+ R_1 plants that expressed low levels of the N protein (0.02-0.2 OD) showed high resistance (100% and 80%) to TSWV-BL and -10W but were all susceptible to INSV-Beg and -LI, showing no detectable delay in symptom expression relative to control N^- plants. In contrast, nearly all N^+ R1 plants with high levels of the N protein (0.20-1.00 OD) showed various levels of protection against TSWV-BL, INSV-Beg and -LI, ranging from a short delay of symptom expression to complete resistance with most of these plants showing various lengths of delay in symptom development relative to control N^- plants. No protection was observed in the high expressors against TSWV-10W. In addition, none of the N^+ R_1 plants were resistant to TSWV-B regardless of the level of N gene expression; however, a short delayed symptom appearance was observed in the N^+ R_1 plants producing high levels of the N protein. All control N^- R_1 plants and transgenic N^+ R_1 plants with undetectable ELISA reactions (0 to 0.02 OD) were susceptible to all the *Tospoviruses* tested.

The inhibition of replication of a distantly related INSV in N. benthamiana protoplasts expressing the TSWV-BL nucleocapsid gene was also studied. In these studies, whole INSV-LI virions were used to infect protoplasts that were isolated from three transgenic lines to investigate how the products of the transgene affect replication of the

incoming virus. Viral replication was determined by measuring the level of the N protein of the infecting INSV in transgenic protoplasts using antibodies specific to the INSV N protein. DAS-ELISA analysis showed that all progenies from a given line were relatively uniform and nearly all R_1 progeny gave an expression level of transgenic N gene similar to their parental transgenic line. These results allowed for the prediction of the expression level of R_1 populations based on that of their parental lines. Protoplasts derived from R_1 plants of the low expressor line N^+-21 supported the replication of INSV-LI whereas protoplasts from R_1 plants of the higher expressor line N^+-37 did not until 42 hours after inoculation at which low levels of viral replication were observed. The same protoplasts at various time intervals (e.g. 0, 19, 30 and 42 hours) were also assayed by DAS-ELISA using antibodies specific to the TSWV-BL N protein to monitor the expression level of the transgene. As expected, protoplast from N^+-21 R_1 plants produced relatively low levels (0.338-0.395 OD405nm) whereas protoplasts from N^+-37 R_1 plants accumulated high levels (0.822-0.865 OD_{405nm}). The expression level was found to be consistent at all time points.

In this aspect of the present invention it has been shown that transgenic *N. benthamiana* plants that accumulate low amounts of the TSWV-BL N protein are highly resistant to the homologous and closely related (TSWV-10W) isolates, while plants that accumulate high amounts of this protein posses moderate levels of protection against both the homologous and distantly related (INSV-Beg and INSV-LI) viruses. More importantly, these findings indicate that transgenic N. benthamiana plants (a systemic host of INSV) are protected against INSV-Beg and INSV-LI isolates.

As discussed above, we have shown that transgenic plants expressing the N gene of TSWV are resistant to homologous isolates, and that such plants expressing the TSWV-BL N gene are resistant to both TSWV and INSV. It has also been shown the best resistance to homologous and closely related isolates was found in transgenic plants accumulating low levels of N protein while transgenic plants with high levels of TSWV-BL N protein were more resistant to serologically distant INSV isolates. This observation led us to suspect the role of

the translated N protein product in the observed protection against homologous and closely related isolates and to speculate that either the N gene itself which was inserted into the plant genome or its transcript was involved in the protection. To test this hypothesis transgenic plants containing the promoterless N gene or expressing the sense or antisense untranslatable N coding sequence were produced. What was discovered was that both sense and antisense untranslatable N gene RNAs provided protection against homologous and closely related, isolates, and that these RNA-mediated protections were most effective in plants that synthesized low levels of the respective RNA species and appears to be achieved through the inhibition of viral replication.

More specifically, the coding sequences introduced into transgenic plants is shown in figure 7. As depicted, the construct pBIN19-N contains the promoterless N gene inserted into the plant transformation vector pBIN19 (see Example IV). All other constructs contain a double 35S promoter of CaMV, a 5'-untranslated leader sequence of alfalfa mosaic virus and a 3'-untranslated/polyadenylation sequence of the nopaline synthase gene. pBI525 is a plant expression vecor and is used in this study as a control; pBI525-mN contains the mutant (untranslatable) form of the N gene; pBI525-asN contains the antisense form of the untranslatable N gene. One nucleotide deletion at the 5'-terminus of the mutant N gene is indicated by the dash symbol. ATG codons are underlined and inframe termination codons in the mutant gene are shown in bold.

EXAMPLE VIII

Primer-directed mutagenesis and cloning of the TSWV-BL N gene was conducted as follows:

Full-length N gene was obtained by reverse transcription and polymerase chain reaction as described in Phytopathology 82:1223 (1992), the disclosure of which is incorporated *in toto* herein. The untranslatable N coding sequence was similarly generated by RT-PCR using oligomer primers A (AGCATTGGATCCATGGTTAACACACTAAGCAAGCAC), which is identical to the S RNA in the 3'-noncoding region of the TSWV-BL N gene, and B (AGCTAATCTAGAACCATGGATGACTCACTAAGGAAAGCATTGTTGC),

complementary to the S RNA in the 5'-terminus of the N gene. The latter oligomer primer contains a frameshift mutation immediately after the translation initiation codon and several termination codons to block possible translation readthroughs. The intact and mutant N gene fragments were purified on a 1.2% agarose gel as described in Example II. The gel-isolated intact and mutant N gene fragments were digested with the appropriate restriction enzyme(s) and directly cloned into BamHI/XbaI-digested plant transformation vector pBIN19 and NcoI-digested plant expression vector pBI525, respectively as described in Example IV. The resulting plasmids were identified and designated as pBIN19-N containing the intact, promoterless N gene, and pBI525-mN and pBI525-asN containing the mutant coding sequence in the sense and antisense orientations, respectively, relative to cauliflower mosaic virus 35S promoter. The translatability of the mutant N coding sequence in the expression cassette was checked by transient expression assay in *Nicotiana tabacum* protoplasts; and the expression cassettes containing the sense or antisense mutant N coding sequence were then excised from plasmid pBI525 by a partial digestion with HindIII/EcoRI (since the N coding sequence contains internal HindIII and EcoRI sites), and ligated into the plant transformation vector pBIN19 that had been cut with the same enzymes. The resulting vectors as well as pBIN19-N were transferred to *A. tumefaciens* strain LBA4404 using the procedure described in Example IV. Leaf discs of *N. tabacum* var Havana cv 423 were inoculated with the A. tumefaciens strain LBA4404 containing various constructs and the resulting transgenic plants were self-pollinated and seeds were selectively germinated on kanamycin medium.

PCR was performed on each R_0 transgenic line as described above. The oligomer primers A and B were used to determine the presence of the N coding sequence of TSWV-BL. The oligomer primer 35S-promoter (CCCACTATCCTTCGCAAGACCC) was combined with either the oligomer primer A or B to confirm the orientation (relative to the CaMV 35S promoter) of the mutant N coding sequence inserted into the plant genome. DAS-ELISA used to detect the N protein in transgenic plants was performed using polyclonal antibodies against the TSWV-BL

N protein. For an estimation of RNA transcript level in transgenic plants by Northern blot, total plant RNAs were isolated according to Napoli [see The Plant Cell 2:279 (1990)], and were separated on a formaldehyde-containing agarose gel (10 µg/lane). The agarose gels were then stained with ethidium bromide to ensure uniformality of total plant RNAs in each lane. Hybridization conditions were as described in the GeneScreen Plus protocol by the manufacturer. Resulting signal blots were compared and normalized based on the N gene transcript band of the control lane (the mN R_1 plant producing a high level of the N gene transcript) included in each blot. The transgenic plants that gave density readings (Hewlet ScanJet and Image Analysis Program) between 100 and 150 were rated as high expressors, while the plants with densities between 15 and 50 were rated as low expressors.

Inoculation of transgenic plants with *Tospovirus* was carried out as described above with inoculation being done at the 3-4 leaf stage except were indicated.

Tobacco protoplasts were prepared from surface-sterilized leaves derived from R_1 plants [see Z. Pflanzanphysiol. 78:453 (1992) with modifications]. The isolated protoplasts (6 x 10^6 protoplasts) were transformed with 0.68 OD_{260nm} of the purified TSWV-BL virion preparation using the PEG method [see Plant Mol. Biol. 8:363 (1987)]. The transformed protoplasts were then cultured at the final density of 1 x 10^6 protoplasts /ml in the culture medium at 26°C in the dark. After various intervals of incubation, the cultured protoplasts were washed twice with W5 solution and lysed by osmotic shock in the enzyme conjugate buffer. Viral multiplication (replication) was estimated by measuring the N protein of the virus using DAS-ELISA.

As described, one aspect of the present invention demonstrated that transgenic tobacco producing none or barely detectable amounts of the N protein were resistant to homologous and closely related isolates. This result suggested that the observed resistance may have been due to trans interactions of the incoming viral N gene RNA with either the N gene transcript produced in the transgenic plants or the N coding sequence itself. To test whether the presence of the nuclear N gene

plays a role, transgenic P°N R_0 lines and R_1 plants from two P°N lines were challenged with four *Tospoviruses* (TSWV-BL, TSWV-10W, INSV-Beg and TSWV-B). Only asymptomatic plants were rated resistant while plants showing any symptoms were rated susceptible. All inoculated R_0 and R_1 plants were susceptible to the viruses.

To further test the possibility that the transcript of the N transgene is involved in the protection, a number of R_0 transgenic plants that produced either the sense or the antisense N gene transcript but not the N protein were inoculated with the homologous isolate. Results appear in the following table:

Form of transgene[a]	Level of N gene RNA[b]	No. of R0 lines tested	No. of lines inoculated[c]	No. of lines resistant
mN	H	8	4	0
	L	17	16	16
	nd	4	1	0
asN	H	6	3	0
	L	9	5	5
	nd	1	0	0
P°N	nd	12	6	0

[a]mN and asN represent plants expressing the sense and antisense untranslatable N genes, respectively, P°N represents plants containing the promoterless N gene;

[b]the level of the N gene RNA was estimated in each line by Northern blots, nd indicates that the N gene transcript was not detected;

[c]30-fold diluted leaf extracts of the N. benthamiana plants infected with TSWV-BL were applied to three leaves of each plant at the 6-7 leaf stage. Each extract was first applied to all test plants followed by control healthy plants. Data were taken daily for 45 days after inoculation and only the asymptomatic plants were rated resistant.

Unlike the controls, which developed typical systemic symptoms 7 to 9 days after inoculation, 16 out of 21 mN plants and 5 our of 8 asN plants were asymptomatic throughout their life cycles. Northern blot analysis of leaf tissues sampled before inoculation showed that all the resistant R_0 lines produced low levels of the sense or antisense N gene RNA, whereas the susceptible R_0 lines produced either none or high levels of the RNA species. Since this data suggested that the resistance of transgenic plants to TSWV-BL was related to their relative levels of N gene transcript, transgenic progenies from four mN

and three asN R_0 lines with either high or low N gene transcript levels were selected by germination on kanamycin-containing media. These transgenic plants were tested for resistance to the four *Tospoviruses* at the 3 to 4 leaf stage, except that some R_1 plants from two asN lines were inoculated at the 6 to 7 leaf stage. The results are summarized in the following table:

R_0 Line	N gene RNA[a]	TSWV-BL	TSWV-10W	INSV-Beg	TSWV-B
Promoterless N gene					
P°N-1	nd	10/10	10/10	10/10	10/10
P°N-2	nd	15/15	10/10	10/10	10/10
N°-3	nd	8/8	6/6	6/6	6/6
Untranslatable N gene					
mN-2	H	20/20	20/20	20/20	20/20
mN-7	H	20/20	20/20	20/20	20/20
mN-13	L	2/20	4/20	20/20	20/20
mN-18	L	4/20	1/20	20/20	20/20
N°-3	nd	24/24	32/32	24/24	24/24
Antisense N gene					
asN-1	L	20/20[b]	20/20	20/20	20/20
asN-4	H	20/20 (16/16)[c]	20/20 (16/16)	20/20	20/20
asN-9	L	19/20 (3/41)	20/20 (5/21)	20/20	20/20
N°-3	nd	16/16 (32/32)	16/16 (20/20)	16/16	16/16

[a]Northern analysis of R_0 lines from which the R_1 plants were derived (see preceding table);

[b]the underlined fractions indicate that most of susceptible R_1 plants displayed a significant delay of symptom appearance;

[c]the fraction in parenthesis represents the inoculation data obtained from plants inoculated at the 6-7 leaf stage; the remaining data in this table were generated from plants inoculated at the 3-4 leaf stage; inoculated plants were observed daily for 45 days after inoculation.

All R_1 plants from high expressor lines mN-2 and mN-7 were susceptible to infections by all Tospoviruses tested, and these plants did not show a delay of symptom appearance as compared to controls. In contrast, high proportions of the R_1 plants from low expressor lines mN-13 and -18 were resistant to homologous (TSWV-BL) and closely related (TSWV-10W) isolates, but not resistant to infections by distantly related *Tospoviruses* (INSV-Beg and TSWV-B). The resistance of asN R_1 plants from low expressor R_0 lines was markedly influenced by the TSWV isolate used for inoculation. All but one of the small R_1 plants (3-4 leaf stage) from low expressor lines asN-1 and -9 became infected, although there was a delay of symptom appearance, when inoculated with the homologous TSWV-BL or closely related TSWV-10W isolates. In contrast, most of the large R_1 plants (6-7 leaf stage) from line asN-9 were resistant to both isolates. In comparison, control R_1 plants and R_1 plants from the high expressor line such as asN-4 displayed no resistance to either of the isolates regardless of the size of test plants. Antisense RNA-mediated protection was not effective against infection by the distantly related INSV-Beg and TSWV-B isolates.

Analyses of data presented in the above two tables suggest that sense and antisense RNA-mediated protections are observed only in low expressors of the N gene. The R1 asN plants that produced high levels of the antisense N gene transcript were as susceptible as control plants. In contrast, the asN low expressors displayed a delay in symptom appearance when inoculated at the 3-4 leaf stage and showed increased levels of resistant when inoculated at the 6-7 leaf stage.

Inhibition of viral replication in tobacco protoplasts expressing the sense or antisense form of untranslatable N coding sequence was also noted. In this instance, whole virion preparations of TSWV-BL were used to transfect protoplasts isolated from transgenic lines to investigate the effect of sense or antisense N gene transcript on replication of the incoming virus. Viral replication was determined by measuring the level of the N protein of the incoming virus in transfected protoplasts, and it was found that protoplasts derived from plants (mN-7 and asN-4) that produced high levels of the respective

RNA transcripts supported the replication of the virus, whereas protoplasts from mN low expressor (mN-18) did not. Protoplasts from an asN low expressor (asN-9) supported much lower levels of viral replication.

Accordingly, in this aspect of the present invention we have shown that transgenic plants expressing sense or antisense form of untranslatable N gene coding sequence are resistant to homologous (TSWV-BL) and closely related (TSWV-10W), but not to distantly related (INSV-Beg and TSWV-B) *Tospoviruses*. The following table provides a comparison of resistance to *Tospoviruses* between transgenic tobacco expressing various forms of the TSWV-BL N gene:

		Form of the Transgene[a]			
Tospovirus	Homology to TSWV-BL N Gene[b]	N	mN	asN	P°N
TSWV-BL	100%	R	R	R[c]	S
TSWV-10W	99%	R	R	R[c]	S
INSV-Beg	60%	R[c]	S	S	S
TSWV-B	78%	S	S	S	S

[a]reactions of transgenic tobacco and *N. benthamiana* plants expressing the intact N gene (N) of TSWV-BL to inoculation with the four *Tospoviruses* are included for comparisons with inoculation results of transgenic plants containing untranslatable (mN) , antisense (asN), and promoterless (P°N) N coding sequences , R = resistant, S = susceptible;

[b]the nucleotide sequences are as reported in Phytopathology 82:1223 (1992) and Phytopathology 83:728 (1993)

[c]level of resistance may depend upon the concentration of inoculum.

These results confirm and extend the earlier aspects of the present invention for RNA-mediated protection with TSWV. Furthermore, the protection is observed in plants producing low rather than high levels of the N gene transcript, and although earlier studies reported herein indicate that tobacco plants which produced high levels of the TSWV-BL N protein displayed resistance to INSV-Beg, this additional data indicates that since resistance to INSV-Beg was not observed in transgenic plants expressing the sense or antisense form of the untranslatable of the N gene thus clearly indicating that protection against INSV-Beg is due to the presence of the N protein and not the N gene transcript. Thus, it appears that two different mechanisms are

involved in protection transgenic plants against TSWV and INSV *Tospoviruses* according to the present invention. One mechanism involves the N gene transcript (RNA-mediated), and another involves the N protein (protein-medicated). In addition, the results of the protoplast experiments indicate that N gene RNA-mediated protection is achieved through a process that inhibits viral replication, and the data contained in the above tables suggest that protection against the distantly related INSV-Beg isolate is conferred by the N protein of TSWV-BI, and not by the gene transcript.

Finally, further studies were conducted to provide still another aspect of the present invention - that a portion of the Tospovirus nucleoprotein gene provide protection of transgenic plants against infection by the *Tospovirus*. It has already been demonstrated above that the N gene RNA protects against homologous and closely realated TSWV isolates while the N protein protects against the homologous isolate and distantly related INSV isolates; that N gene RNE-mediated protection is effective in plants expressing low levels of the N gene whereas N protein-mediated protection requires high levels of N protein accumulation; and that the N gene RNA-mediated protection is achieved through inhibition of viral replication. Based upon this prior data, we next set out to determine whether a portion of the N gene might work against infection by the virus. We found, as discussed below, that transgenic plants expressing about one-half of the N gene sequence is resistant to the virus.

The following describes the cloning of one-half N gene fragments of TSWV-BL in order to demonstrate this final aspect of the present invention. The first and second halves of both the translatable and untranslatable N gene were generqated by reverse transcription and then PCR as described above. As depicted in figure 8, the nucleotide deletion or insertions at the 5'-terminals of the untranslatable half N gene fragments are indicated by the dash symbol; ATG codons are underlined and all possible termination codons immediately after the initiation codon of the untranslatable half N gene fragments are shown in bold.

The first half of the N gene was produced by RT-PCR using oligoprimers I (5'-TAGAGTGGATCCATGGTTAAGGTAATCCATAGGCTTGAC), which is complementary to the central region of the TSWV-BL N gene, and II (5'-AGCTAAGCATGGTTAAGCTCACTAAGGAAAGCATTGTTGC) for the translatable or III (5'-AGGTAATCTAGAAGCATGGATGACTCACTAAGGAAAGCATTGTTGC) for the untranslatable first half N gene fragment, the latter two oligomer primers are identical to the 5'-terminus of the N gene. Similarly, ,the second half of the N gene was produced by RT-PCR using oligomer primers iv (5'-AGCATTGGATCCATGGTTAACACACTAAGCAAGCAC) which is complementary to the 3'-noncoding region of the TSWV-BL N gene, and v (5'-TACAGTTCTAGAACCATGGATGATGCAAAGTCTGTGAGG) for the translatable or vi (5'-AGATTCTCTAGACCATGGTGACTTGATGAGCAAAGTCTGTGAGGCTTGC) for the untranslatablesecond half N gene fragment, the latter two oligomer primers are identical to the central region of the N gene. The oligomer primer iii contains a frameshift mutation immediately after the translation codon and several termination codons to block possible translation readthroughs while the oligomer primer vi contains several inframe termination codons immediately after the translation initiation codon.

The half gene fragments were purified on a 1.2% agarose gel as described above, and the gel-isolated gene fragments were digested with the restriction enzyme *Nco*I and directly cloned into *Nco*I -digested plant expression vector pBI525. The resluting plasmids were identified and designated as (1) pBI525-1N containing the first half translatable N gene, (2) pBI525-1N' containing the first half untranslatable N gene, (3) pBI525-1N$^-$ containing the first half translatable N gene in the antisense orientation, (4) pBI525-2N containing the second half translatable N gene, (5) pBI525-2n' containing the second half untranslatable N gene, and (6) pBI525-2N$^-$ containing the second half translatable N gene in the antisense orientation. The expressin cassettes were then excised from plasmid pBI525 by digestion with *Hind*III/*Eco*RI and ligated as described above into the plant transformation vector pBIN19 that had been cut with the

same enzymes. The resulting vectors as well as plasmid pBIN19 were transferred to *A. tumefaciens* strain LBA4404, using the procedure described by Holsters supra. Leaf discs of N. benthamiana were inoculated with *A. tumefaciens* strain LBA4404 containing the various constructs. Transgenic plants were self-pollinated and seeds were selectively germinated on kanamycin as described above.

Analysis of transgenic plants by PCR and Northern hybridization PCR was performed on each R_0 transgenic line as described previously. The oligomer primers I to vi were used to determine the presence of the N coding sequence of TSWV-BL. The oligomer primer 35S-Promoter (see Example VIII) was combined with one of the above oligomer primers to confirm the orientation (relative to the CaMV 35S promoter) of the half gene sequences inserted into the plant genome. Northern analysis was conducted as described in Example VIII.

Lettuce isolate of TSWV (TSWV-BL) was used to challenge transgenic plants. Inoculation was done using test plants at the 3-4 leaf stage as described above. To avoid the possibility of escapes, control pants were used in each experiment and each inoculum extract was used to first inoculate the transgenic plants followed by control plants.

The various constructs used in this aspect of the present invention are illustrated in figure 8. Translatable and untranslatable half N gene fragemnts were synthesized by RT-PCR and then cloned directly into the plant expression vector pBI525. The oligomer primers iii and vi, used for generation of untranslatable half N gene fragments by RT-PCR, contains a mutation immediately after the translation initiation codon and the resulting reading frame contains several termination codons to block possible translation readthroughs. Thus, both first and second half untranslatable N gene fragments should be incapable of prodcing the truncated N protein fragments when introduced into plants. Both translatable and untranslatable half N gene fragements were then placed downstream of the CaMV 35S promoter of the vector pBI525 in the sense orientation or in the antisense orientation. The expressin of the half N coding sequences of TSWV-BL was thus controlled by a double CaMV 35S promoter fused to the 5'-

untranslated leader sequence of alfalfa mosaic virus (ALMV) of the expression vector pBI525. Expression vectors that utilize the stacked double CaMV 35S promoter elements are known to yield higher levels of mRNA trnscription than similar vectors with a single 35S promoter element. Expression cassettes were transferred from the vector pBI525 to the pant transformation vector pBIN19. The resluting plasmids as well as the control plasmid pBIN19 were then transferred into *A. tumefaciens* strain LBA4404. Transgenic plants were obtained with nomenclature of the transgenic lines shown in figure 8.

All the kanamycin-resistant transgenic lines were confirmed by PCR to contain the proper N coding sequences in the expected orientations. Each transgeinc R0 line which was grown for seeds was then assayed using Northern blot. Six out of six 1N, four out of six 1N', six out of six $1N^-$, six out of six 2N, seven out of eight 2N', and six out of seven $2N^-$ transgenic R_0 lines were found to produce half N gene RNAs.

A set of transgenic R_0 plants was challenged with the homologous isolate TSWV-BL. Only asymptomatic plants were rated resistant while the plants showing any symptom (local lesions or systemic infections) were rated susceptible. All the inoculated R_0 control plants were susceptible to the virus; in contrast, two out of nine 1N', two out of six $1N^-$, four out of ten 2N', and one out of eight $2N^-$ R_0 lines were found to be completely resistant to the virus infection. Although none of the 1N and 2N R_0 lines showed high levels of resistance, some of those plants displayed significant delays of symptom appearence.

Another set of transgenic R_0 lines was brought to maturity for seed production. Seedlings were germinated on kanamycin-containing medium and inoculated with TSWV-BL. As shown in the following table, control seedlings and seedlings from some of the transgenic lines were susceptible to the isolate whereas seedlings from lines 1N-151, 1N'-123, and 2N'-134 showed variojs levels of protection , ranging from delays in symptom expression to compete resistance.

	No. plants infected/No. plants inoculated		
R_0 line	6DPI	15DPI	30DPI
Control	50/50		
1N-149	17/17		
1N-151	2/20	13/20	17/20
1N'-123	16/20	17/20	17/20
1N'-124	20/20		
1N'-126	19/19		
1N"-130	12/15	15/15	
1N"-132	18/19	19/19	
2N-155	20/20		
2N'-134	0/20	10/20	10/20
2N'-135	19/19		
2N"-142	20/20		
2N"-143	20/20		

In the above table, 30-fold diluted extracts of infected *N. benthamiana* were used to inoculate transgenic plants at the 3-4 leaf stage followed by control transgenic plants. DPI = days post inoculation.

In summary, this aspect of the present invention shows that transgenic plants expressing the first or the second half of either translatable or untranslatable N gene fragment are highly resistant to the homologous TSWV-BL isolate. This result demonstrates that a portin of the N gene is sufficient for resistance to the virus.

A listing of all nucleotide and amino acid sequences described in the foregoing description of the present invention is as follows:

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Dennis Gonsalves and Sheng-Zhi Pang

(ii) TITLE OF INVENTION: Tomato Spotted Wilt Virus

(iii) NUMBER OF SEQUENCES: 30

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCAGGCAAA ACTCGCAGAA CTTGC 25

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCAAGTTCTG CGAGTTTTGC CTGCT 25

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGCTAACCAT GGTTAAGCTC ACTAAGGAAA GC 32

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGCATTCCAT GGTTAACACA CTAAGCAAGC AC 32

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2265 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAAGTTGAAA GCAACAACAG AACTGTAAAT TCTCTTGCAG TGAAATCTCT 50
GCTCATGTCA GCAGAAAACA ACATCATGCC TAACTCTCAA GCTTCCACTG 100
ATTCTCATTT CAAGCTGAGC CTCTGGCTAA GGGTTCCAAA GGTTTTGAAG 150

CAGGTTTCCA TTCAGAAATT GTTCAAGGTT GCAGGAGATG AAACAAACAA 200
AACATTTTAT TTATCTATTG CCTGCATTCC AAACCATAAC AGTGTTGAGA 250
CAGCTTTAAA CATTACTGTT ATTTGCAAGC ATCAGCTCCC AATTCGCAAA 300
TGCAAAGCTC CTTTTGAATT ATCAATGATG TTTTCTGATT TAAAGGAGCC 350
TTAGAACATT GTTCATGACC GTTCATACCC CAAAGGATCG GTTCCAATGC 400
TCTGGGTCGA AACTCAGACA TCTTTGCACA AGTTCTTTGC AACTAACTTG 450
CAAGAAGATG TAATCATCTA CACTTTGAAC AACCTTGAGC TAACTCCTGG 500
AAAGTTAGAT TTAGGTGAAA GAACCTTGAA TTACAGTGAA GATGCCTACA 550,
AAAGGAAATA TTTCCTTTCA AAAACACTTG AATGTCTTCC ATCTAACACA 600
CAAACTATGT CTTACTTAGA CAGCATCCAA ATCCCTTCAT GGAAGATAGA 650
CTTTGCCAGA GGAGAAATTA AAATTTCTCC ACAATCTATT TCAGTTGCAA 700
AATCTTTGTT AAAGCTTGAT TTAAGCGGGA TCAAAAAGAA AGAATCTAAG 750
GTTAAGGAAG CGTATGCTTC AGGATCAAAA TAATCTTGCT TTGTCCAGCT 800
TTTTCTAATT ATGTTATGTT TATTTTCTTT CTTTACTTAT AATTATTTCT 850
CTGTTTGTCA TCTCTTTCAA ATTCCTCCTG TCTAGTAGAA ACCATAAAAA 900
CAAAAAATAA AAATGAAAAT AAAATTAAAA TAAAATAAAA TCAAAAAATG 1000
AAATAAAAAC AACAAAAAAT TAAAAAACGA AAAACCAAAA AGACCCGAAA 1050
GGGACCAATT TGGCCAAATT TGGGTTTTGT TTTTGTTTTT TGTTTTTTGT 1100
TTTTTATTTT TTATTTTATT TTTATTTTAT TTTATTTTTA TTTTATTTTT 1150
ATTTTATTTA TTTTTTGTTT TCGTTGTTTT TGTTATTTTA TTATTTATTA 1200
AGCAGAACAC ACAGAAAGCA AACTTTAATT AAACACACTT ATTTAAAATT 1250
TAAGACACTA AGCAAGCACA AGCAATAAAG ATAAAGAAAG CTTTATATAT 1300
TTATAGGCTT TTTTATAATT TAACTTACAG CTGCTTTCAA GCAAGTTCTG 1350
CGAGTTTTGC CTGCTTTTTA ACCCCGAACA TTTCATAGAA CTTGTTAAGA 1400
GTTTCACTGT AATGTTCCAT AGCAACACTC CCTTTAGCAT TAGGATTGCT 1450
GGAGCTAAGT ATAGCAGCAT ACTCTTTCCC CTTCTTCACC TGATCTTCAT 1500
TCATTTCAAA TGCTTTGCTT TTCAGCACAG TGCAAACTTT TCCTAAGGCT 1550
TCCTTGGTGT CATACTTCTT TGGGTCGATC CCGAGGTCCT TGTATTTTGC 1600
ATCCTGATAT ATAGCCAAGA CAACACTGAT CATCTCAAAG CTATCAACTG 1650
AAGCAATAAG AGGTAAGCTA CCTCCCAGCA TTATGGCAAG TCTCACAGAC 1700
TTTGCATCAT CGAGAGGTAA TCCATAGGCT TGAATCAAAG GATGGGAAGC 1750
AATCTTAGAT TTGATAGTAT TGAGATTCTC AGAATTCCCA GTTTCTTCAA 1800
CAAGCCTGAC CCTGATCAAG CTATCAAGCC TTCTGAAGGT CATGTCAGTG 1850
CCTCCAATCC TGTCTGAAGT TTTCTTTATG GTAATTTTAC CAAAAGTAAA 1900
ATCGCTTTGC TTAATAACCT TCATTATGCT CTGACGATTC TTTAGGAATG 1950

TCAGACATGA AATAACGCTC ATCTTCTTGA TCTGGTCGAT GTTTTCCAGA 2000
CAAAAAGTCT TGAAGTTGAA TGCTACCAGA TTCTGATCTT CCTCAAACTC 2050
AAGGTCTTTG CCTTGTGTCA ACAAAGCAAC AATGCTTTCC TTAGTGAGCT 2100
TAACCTTAGA CATGATGATC GTAAAAGTTG TTATAGCTTT GACCGTATGT 2150
AACTCAAGGT GCGAAAGTGC AACTCTGTAT CCCGCAGTCG TTTCTTAGGT 2200
TCTTAATGTG ATGATTTGTA AGACTGAGTG TTAACGTATG AACACAAAAT 2250
TGACACGATT GCTCT 2265

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1709 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGCAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATCCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTACACCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900
TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050

TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTTTT AAGCACAACA CACAGAAAGCA AACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCACA AACAATAAA 1200
GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300
ATTTGATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCCTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650
TTGAATCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCC 1709

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 260 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gln Val Glu Ser Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys
5 10 15
Ser Leu Leu Met Ser Ala Glu Asn Asn Ile Met Pro Asn Ser Gln
20 25 30
Ala Ser Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Val
35 40 45
Pro Lys Val Leu Lys Gln Val Ser Ile Gln Lys Leu Phe Lys Val
50 55 60
Ala Gly Asp Glu Thr Asn Lys Thr Phe Tyr Leu Ser Ile Ala Cys
65 70 75
Ile Pro Asn His Asn Ser Val Glu Thr Ala Leu Asn Ile Thr Val
80 85 90
Ile Cys Lys His Gln Leu Pro Ile Arg Lys Cys Lys Ala Pro Phe
95 100 105
Glu Leu Ser Met Met Phe Ser Asp Leu Lys Glu Pro Tyr Asn Ile
110 115 120
Val His Asp Pro Ser Tyr Pro Lys Gly Ser Val Pro Met Leu Trp
125 130 135

Leu Glu Thr His Thr Ser Leu His Lys Phe Phe Ala Thr Asn Leu
140 145 150
Gln Glu Asp Val Ile Ile Tyr Thr Leu Asn Asn Leu Glu Leu Thr
155 160 165
Pro Gly Lys Leu Asp Leu Gly Glu Arg Thr Leu Asn Tyr Ser Glu
170 175 180
Asp Ala Tyr Lys Arg Asp Tyr Phe Leu Ser Lys Thr Leu Glu Cys
185 190 195
Leu Pro Ser Asn Thr Gln Thr Met Ser Tyr Leu Asp Ser Ile Gln
200 205 210
Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Lys Ile
215 220 225
Ser Pro Gln Ser Ile Ser Val Ala Lys Ser Leu Leu Lys Leu Asp
230 235 240
Leu Ser Gly Ile Lys Lys Lys Glu Ser Lys Val Lys Glu Ala Tyr
245 250 255
Ala Ser Gly Ser Lys
260

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 858 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTAACACACT AAGCAAGCAC AAACAATAAA GATAAAGAAA GCTTTATATA 50
TTTATAGGCT TTTTTATAAT TTAACTTACA GCTGCTTTTA AGCAAGTTCT 100
GTGAGTTTTG CCTGTTTTTT AACCCCAAAC ATTTCATAGA ACTTGTTAAG 150
GGTTTCACTG TAATGTTCCA TAGCAATACT TCCTTTAGCA TTAGGATTGC 200
TGGAGCTAAG TATAGCAGCA TACTCTTTCC CCTTCTTCAC CTGATCTTCA 250
TTCATTTCAA ATGCTTTTCT TTTCAGCACA GTGCAAACTT TTCCTAAGGC 300
TTCCCTGGTG TCATACTTCT TTGGGTCGAT CCCGAGATCC TTGTATTTTG 350
CATCCTGATA TATAGCCAAG ACAACACTGA TCATCTCAAA GCTATCAACT 400
GAAGCAATAA GAGGTAAGCT ACCTCCCAGC ATTATGGCAA GCCTCACAGA 450
CTTTGCATCA TCAAGAGGTA ATCCATAGGC TTGACTCAAA GGGTGGGAAG 500
CAATCTTAGA TTTGATAGTA TTGAGATTCT CAGAATTCCC AGTTTCCTCA 550
ACAAGCCTGA CCCTGATCAA GCTATCAAGC CTTCTGAAGG TCATGTCAGT 600
GGCTCCAATC CTGTCTGAAG TTTTCTTTAT GGTAATTTTA CCAAAAGTAA 650
AATCGCTTTG CTTAATAACC TTCATTATGC TCTGACGATT CTTCAGGAAT 700

GTCAGACATG AAATAATGCT CATCTTTTTG ATCTGGTCAA GGTTTTCCAG 750
ACAAAAAGTC TTGAAGTTGA ATGCTACCAG ATTCTGATCT TCCTCAAACT 800
CAAGGTCTTT GCCTTGTGTC AACAAAGCAA CAATGCTTTC CTTAGTGAGC 850
TTAACCAT 858

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2028 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGCAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATCCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTACACCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900
TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050
TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGC AAACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCAC AAACAATAAA 1200

GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300
ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCGTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600,
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650
TTGACTCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCCC AGTTTCCTCA ACAAGCCTGA CCCTGATCAA GCTATCAAGC 1750
CTTCTGAAGG TCATGTCAGT GGCTCCAATC CTGTCTGAAG TTTTCTTTAT 1800
GGTAATTTTA CCAAAAGTAA AATCGCTTTG CTTAATAACC TTCATTATGC 1850
TCTGACGATT CTTCAGGAAT GTCAGACATG AAATAATGCT CATCTTTTTG 1900
ATCTGGTCAA GGTTTTCCAG ACAAAAAGTC TTGAAGTTGA ATGCTACCAG 1950
ATTCTGATCT TCCTCAAACT CAAGGTCTTT GCCTTGTGTC AACAAAGCAA 2000
CAATGCTTTC CTTAGTGAGC TTAACCAT 2028

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TTCTGGTCTT CTTCAAACT CA 22

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGTAGCCAT GAGCAAAG 18

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 467 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Ser Ser Gly Val Tyr Glu Ser Ile Ile Gln Thr Lys Ala Ser
5 10 15
Val Trp Gly Ser Thr Ala Ser Gly Lys Ser Ile Val Asp Ser Tyr
20 25 30
Trp Ile Tyr Glu Phe Pro Thr Gly Ser Pro Leu Val Gln Thr Gln
35 40 45
Leu Tyr Ser Asp Ser Arg Ser Lys Ser Ser Phe Gly Tyr Thr Ser
50 55 60
Lys Ile Gly Asp Ile Pro Ala Val Glu Glu Glu Ile Leu Ser Gln
65 70 75
Asn Val His Ile Pro Val Phe Asp Asp Ile Asp Phe Ser Ile Asn
80 85 90
Ile Asn Asp Ser Phe Leu Ala Ile Ser Val Cys Ser Asn Thr Val
95 100 105
Asn Thr Asn Gly Val Lys His Gln Gly His Leu Lys Val Leu Ser
110 115 120
Leu Ala Gln Leu His Pro Phe Glu Pro Val Met Ser Arg Ser Glu
125 130 135
Ile Ala Ser Arg Phe Arg Leu Gln Glu Glu Asp Ile Ile Pro Asp
140 145 150
Asp Lys Tyr Ile Ser Ala Ala Asn Lys Gly Ser Leu Ser Cys Val
155 160 165
Lys Glu His Thr Tyr Lys Val Glu Met Ser His Asn Gln Ala Leu
170 175 180
Gly Lys Val Asn Val Leu Ser Pro Asn Arg Asn Val His Glu Trp
185 190 195
Leu Tyr Ser Phe Lys Pro Asn Glu Asn Gln Ile Glu Ser Asn Asn
200 205 210
Arg Thr Val Asn Ser Leu Ala Val Lys Ser Leu Leu Met Ala Thr
215 220 225
Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Phe Val Lys Ala Ser
230 235 240
Thr Asp Ser His Phe Lys Leu Ser Leu Gln Leu Arg Ile Pro Lys
245 250 255
Val Leu Lys Gln Ile Ala Ile Gln Lys Leu Phe Lys Phe Ala Gly
260 265 270
Asp Glu Thr Gly Lys Ser Phe Tyr Leu Ser Ile Ala Cys Ile Pro
275 280 285

Asn His Asn Ser Val Glu Thr Ala Leu Asn Val Thr Val Ile Cys
290 295 300
Arg His Gln Leu Pro Ile Pro Lys Ser Lys Ala Pro Phe Glu Leu
305 310 315
Ser Met Ile Phe Ser Asp Leu Lys Glu Pro Tyr Asn Thr Val His
320 325 330
Asp Pro Ser Tyr Pro Gln Arg Ile Val His Ala Leu Leu Glu Thr
335 340 345
His Thr Ser Phe Ala Gln Val Leu Cys Asn Lys Leu Gln Glu Asp
350 355 360
Val Ile Ile Tyr Thr Ile Asn Ser Pro Glu Leu Thr Pro Ala Lys
365 370 375
Leu Asp Leu Gly Glu Arg Thr Leu Asn Tyr Ser Glu Asp Ala Ser
380 385 390
Lys Lys Lys Tyr Phe Leu Ser Lys Thr Leu Glu Cys Leu Pro Val
395 400 405
Asn Val Gln Thr Met Ser Tyr Leu Asp Ser Ile Gln Ile Pro Ser
410 415 420
Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Arg Ile Ser Pro Gln
425 430 435
Ser Thr Pro Ile Ala Arg Ser Leu Leu Lys Leu Asp Leu Ser Lys
440 445 450
Ile Lys Glu Lys Lys Ser Leu Thr Trp Glu Thr Ser Ser Tyr Asp
455 460 465
Leu Glu;

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 258 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Ser Lys Val Lys Leu Thr Lys Glu Asn Ile Val Ser Leu Leu
5 10 15
Thr Gln Ser Ala Asp Val Glu Phe Glu Glu Asp Gln Asn Gln Val
20 25 30
Ala Phe Asn Phe Lys Thr Phe Cys Gln Glu Asn Leu Asp Leu Ile
35 40 45
Lys Lys Met Ser Ile Thr Ser Cys Leu Thr Phe Leu Lys Asn Arg
50 55 60
Gln Gly Ile Met Lys Val Val Asn Gln Ser Asp Phe Thr Phe Gly
65 70 75

Lys Val Thr Ile Lys Lys Asn Ser Glu Arg Val Gly Ala Lys Asp
80 85 90
Met Thr Phe Arg Arg Leu Asp Ser Met Ile Arg Val Lys Leu Ile
95 100 105
Glu Glu Thr Ala Asn Asn Glu Asn Leu Ala Ile Ile Lys Ala Lys
110 115 120
Ile Ala Ser His Pro Leu Val Gln Ala Tyr Gly Leu Pro Leu Ala
125 130 135
Asp Ala Lys Ser Val Arg Leu Ala Ile Met Leu Gly Gly Ser Ile
140 145 150
Pro Leu Ile Ala Ser Val Asp Ser Phe Glu Met Ile Ser Val Val
155 160 165
Leu Ala Ile Tyr Gln Asp Ala Lys Tyr Lys Glu Leu Gly Ile Glu
170 175 180
Pro Thr Lys Tyr Asn Thr Lys Glu Ala Leu Gly Lys Val Cys Thr
185 190 195
Val Leu Lys Ser Lys Gly Phe Thr Met Asp Asp Ala Gln Ile Asn
200 205 210
Lys Gly Lys Glu Tyr Ala Lys Ile Leu Ser Ser Cys Asn Pro Asn
215 220 225
Ala Lys Gly Ser Ile Ala Met Asp Tyr Tyr Ser Asp Asn Leu Asp
230 235 240
Lys Phe Tyr Glu Met Phe Gly Val Lys Lys Glu Ala Lys Ile Ala
245 250 255
Gly Val Ala

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3049 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DAN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGAGCAATTG GGTCATTTTT TATTCTAAAT CGAACCTCAA CTAGCAAATC 50
TCAGAACTGT AATAAGCACA AGAGCACAAG AGCCACAATG TCATCAGGTG 100
TTTATGAATC GATCATTCAG ACAAAGGCTT CAGTTTGGGG ATCGACAGCA 150
TCTGGTAAGT CCATCGTGGA TTCTTACTGG ATTTATGAGT TTCCAACTGG 200
TTCTCCACTG GTTCAAACTC AGTTGTACTC TGATTCGAGG AGCAAAAGTA 250
GCTTCGGCTA CACTTCAAAA ATTGGTGATA TTCCTGCTGT AGAGGAGGAA 300
ATTTTATCTC AGAACGTTCA TATCCCAGTG TTTGATGATA TTGATTTCAG 350
CATCAATATC AATGATTCTT TCTTGGCAAT TTCTGTTTGT TCCAACACAG 400

TTAACACCAA TGGAGTGAAG CATCAGGGTC ATCTTAAAGT TCTTTCTCTT 450
GCCGAATTGC ATCCCTTTGA ACCTGTGATG AGCAGGTCAG AGATTGCTAG 500
CAGATTCCGG CTCCAAGAAG AAGATATAAT TCCTGATGAC AAATATATAT 550
CTGCTGCTAA CAAGGGATCT GTCTCCTGTG TCAAAGAACA TACTTACAAA 600
GTCGAAATGA GGCACAATCA GGCTTTAGGC AAAGTGAATG TTCTTTCTCC 650
TAACAGAAAT GTTCATGAGT GGCTGTATAG TTTCAAACCA AATTTCAACC 700
AGATCGAAAG TAATAACAGA ACTGTAAATT CTCTTGCAGT CAAATCTTTG 750
CTGATGGCTA CAGAAAACAA CATTATGCCT AACTCTCAAG CTTTTGTTAA 800
AGCTTGTACT GATTCTCATT TTAAGTTGAG CCTTTGGCTG AGAATTCCAA 850
AAGTTTTGAA GCAAATAGCC ATACAGAAGC TCTTCAAGTT TGCAGGAGAC 900
GAAACCGGTA AAAGTTTCTA TTTGTCTATT GCATGCATCC CAAATCACAA 950
CAGTGTGGAA ACAGCTTTAA ATGTCACTGT TATATGTAGA CATCAGCTTC 1000
CAATCCCTAA GTCCAAAGCT CCTTTTGAAT TATCAATGAT TTTCTCCGAT 1050
CTGAAAGAGC CTTACAACAC TGTGCATGAT CCTTCATATC CTCAAAGGAT 1100
TGTTCATGCT TTGCTTGAGA CTCACACTTC CTTTGCACAA GTTCTCTGCA 1150
ACAAGCTGCA AGAAGATGTG ATCATATATA CTATAAACAG CCCTGAACTA 1200
ACCCCAGCTA AGCTGGATCT AGGTGAAAGA ACCTTGAACT ACAGTGAAGA 1250
TGCTTCGAAG AAGAAGTATT TTCTTTCAAA AACACTCGAA TGCTTGCCAG 1300
TAAATGTGCA GACTATGTCT TATTTGGATA GCATCCAGAT TCCTTCATGG 1350
AAGATAGACT TTGCCAGAGG AGAGATCAGA ATCTCCCCTC AATCTACTCC 1400
TATTGCAAGA TCTTTGCTCA AGCTGGATTT GAGCAAGATC AAGGAAAAGA 1450
AGTCCTTGAC TTGGGAAACA TCCAGCTATG ATCTAGAATA AAAGTGGCTC 1500
ATACTACTCT AAGTAGTATT TGTCAACTTG CTTATCCTTT ATGTTGTTTA 1550
TTTCTTTTAA ATCTAAAGTA AGTTAGATTC AAGTAGTTTA GTATGCTATA 1600
GCATTATTAC AAAAAATACA AAAAAATACA AAAAAATACA AAAAATATAA 1650
AAAACCCAAA AAGATCCCAA AAGGGACGAT TTGGTTGATT TACTCTGTTT 1700
TAGGCTTATC TAAGCTGCTT TTGTTTGAGC AAAATAACAT TGTAACATGC 1750
AATAACTGGA ATTTAAAGTC CTAAAAGAAG TTTCAAAGGA CAGCTTAGCC 1800
AAAATTGGTT TTTGTTTTTG TTTTTTTGTT TTTTGTTTTT TTGTTTTATT 1850
TTTATTTTTA GTTTATTTTT TGTTTTTGTT ATTTTTATTT TTATTTTATT 1900
TTCTTTTATT TTATTTATAT ATATATCAAA CACAATCCAC ACAAATAATT 1950
TTAATTTCAA ACATTCTACT GATTTAACAC ACTTAGCCTG ACTTTATCAC 2000
ACTTAACACG CTTAGTTAGG CTTTAACACA CTGAACTGAA TTAAAACACA 2050
CTTAGTATTA TGCATCTCTT AATTAACACA CTTTAATAAT ATGCATCTCT 2100
GAATCAGCCT TAAAGAAGCT TTTATGCAAC ACCAGCAATC TTGGCCTCTT 2150

TCTTAACTCC AAACATTTCA TAGAATTTGT CAAGATTATC ACTGTAATAG 2200
TCCATAGCAA TGCTTCCCTT AGCATTGGGA TTGCAAGAAC TAAGTATCTT 2250
GGCATATTCT TTCCCTTTGT TTATCTGTGC ATCATCCATT GTAAATCCTT 2300
TGCTTTTAAG CACTGTGCAA ACCTTCCCCA GAGCTTCCTT AGTGTTGTAC 2350
TTAGTTGGTT CAATCCCTAA CTCCTTGTAC TTTGCATCTT GATATATGGC 2400
AAGAACAACA CTGATCATCT CGAAGCTGTC AACAGAAGCA ATGAGAGGGA 2450
TACTACCTCC AAGCATTATA GCAAGTCTCA CAGATTTTGC ATCTGCCAGA 2500
GGGAGCCCGT AAGCTTGGAC CAAAGGGTGG GAGGCAATTT TTGCTTTGAT 2550
AATAGCAAGA TTCTCATTGT TTGCAGTCTC TTCTATGAGC TTCACTCTTA 2600
TCATGCTATC AAGCCTCCTG AAAGTCATAT CCTTAGCTCC AACTCTTTCA 2650
GAATTTTTCT TTATCGTGAC CTTACCAAAA GTAAAATCAC TTTGGTTCAC 2700
AACTTTCATA ATGCCTTGGC GATTCTTCAA GAAAGTCAAA CATGAAGTGA 2750
TACTCATTTT CTTAATCAGG TCAAGATTTT CCTGACAGAA AGTCTTAAAG 2800
TTGAATGCGA CCTGGTTCTG GTCTTCTTCA AACTCAACAT CTGCAGATTG 2850
AGTTAAAAGA GAGACAATGT TTTCTTTTGT GAGCTTGACC TTAGACATGG 2900
TGGCAGTTTA GATCTAGACC TTTCTCGAGA GATAAGATTC AAGGTGAGAA 2950
AGTGCAACAC TGTAGACCGC GGTCGTTACT TATCCTGTTA ATGTGATGAT 3000
TTGTATTGCT GAGTATTAGG TTTTTGAATA AAATTGACAC AATTGCTCT 3049

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 778 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATG CAA CAC CAG CAA TCT TGG CCT CTT TCT TAA CTC CAA 39
ACA TTT CAT AGA ATT TGT CAA GAT TAT CAC TGT AAT AGT 78
CCA TAG CAA TGC TTC CCT TAG CAT TGG GAT TGC AAG AAC 117
TAA GTA TCT TGG CAT ATT CTT TCC CTT TGT TTA TCT GTG 156
CAT CAT CCA TTG TAA ATC CTT TGC TTT TAA GCA CTG TGC 195
AAA CCT TCC CCA GAG CTT CCT TAG TGT TGT ACT TAG TTG 234
GTT CAA TCC CTA ACT CCT TGT ACT TTG CAT CTT GAT ATA 273
TGG CAA GAA CAA CAC TGA TCA TCT CGA AGC TGT CAA CAG 312
AAG CAA TGA GAG GGA TAC TAC CTC CAA GCA TTA TAG CAA 351
GTC TCA CAG ATT TTG CAT CTG CCA GAG GCA GCC CGT AAG 390

CTT GGA CCA AAG GGT GGG AGG CAA TTT TTG CTT TGA TAA 429
TAG CAA GAT TCT CAT TGT TTG CAG TCT CTT CTA TGA GCT 468
TCA CTC TTA TCA TGC TAT CAA GCC TCC TGA AAG TCA TAT 507
CCT TAG CTC CAA CTC TTT CAG AAT TTT TCT TTA TCG TGA 546
CCT TAC CAA AAG TAA AAT CAC TTT GGT TCA CAA CTT TCA 585
TAA TGC CTT GGC GAT TCT TCA AGA AAG TCA AAC ATG AAG 624
TGA TAC TCA TTT TCT TAA TCA GGT CAA GAT TTT CCT GAC 663
AGA AAG TCT TAA AGT TGA ATG CGA CCT GGT TCT GGT CTT 702
CTT CAA ACT CAA CAT CTG CAG AIT GAG TTA AAA GAG AGA 741
CAA TGT TTT CTT TTG TGA GCT TGA CCT TAG ACA TGG 778

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTTCTGAGAT TTGCTAGT 18

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTATATCTTC TTCTTGGA 18

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1401 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATG TCA TCA GGT GTT TAT GAA TCG ATC ATT CAG ACA AAG 39
GCT TCA GTT TGG GGA TCG ACA GCA TCT GGT AAG TCC ATC 78

GTG GAT TCT TAC TGG ATT TAT GAG TTT CCA ACT GGT TCT 117
CCA CTG GTT CAA ACT CAG TTG TAC TCT GAT TCG AGG AGC 156
AAA AGT AGC TTC GGC TAC ACT TCA AAA ATT GGT GAT ATT 195
CCT GCT GTA GAG GAG GAA ATT TTA TCT CAG AAC GTT CAT 234
ATC CCA GTG TTT GAT GAT ATT GAT TTC AGC ATC AAT ATC 273
AAT GAT TCT TTC TTG GCA ATT TCT GTT TGT TCC AAC ACA 312
GTT AAC ACC AAT GGA GTG AAG CAT CAG GGT CAT CTT AAA 351
GTT CTT TCT CTT GCC CAA TTG CAT CCC TTT GAA CCT GTG 390
ATG AGC AGG TCA GAG ATT GCT AGC AGA TTC CGG CTC CAA 429
GAA GAA GAT ATA ATT CCT GAT GAC AAA TAT ATA TGT GCT 468
GCT AAC AAG GGA TCT CTC TCC TGT GTC AAA GAA CAT ACT 507
TAC AAA GTC GAA ATG AGC CAC AAT CAG GCT TTA GGC AAA 546
GTG AAT GTT CTT TCT CCT AAC AGA AAT GTT CAT GAG TGG 585
CTG TAT AGT TTC AAA CCA AAT TTC AAC CAG ATC GAA AGT 624
AAT AAC AGA ACT GTA AAT TCT CTT GCA GTC AAA TCT TTG 663
CTC ATG GCT ACA GAA AAC AAC ATT ATG CCT AAC TCT CAA 702
GCT TTT GTT AAA GCT TCT ACT GAT TCT CAT TTT AAG TTG 741
AGC CTT TGG CTG AGA ATT CCA AAA GTT TTG AAG CAA ATA 780
GCC ATA CAG AAG CTC TTC AAG TTT GCA GGA GAC GAA ACC 819
GGT AAA AGT TTC TAT TTG TCT ATT GCA TGC ATC CCA AAT 858
CAC AAC AGT GTG GAA ACA GCT TTA AAT GTC ACT GTT ATA 897
TGT AGA CAT CAG CTT CCA ATC CCT AAG TCC AAA GCT CCT 936
TTT GAA TTA TCA ATG ATT TTC TCC GAT CTG AAA GAG CCT 975
TAC AAC ACT GTG CAT GAT CCT TCA TAT CCT CAA AGG ATT 1014
GTT CAT GCT TTG CTT GAG ACT CAC ACT TCC TTT GCA CAA 1053
GTT CTC TGC AAC AAG CTG CAA GAA GAT GTG ATC ATA TAT 1092
ACT ATA AAC AGC CCT GAA CTA ACC CCA GCT AAG CTG GAT 1131
CTA GGT GAA AGA ACC TTG AAC TAC AGT GAA GAT GCT TCG 1170
AAG AAG AAG TAT TTT CTT TCA AAA ACA CTC GAA TGC TTG 1209
CCA GTA AAT GTG CAG ACT ATG TCT TAT TTG GAT AGC ATC 1248
CAG ATT CCT TCA TGG AAG ATA GAC TTT GCC AGA GGA GAG 1287
ATC AGA ATC TCC CCT CAA TCT ACT CCT ATT GCA AGA TCT 1326
TTG CTC AAG CTG GAT TTG AGC AAG ATC AAG GAA AAG AAG 1365
TCC TTG ACT TGG GAA ACA TCC AGC TAT GAT CTA GAA 1401

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATG TCT AAG GTC AAG CTC ACA AAA GAA AAC ATT GTC TCT CTT TTA 45
ACT CAA TCT GCA GAT GTT GAG TTT GAA GAA GAC CAG AAC CAG GTC 90
GCA TTC AAC TTT AAG ACT TTC TGT CAG GAA AAT CTT GAC CTG ATT 135
AAG AAA ATG AGT ATC ACT TCA TGT TTG ACT TTC TTG AAG AAT CGC 180
CAA GGC ATT ATG AAA GTT GTG AAC CAA AGT GAT TTT ACT TTT GGT 225
AAG GTC ACG ATA AAG AAA AAT TCT GAA AGA GTT GGA GCT AAG GAT 270
ATG ACT TTC AGG AGG CTT GAT AGC ATG ATA AGA GTG AAG CTC ATA 315
GAA GAG ACT GCA AAC AAT GAG AAT CTT GCT ATT ATC AAA GCA AAA 360
ATT GCC TCC CAC CCT TTG GTC CAA GCT TAC GGG CTG CCT CTG GCA 405
GAT GCA AAA TCT GTG AGA CTT GCT ATA ATG CTT GGA GGT AGT ATC 450
CCT CTC ATT GCT TCT GTT GAC AGC TTC GAG ATG ATC AGT GTT GTT 495
CTT GCC ATA TAT CAA GAT GCA AAG TAC AAG GAG TTA GGG ATT GAA 540
CCA ACT AAG TAC AAC ACT AAG GAA GCT CTG GGG AAG GTT TGC ACA 585
GTG CTT AAA AGC AAA GGA TTT ACA ATG GAT GAT GCA CAG ATA AAC 630
AAA GGG AAA GAA TAT GCC AAG ATA CTT AGT TCT TGC AAT CCC AAT 675
GCT AAG GGA AGC ATT GCT ATG GAC TAT TAC AGT GAT AAT CTT GAC 720
AAA TTC TAT GAA ATG TTT GGA GTT AAG AAA GAG GCC AAG ATT GCT 765
GGT GTT GCA TAA 777

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TACTTATCTA GAACCATGGA CAAAGCAAAG ATTACCAAGG 40

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs

(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TACAGTGGAT CCATGGTTAT TTCAAATAAT TTATAAAAGC AC 42

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AGCATTGGAT CCATGGTTAA CACACTAAGC AAGCAC 36

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGCTAATCTA GAACCATGGA TGACTCACTA AGGAAAGCAT TGTTGC 46

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCCACTATCC TTCGCAAGAC CC 22

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TACAGTGGAT CCATGGTTAA GGTAATCCAT AGGCTTGAC 39

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AGCTAACCAT GGTTAAGCTC ACTAAGGAAA GCATTGTTGC 40

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AGCTAATCTA GAACCATGGA TGACTCACTA AGGAAAGCAT TGTTGC 46

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AGCATTGGAT CCATGGTTAA CACACTAAGC AAGCAC 36

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TACAGTTCTA GAACCATGGA TGATGCAAAG TCTGTGAGG 39

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 49 base pairs
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AGATTCTCTA GACCATGGTG ACTTGATGAG CAAAGTCTGT GAGGCTTGC 49

Thus while we have illustrated and described the preferred embodiments of our invention, it is to be understood that this invention is capable of variation and modification, and we therefore do not wish to be limited to the precise terms set forth, but desire to avail ourselves of such changes and alterations which may be made for adapting the invention to various usages and conditions. Such variations and modifications, for example, would include the substitution of structurally similar nucleic acid sequences in which the difference between the sequence shown and the variation sequence is such that little if any advantages are available with the variation sequence, i.e. that the sequences produce substantially similar results as described above. Thus, changes in sequence by the substitution, deletion, insertion or addition of nucleotides (in the nucleotide sequences) or amino acids (in the peptide sequences) which do not substantially alter the function of those sequences specifically described above are deemed to be within the scope of the present invention. In addition, it is our intention that the present invention may be modified to join the N genes of various isolates that provide resistance or immunity to *Tospovirus* infection of plants according to the present invention into a single cassette, and to use this cassette as a transgene in order to provide broad resistance to the Tospoviruses, especially to TSWV-BL, TSWV-B, and INSV. Accordingly, such changes and alterations are properly intended to be within the full range of equivalents, and therefore within the purview of the following claims.

Having thus described our invention and the manner and a process of making and using it in such full, clear, concise and exact terms so as

to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same;

We Claim:

1. An isolated nucleotide sequence which is selected from the group

AAATTGTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGGAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCGAAAG CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GGAAGGATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATGCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTAGAGCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900
TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050
TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGCA AACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCACA AACAATAAA 1200
GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300
ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCCTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650
TTGAATCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCC 1709;

TTAACACACT AAGCAAGCAC AAACAATAAA GATAAAGAAA GCTTTATATA 50
TTTATAGGCT TTTTTATAAT TTAACTTACA GCTGCTTTTA AGCAAGTTCT 100
GTGAGTTTTG CCTGTTTTTT AACCCCAAAC ATTTCATAGA ACTTGTTAAG 150
GGTTTCACTG TAATGTTCCA TAGCAATACT TCCTTTAGCA TTAGGATTGC 200
TGGAGCTAAG TATAGCAGCA TACTCTTTCC CCTTCTTCAC CTGATCTTCA 250
TTCATTTCAA ATGCTTTTCT TTTCAGCACA GTGCAAACTT TTCCTAAGGC 300
TTCCCTGGTG TCATACTTCT TTGGGTCGAT CCCGAGATCC TTGTATTTTG 350

CATCCTGATA TATAGCCAAG ACAACACTGA TCATCTCAAA GCTATCAACT 400
GAAGCAATAA GAGGTAAGCT ACCTCCCAGC ATTATGGCAA GCCTCACAGA 450
CTTTGCATCA TCAAGAGGTA ATCCATAGGC TTGACTCAAA GGGTGGGAAG 500
CAATGTTAGA TTTGATAGTA TTGAGATTCT CAGAATTCCC AGTTTCCTCA 550
ACAAGCCTGA CCCTGATGAA GCTATCAAGC CTTCTGAAGG TCATGTCAGT 600
GGCTCCAATC CTGTCTGAAG TTTTCTTTAT GGTAATTTTA CCAAAAGTAA 650
AATGGTTTTG CTTAATAACC TTCATTATGC TCTGACGATT CTTCAGGAAT 700
GTCAGACATG AAATAATGCT CATCTTTTTG ATCTGGTCAA GGTTTTCCAG 750
ACAAAAAGTC TTGAAGTTGA ATGCTACCAG ATTCTGATCT TCCTCAAACT 800
CAAGGTCTTT GCCTTGTGTC AACAAAGCAA CAATGCTTTC CTTAGTGAGC 850
TTAACCAT 858;

AAATTGTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA 50
TGCCTAACTC TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG 100
CTGAGCCTCT GGCTAAGGGT TCCAAAGGTT TTGAAGCAGA TTTCCATTCA 150
GAAATTGTTC AAGGTTGCAG GAGATGAAAC AAATAAAACA TTTTATTTAT 200
CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC TTTAAACATT 250
ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300
TGAATTATCA ATGAATGTTT CTGATTTAAA GGAGCCTTAC AACATTATTC 350
ATGATCCTTC ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC 400
ACATCTTTTG CACAAGTTCT TTGCAACAAC TTGCAAGAAG ATGTGATCAT 450
CTACACCTTG AACAACCATG AGCTAACTCC TGGAAAGTTA GATTTAGGTG 500
AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA ATATTTCCTT 550
TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600
AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA 650
TTAAAATTTC TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT 700
GATTTAAGCG GGATTAAAAA GAAAGAATCT AAGATTAAGG AAGCATATGC 750
TTCAGGATCA AAATGATCTT GCTGTGTCCA GCTTTTTCTA ATTATGTTAT 800
GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG TCATTTCTTT 850
CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900
TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA 950
AATTAAAAAA CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA 1000
AATTTGGGGT TTGTTTTTGT TTTTTGTTTT TTTGTTTTTT GTTTTTATTT 1050
TTATTTTTAT TTTTATTTTT ATTTTATTTT ATTTTATGTT TTTGTTGTTT 1100
TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGC AAACTTTAAT 1150
TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCAC AAACAATAAA 1200
GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA 1250
GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC 1300
ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 1350
TCCTTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC 1400
CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA 1450
GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500
CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA 1550
TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC 1600
ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 1650

TTGACTCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT 1700
CAGAATTCCC AGTTTCCTCA ACAAGCCTGA CCCTGATCAA GCTATCAAGC 1750
CTTCTGAAGG TCATGTCAGT GGCTCCAATC CTGTCTGAAG TTTTCTTTAT 1800
GGTAATTTTA CCAAAAGTAA AATCGCTTTG CTTAATAACC TTCATTATGC 1850
TCTGACGATT CTTCAGGAAT GTCAGACATG AAATAATGCT CATCTTTTTG 1900
ATGTGGTCAA GGTTTTCCAG ACAAAAAGTC TTGAAGTTGA ATGCTACCAG 1950
ATTGTGATCT TCCTCAAACT CAAGGTCTTT GCCTTGTGTC AACAAAGCAA 2000
CAATGCTTTC CTTAGTGAGC TTAACCAT 2028; and

AGAGCAATTG GGTCATTTTT TATTCTAAAT CGAACCTCAA CTAGCAAATC 50
TCAGAACTGT AATAAGCACA AGAGCACAAG AGCCACAATG TCATCAGGTG 100
TTTATGAATC GATCATTCAG ACAAAGGCTT CAGTTTGGGG ATCGACAGCA 150
TCTGGTAAGT CCATCGTGGA TTCTTACTGG ATTTATGAGT TTCCAACTGG 200
TTGTCCACTG GTTCAAACTC AGTTGTACTC TGATTCGAGG AGCAAAAGTA 250
GCTTCGGCTA CACTTCAAAA ATTGGTGATA TTCCTGCTGT AGAGGAGGAA 300
ATTTTATCTC AGAACGTTCA TATCCCAGTG TTTGATGATA TTGATTTCAG 350
CATCAATATC AATGATTCTT TCTTGGCAAT TTCTGTTTGT TCCAACACAG 400
TTAACACCAA TGGAGTGAAG CATCAGGGTC ATCTTAAAGT TCTTTCTCTT 450
GCCCAATTGC ATCCCTTTGA ACCTGTGATG AGCAGGTCAG AGATTGCTAG 500
CAGATTCCGG CTCCAAGAAG AAGATATAAT TCCTGATGAC AAATATATAT 550
CTGCTGCTAA CAAGGGATCT CTCTCCTGTG TCAAAGAACA TACTTACAAA 600
GTCGAAATGA GCCACAATCA GGCTTTAGGC AAAGTGAATG TTCTTTCTCC 650
TAACAGAAAT GTTCATGAGT GGCTGTATAG TTTCAAACCA AATTTCAACC 700
AGATCGAAAG TAATAACAGA ACTGTAAATT CTCTTGCAGT CAAATCTTTG 750
CTCATGGCTA CAGAAAACAA CATTATGCCT AACTCTCAAG CTTTTGTTAA 800
AGCTTCTACT GATTCTCATT TTAAGTTGAG CCTTTGGCTG AGAATTCCAA 850
AAGTTTTGAA GCAAATAGCC ATACAGAAGC TCTTCAAGTT TGCAGGAGAC 900
GAAACCGGTA AAAGTTTCTA TTTGTCTATT GCATGCATCC CAAATCACAA 950
CAGTGTGGAA ACAGCTTTAA ATGTCACTGT TATATGTAGA CATCAGCTTC 1000
CAATCCCTAA GTCCAAAGCT CCTTTTGAAT TATCAATGAT TTTCTCCGAT 1050
CTGAAAGAGC CTTACAACAC TGTGCATGAT CCTTCATATC CTCAAAGGAT 1100
TGTTCATGCT TTGCTTGAGA CTCACACTTC CTTTGCACAA GTTCTCTGCA 1150
ACAAGCTGCA AGAAGATGTG ATCATATATA CTATAAACAG CCCTGAACTA 1200
ACCCCAGCTA AGCTGGATCT AGGTGAAAGA ACCTTGAACT ACAGTGAAGA 1250
TGCTTCGAAG AAGAAGTATT TTCTTTCAAA AACACTCGAA TGCTTGCCAG 1300
TAAATGTGCA GACTATGTCT TATTTGGATA GCATCCAGAT TCCTTCATGG 1350
AAGATAGACT TTGCCAGAGG AGAGATCAGA ATCTCCCCTC AATCTACTCC 1400
TATTGCAAGA TCTTTGCTCA AGCTGGATTT GAGCAAGATC AAGGAAAAGA 1450
AGTCCTTGAC TTGGGAAACA TCCAGCTATG ATCTAGAATA AAAGTGGCTC 1500
ATAGTACTCT AAGTAGTATT TGTCAACTTG CTTATCCTTT ATGTTGTTTA 1550
TTTCTTTTAA ATCTAAAGTA AGTTAGATTC AAGTAGTTTA GTATGCTATA 1600
GCATTATTAC AAAAAATACA AAAAAATACA AAAAAATACA AAAAATATAA 1650
AAAACCCAAA AAGATCCCAA AAGGGACGAT TTGGTTGATT TACTCTGTTT 1700
TAGGCTTATC TAAGCTGCTT TTGTTTGAGC AAAATAACAT TGTAACATGC 1750
AATAACTGGA ATTTAAAGTC CTAAAAGAAG TTTCAAAGGA CAGCTTAGCC 1800

AAAATTGGTT TTTGTTTTTG TTTTTTTGTT TTTGTTTTT TTGTTTTATT 1850
TTTATTTTTA GTTTATTTTT TGTTTTTGTT ATTTTTATTT TTATTTTATT 1900
TTCTTTTATT TTATTTATAT ATATATCAAA CACAATCCAC ACAAATAATT 1950
TTAATTTCAA ACATTCTACT GATTTAACAC ACTTAGCCTG ACTTTATCAC 2000
ACTTAACACG CTTAGTTAGG CTTTAACACA CTGAACTGAA TTAAAACACA 2050
CTTAGTATTA TGCATGTCTT AATTAACACA CTTTAATAAT ATGCATCTCT 2100
GAATGAGCCT TAAAGAAGCT TTTATTGCAAC ACCAGCAATC TTGGCCTCTT 2150
TCTTAACTCC AAACATTTCA TAGAATTTGT CAAGATTATC ACTGTAATAG 2200
TCCATAGCAA TGCTTCCCTT AGCATTGGGA TTGCAAGAAC TAAGTATCTT 2250
GGCATATTCT TTCCCTTTGT TTATCTGTGC ATCATCCATT GTAAATCCTT 2300
TGCTTTTAAG CACTGTGCAA ACCTTCCCCA GAGCTTCCTT AGTGTTGTAC 2350
TTAGTTGGTT CAATCCCTAA CTCCTTGTAC TTTGCATCTT GATATATGGC 2400
AAGAACAACA CTGATCATCT CGAAGCTGTC AACAGAAGCA ATGAGAGGGA 2450
TAGTACCTCC AAGCATTATA GCAAGTCTCA CAGATTTTGC ATCTGCCAGA 2500
GGCAGCCCGT AAGCTTGGAC CAAAGGGTGG GAGGCAATTT TTGCTTTGAT 2550
AATAGCAAGA TTCTCATTGT TTGCAGTCTC TTCTATGAGC TTCACTCTTA 2600
TCATGCTATC AAGCCTCCTG AAAGTCATAT CCTTAGCTCC AACTCTTTCA 2650
GAATTTTTCT TTATCGTGAC CTTACCAAAA GTAAAATCAC TTTGGTTCAC 2700
AAGTTTCATA ATGCCTTGGC GATTCTTCAA GAAAGTCAAA CATGAAGTGA 2750
TACTCATTTT CTTAATCAGG TCAAGATTTT CCTGACAGAA AGTCTTAAAG 2800
TTGAATGCGA CCTGGTTCTG GTCTTCTTCA AACTCAACAT CTGCAGATTG 2850
AGTTAAAAGA GAGACAATGT TTTCTTTTGT GAGCTTGACC TTAGACATGG 2900
TGGCAGTTTA GATCTAGACC TTTCTCGAGA GATAAGATTC AAGGTGAGAA 2950
AGTGCAACAC TGTAGACCGC GGTCGTTACT TATCCTGTTA ATGTGATGAT 3000
TTGTATTGCT GAGTATTAGG TTTTTGAATA AAATTGACAC AATTGCTCT 3049

2. A plant susceptible to infection by *Tospoviruses* which has a transgene inserted into its genome to render it resistant to infection by Tospoviruses, said transgene being selected from the group consisting of the nucleoprotein gene of TSWV-BL, TSWV-10W, INSV-LI, TSWV-B, a *Tospovirus* , said transgene consisting of partial or full length nucleoprotein gene sequences from TSWV-BL, TSWV-10W, TSWV-B, INSV-Beg and INSV-IL, the translatable or untranslatable sequences of said nucleoprotein gene sequences, and the sense or antisense sequences of said nucleoprotein gene sequences.

3. A method for providing a host plant with resistance to infection by *Tospoviruses* which comprises inserting a transgene into the host plant which gene is selected from the nucleoprotein gene of TSWV-BL, TSWV-10W, INSV-Beg, INSV-LI, TSWV-B, or mixtures of nucleotide sequences taken from the nucleoprotein gene.

Fig. 1


Viral RNAs
primer JSL90-46
AAAAA S RNA
reverse transcriptase
AGT
GTA
3'
5'
cDNA (first strand)
PCR
AGT
GTA
nucleoprotein gene
cloning
EcoRI
AGT
GTA
HindIII
Nos 3'
AMV 5'-UT
35S-35S
pBI525-NP+


A at 405 nm
2
1
0
30 min
60 min
90 min
NP-1
NP-2
NP+1
NP+2
NP+3

Fig. 2


1
3050
S RNA
5'
NS protein
Intergenic
N protein
3'
L1
19
2012
S7
2221
3050
L22
493
2860
L30
1018
2593
S6
1605
3004

Fig. 3

Fig. 4


TSWV-CPNH1
TSWV-BL
TSWV-L3
TSWV-B
TSWV-I

Fig. 5



Fig. 6



The NP accumulated in plants (ELISA, A at 405nm)

Fig. 7


pBI525
35S-35S
AMV 5'-UT
Nos 3'
No
pBIN19-N
TSWV-BL N gene
poN
ATGGTTAAGGTCACTAAGGAAAGCATTGTTGCTTTGTTGACA
ATGGATGA-CTCACTAAGGAAAGCATTGTTGCTTTGTTGACA
pBI525-mN
35S-35S
AMV 5'-UT
Untranslatable N gene
Nos 3'
mN
pBI525-asN
35S-35S
AMV 5'-UT
Untranslatable N gene
Nos 3'
asN



FIG. 8

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Includes Reference to PCT International Applications)	ATTORNEY'S DOCKET NUMBER 19603/10301

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **TOMATO SPOTTED WILT VIRUS**

the specification of which (check only one item below):

[ ] is attached hereto.

[ ] was filed as United States application
Serial No. _____
on _____
and was amended
on _____ (if applicable).

[X] was filed as PCT international application
Number PCT/US94/01046
on January 27, 1994
and was assigned U.S. Serial No. 08/495,484.

I hereby state that I have reviewed and understand the contents of the above-identified specifications, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (IF PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
			[ ] YES [ ] NO
			[ ] YES [ ] NO

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (Continued) (Includes Reference to PCT International Applications)	ATTORNEY'S DOCKET NUMBER 19603/10301

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT International filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S. APPLICATIONS		STATUS (Check One)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
08/010,410	29 January 1993			X

PCT APPLICATIONS DESIGNATING THE U.S.					
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL NUMBERS ASSIGNED (if any)			
PCT/US94/01046	27 January 1994				

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Michael L. Goldman, Reg. No. 30,727; Susan J. Timian, Reg. No. 34,103

Send Correspondence to: **Michael L. Goldman** **Nixon, Hargrave, Devans & Doyle** **Clinton Square, P.O. Box 1051** **Rochester, New York 14603**	Direct Telephone Calls to: (name and telephone number) **Michael L. Goldman** **(716) 263-1304**

201	FULL NAME OF INVENTOR	FAMILY NAME Gonsalves	FIRST GIVEN NAME Dennis	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY Geneva	STATE/FOREIGN COUNTRY New York	COUNTRY OF CITIZENSHIP USA
	POST OFFICE ADDRESS	P.O. ADDRESS 595 Castle Street	CITY Geneva	STATE & ZIP CODE/COUNTRY New York 14456
202	FULL NAME OF INVENTOR	FAMILY NAME Pang	FIRST GIVEN NAME Sheng-Zhi	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY ~~Geneva~~ Chesterfield	STATE/FOREIGN COUNTRY ~~New York~~ Missouri	COUNTRY OF CITIZENSHIP China
	POST OFFICE ADDRESS	P.O. ADDRESS ~~666 West North Street~~ 893 J Foxsprings Dr.	CITY ~~Geneva~~ Chesterfield	STATE & ZIP CODE/COUNTRY ~~New York 14456~~ Missouri 63198

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201 GONSALVES	SIGNATURE OF INVENTOR 202 PANG	
Dennis Gonsalves	Shengzhi Pang	
DATE September 14, 1995	DATE Sept. 19, 1995	

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Gonsalves, Dennis
Pang, Sheng-Zhi

(ii) TITLE OF INVENTION: TOMATO SPOTTED WILT VIRUS

(iii) NUMBER OF SEQUENCES: 30

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Nixon Peabody LLP
(B) STREET: Clinton Square, P.O. Box 1051
(C) CITY: Rochester
(D) STATE: New York
(E) COUNTRY: U.S.A.
(F) ZIP: 14603

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/495,484
(B) FILING DATE: 27-JAN-1994
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Goldman, Michael L.
(B) REGISTRATION NUMBER: 30,727
(C) REFERENCE/DOCKET NUMBER: 19603/10303

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (716) 263-1304
(B) TELEFAX: (716) 263-1600

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCAGGCAAA ACTCGCAGAA CTTGC 25

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GCAAGTTCTG CGAGTTTTGC CTGCT 25

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGCTAACCAT GGTTAAGCTC ACTAAGGAAA GC 32

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AGCATTCCAT GGTTAACACA CTAAGCAAGC AC 32

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2216 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
CAAGTTGAAA GCAACAACAG AACTGTAAAT TCTCTTGCAG TGAAATCTCT GCTCATGTCA     60
GCAGAAAACA ACATCATGCC TAACTCTCAA GCTTCCACTG ATTCTCATTT CAAGCTGAGC    120
CTCTGGCTAA GGGTTCCAAA GGTTTTGAAG CAGGTTTCCA TTCAGAAATT GTTCAAGGTT    180
GCAGGAGATG AAACAAACAA AACATTTTAT TTATCTATTG CCTGCATTCC AAACCATAAC    240
AGTGTTGAGA CAGCTTTAAA CATTACTGTT ATTTGCAAGC ATCAGCTCCC AATTCGCAAA    300
TGCAAAGCTC CTTTTGAATT ATCAATGATG TTTTCTGATT TAAAGGAGCC TTACAACATT    360
GTTCATGACC CTTCATACCC CAAAGGATCG GTTCCAATGC TCTGGCTCGA AACTCACACA    420
TCTTTGCACA AGTTCTTTGC AACTAACTTG CAAGAAGATG TAATCATCTA CACTTTGAAC    480
AACCTTGAGC TAACTCCTGG AAAGTTAGAT TTAGGTGAAA GAACCTTGAA TTACAGTGAA    540
GATGCCTACA AAAGGAAATA TTTCCTTTCA AAAACACTTG AATGTCTTCC ATCTAACACA    600
CAAACTATGT CTTACTTAGA CAGCATCCAA ATCCCTTCAT GGAAGATAGA CTTTGCCAGA    660
GGAGAAATTA AAATTTCTCC ACAATCTATT TCAGTTGCAA AATCTTTGTT AAAGCTTGAT    720
TTAAGCGGGA TCAAAAAGAA AGAATCTAAG GTTAAGGAAG CGTATGCTTC AGGATCAAAA    780
TAATCTTGCT TTGTCCAGCT TTTTCTAATT ATGTTATGTT TATTTTCTTT CTTTACTTAT    840
AATTATTTCT CTGTTTGTCA TCTCTTTCAA ATTCCTCCTG TCTAGTAGAA ACCATAAAAA    900
CAAAAAATAA AAATGAAAAT AAAATTAAAA TAAAATAAAA TCAAAAAATG AAATAAAAAC    960
AACAAAAAAT TAAAAAACGA AAAACCAAAA AGACCCGAAA GGGACCAATT TGGCCAAATT   1020
TGGGTTTTGT TTTTGTTTTT TGTTTTTTGT TTTTTATTTT TTATTTTATT TTTATTTTAT   1080
TTTATTTTTA TTTTATTTTT ATTTTATTTA TTTTTTGTTT TCGTTGTTTT TGTTATTTTA   1140
TTATTTATTA AGCACAACAC ACAGAAAGCA AACTTTAATT AAACACACTT ATTTAAAATT   1200
TAACACACTA AGCAAGCACA AGCAATAAAG ATAAAGAAAG CTTTATATAT TTATAGGCTT   1260
TTTTATAATT TAACTTACAG CTGCTTTCAA GCAAGTTCTG CGAGTTTTGC CTGCTTTTTA   1320
ACCCCGAACA TTTCATAGAA CTTGTTAAGA GTTTCACTGT AATGTTCCAT AGCAACACTC   1380
CCTTTAGCAT TAGGATTGCT GGAGCTAAGT ATAGCAGCAT ACTCTTTCCC CTTCTTCACC   1440
```

TGATCTTCAT TCATTTCAAA TGCTTTGCTT TTCAGCACAG TGCAAACTTT TCCTAAGGCT 1500

TCCTTGGTGT CATACTTCTT TGGGTCGATC CCGAGGTCCT TGTATTTTGC ATCCTGATAT 1560

ATAGCCAAGA CAACACTGAT CATCTCAAAG CTATCAACTG AAGCAATAAG AGGTAAGCTA 1620

CCTCCCAGCA TTATGGCAAG TCTCACAGAC TTTGCATCAT CGAGAGGTAA TCCATAGGCT 1680

TGAATCAAAG GATGGGAAGC AATCTTAGAT TTGATAGTAT TGAGATTCTC AGAATTCCCA 1740

GTTTCTTCAA CAAGCCTGAC CCTGATCAAG CTATCAAGCC TTCTGAAGGT CATGTCAGTG 1800

CCTCCAATCC TGTCTGAAGT TTTCTTTATG GTAATTTTAC CAAAAGTAAA ATCGCTTTGC 1860

TTAATAACCT TCATTATGCT CTGACGATTC TTTAGGAATG TCAGACATGA AATAACGCTC 1920

ATCTTCTTGA TCTGGTCGAT GTTTTCCAGA CAAAAAGTCT TGAAGTTGAA TGCTACCAGA 1980

TTCTGATCTT CCTCAAACTC AAGGTCTTTG CCTTGTGTCA ACAAAGCAAC AATGCTTTCC 2040

TTAGTGAGCT TAACCTTAGA CATGATGATC GTAAAAGTTG TTATATGCTT TGACCGTATG 2100

TAACTCAAGG TGCGAAAGTG CAACTCTGTA TCCCGCAGTC GTTTCTTAGG TTCTTAATGT 2160

GATGATTTGT AAGACTGAGT GTTAAGGTAT GAACACAAAA TTGACACGAT TGCTCT 2216

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1709 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA TGCCTAACTC 60

TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG CTGAGCCTCT GGCTAAGGGT 120

TCCAAAGGTT TTGAAGCAGA TTTCCATTCA GAAATTGTTC AAGGTTGCAG GAGATGAAAC 180

AAATAAAACA TTTTATTTAT CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC 240

TTTAAACATT ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300

TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC ATGATCCTTC 360

ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC ACATCTTTTG CACAAGTTCT 420

TTGCAACAAC TTGCAAGAAG ATGTGATCAT CTACACCTTG AACAACCATG AGCTAACTCC 480

TGGAAAGTTA GATTTAGGTG AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA 540

ATATTTCCTT TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600

AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA TTAAAATTTC 660

TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT GATTTAAGCG GGATTAAAAA 720

GAAAGAATCT AAGATTAAGG AAGCATATGC TTCAGGATCA AAATGATCTT GCTGTGTCCA 780

GCTTTTTCTA ATTATGTTAT GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG 840

TCATTTCTTT CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900

TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA AATTAAAAAA 960

CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA AATTTGGGGT TTGTTTTTGT 1020

TTTTTGTTTT TTTGTTTTTT GTTTTTATTT TTATTTTTAT TTTTATTTTT ATTTTATTTT 1080

ATTTTATGTT TTTGTTGTTT TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGC 1140

AAACTTTAAT TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCAC AAACAATAAA 1200

GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA GCTGCTTTTA 1260

AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC ATTTCATAGA ACTTGTTAAG 1320

GGTTTCACTG TAATGTTCCA TAGCAATACT TCCTTTAGCA TTAGGATTGC TGGAGCTAAG 1380

TATAGCAGCA TACTCTTTCC CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT 1440

TTTCAGCACA GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500

CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA TCATCTCAAA 1560

GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC ATTATGGCAA GCCTCACAGA 1620

CTTTGCATCA TCAAGAGGTA ATCCATAGGC TTGAATCAAA GGGTGGGAAG CAATCTTAGA 1680

TTTGATAGTA TTGAGATTCT CAGAATTCC 1709

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 260 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
Gln Val Glu Ser Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys Ser
1               5                  10                  15

Leu Leu Met Ser Ala Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Ser
            20                  25                  30

Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Val Pro Lys Val
        35                  40                  45

Leu Lys Gln Val Ser Ile Gln Lys Leu Phe Lys Val Ala Gly Asp Glu
    50                  55                  60

Thr Asn Lys Thr Phe Tyr Leu Ser Ile Ala Cys Ile Pro Asn His Asn
65                  70                  75                  80

Ser Val Glu Thr Ala Leu Asn Ile Thr Val Ile Cys Lys His Gln Leu
                85                  90                  95

Pro Ile Arg Lys Cys Lys Ala Pro Phe Glu Leu Ser Met Met Phe Ser
            100                 105                 110

Asp Leu Lys Glu Pro Tyr Asn Ile Val His Asp Pro Ser Tyr Pro Lys
        115                 120                 125

Gly Ser Val Pro Met Leu Trp Leu Glu Thr His Thr Ser Leu His Lys
    130                 135                 140

Phe Phe Ala Thr Asn Leu Gln Glu Asp Val Ile Ile Tyr Thr Leu Asn
145                 150                 155                 160

Asn Leu Glu Leu Thr Pro Gly Lys Leu Asp Leu Gly Glu Arg Thr Leu
                165                 170                 175

Asn Tyr Ser Glu Asp Ala Tyr Lys Arg Lys Tyr Phe Leu Ser Lys Thr
            180                 185                 190

Leu Glu Cys Leu Pro Ser Asn Thr Gln Thr Met Ser Tyr Leu Asp Ser
        195                 200                 205

Ile Gln Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Lys
    210                 215                 220

Ile Ser Pro Gln Ser Ile Ser Val Ala Lys Ser Leu Leu Lys Leu Asp
225                 230                 235                 240

Leu Ser Gly Ile Lys Lys Lys Glu Ser Lys Val Lys Glu Ala Tyr Ala
                245                 250                 255

Ser Gly Ser Lys
            260
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 858 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTAACACACT AAGCAAGCAC AAACAATAAA GATAAAGAAA GCTTTATATA TTTATAGGCT 60

TTTTTATAAT TTAACTTACA GCTGCTTTTA AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT 120

AACCCCAAAC ATTTCATAGA ACTTGTTAAG GGTTTCACTG TAATGTTCCA TAGCAATACT 180

TCCTTTAGCA TTAGGATTGC TGGAGCTAAG TATAGCAGCA TACTCTTTCC CCTTCTTCAC 240

CTGATCTTCA TTCATTTCAA ATGCTTTTCT TTTCAGCACA GTGCAAACTT TTCCTAAGGC 300

TTCCCTGGTG TCATACTTCT TTGGGTCGAT CCCGAGATCC TTGTATTTTG CATCCTGATA 360

TATAGCCAAG ACAACACTGA TCATCTCAAA GCTATCAACT GAAGCAATAA GAGGTAAGCT 420

ACCTCCCAGC ATTATGGCAA GCCTCACAGA CTTTGCATCA TCAAGAGGTA ATCCATAGGC 480

TTGACTCAAA GGGTGGGAAG CAATCTTAGA TTTGATAGTA TTGAGATTCT CAGAATTCCC 540

AGTTTCCTCA ACAAGCCTGA CCCTGATCAA GCTATCAAGC CTTCTGAAGG TCATGTCAGT 600

GGCTCCAATC CTGTCTGAAG TTTTCTTTAT GGTAATTTTA CCAAAAGTAA AATCGCTTTG 660

CTTAATAACC TTCATTATGC TCTGACGATT CTTCAGGAAT GTCAGACATG AAATAATGCT 720

CATCTTTTTG ATCTGGTCAA GGTTTTCCAG ACAAAAAGTC TTGAAGTTGA ATGCTACCAG 780

ATTCTGATCT TCCTCAAACT CAAGGTCTTT GCCTTGTGTC AACAAAGCAA CAATGCTTTC 840

CTTAGTGAGC TTAACCAT 858

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2028 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAATTCTCTT GCAGTGAAAT CTCTGCTCAT GTTAGCAGAA AACAACATCA TGCCTAACTC 60

TCAAGCTTTT GTCAAAGCTT CTACTGATTC TAATTTCAAG CTGAGCCTCT GGCTAAGGGT 120

TCCAAAGGTT TTGAAGCAGA TTTCCATTCA GAAATTGTTC AAGGTTGCAG GAGATGAAAC 180

AAATAAAACA TTTTATTTAT CTATTGCCTG CATTCCAAAC CATAACAGTG TTGAGACAGC 240

TTTAAACATT ACTGTTATTT GCAAGCATCA GCTCCCAATT CGTAAATGTA AAACTCCTTT 300

TGAATTATCA ATGATGTTTT CTGATTTAAA GGAGCCTTAC AACATTATTC ATGATCCTTC 360

ATATCCCCAA AGGATTGTTC ATGCTCTGCT TGAAACTCAC ACATCTTTTG CACAAGTTCT 420

TTGCAACAAC TTGCAAGAAG ATGTGATCAT CTACACCTTG AACAACCATG AGCTAACTCC 480

TGGAAAGTTA GATTTAGGTG AAATAACTTT GAATTACAAT GAAGACGCCT ACAAAAGGAA 540

ATATTTCCTT TCAAAAACAC TTGAATGTCT TCCATCTAAC ATACAAACTA TGTCTTATTT 600

AGACAGCATC CAAATCCCTT CCTGGAAGAT AGACTTTGCC AGGGGAGAAA TTAAAATTTC 660

TCCACAATCT ATTTCAGTTG CAAAATCTTT GTTAAATCTT GATTTAAGCG GGATTAAAAA 720

GAAAGAATCT AAGATTAAGG AAGCATATGC TTCAGGATCA AAATGATCTT GCTGTGTCCA 780

GCTTTTTCTA ATTATGTTAT GTTTATTTTC TTTCTTTACT TATAATTATT TTTCTGTTTG 840

TCATTTCTTT CAAATTCCTC CTGTCTAGTA GAAACCATAA AAACAAAAAT AAAAATAAAA 900

TAAAATCAAA ATAAAATAAA AATCAAAAAA TGAAATAAAA GCAACAAAAA AATTAAAAAA 960

CAAAAAACCA AAAAAGATCC CGAAAGGACA ATTTTGGCCA AATTTGGGGT TTGTTTTTGT 1020

TTTTTGTTTT TTTGTTTTTT GTTTTTATTT TTATTTTTAT TTTTATTTTT ATTTTATTTT 1080

ATTTTATGTT TTTGTTGTTT TTGTTATTTT GTTATTTATT AAGCACAACA CACAGAAAGC 1140

AAACTTTAAT TAAACACACT TATTTAAAAT TTAACACACT AAGCAAGCAC AAACAATAAA 1200

GATAAAGAAA GCTTTATATA TTTATAGGCT TTTTTATAAT TTAACTTACA GCTGCTTTTA 1260

AGCAAGTTCT GTGAGTTTTG CCTGTTTTTT AACCCCAAAC ATTTCATAGA ACTTGTTAAG 1320

GGTTTCACTG TAATGTTCCA TAGCAATACT TCCTTTAGCA TTAGGATTGC TGGAGCTAAG 1380

TATAGCAGCA TACTCTTTCC CCTTCTTCAC CTGATCTTCA TTCATTTCAA ATGCTTTTCT 1440

TTTCAGCACA GTGCAAACTT TTCCTAAGGC TTCCCTGGTG TCATACTTCT TTGGGTCGAT 1500

CCCGAGATCC TTGTATTTTG CATCCTGATA TATAGCCAAG ACAACACTGA TCATCTCAAA 1560

GCTATCAACT GAAGCAATAA GAGGTAAGCT ACCTCCCAGC ATTATGGCAA GCCTCACAGA 1620

CTTTGCATCA TCAAGAGGTA ATCCATAGGC TTGACTCAAA GGGTGGGAAG CAATCTTAGA 1680

TTTGATAGTA TTGAGATTCT CAGAATTCCC AGTTTCCTCA ACAAGCCTGA CCCTGATCAA 1740

GCTATCAAGC CTTCTGAAGG TCATGTCAGT GGCTCCAATC CTGTCTGAAG TTTTCTTTAT 1800

GGTAATTTTA CCAAAAGTAA AATCGCTTTG CTTAATAACC TTCATTATGC TCTGACGATT 1860

CTTCAGGAAT GTCAGACATG AAATAATGCT CATCTTTTTG ATCTGGTCAA GGTTTTCCAG 1920

ACAAAAAGTC TTGAAGTTGA ATGCTACCAG ATTCTGATCT TCCTCAAACT CAAGGTCTTT 1980

GCCTTGTGTC AACAAAGCAA CAATGCTTTC CTTAGTGAGC TTAACCAT 2028

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TTCTGGTCTT CTTCAAACTC A 21

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CTGTAGCCAT GAGCAAAG 18

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 467 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```
Met Ser Ser Gly Val Tyr Glu Ser Ile Ile Gln Thr Lys Ala Ser Val
1               5                  10                  15

Trp Gly Ser Thr Ala Ser Gly Lys Ser Ile Val Asp Ser Tyr Trp Ile
            20                  25                  30

Tyr Glu Phe Pro Thr Gly Ser Pro Leu Val Gln Thr Gln Leu Tyr Ser
        35                  40                  45

Asp Ser Arg Ser Lys Ser Ser Phe Gly Tyr Thr Ser Lys Ile Gly Asp
    50                  55                  60

Ile Pro Ala Val Glu Glu Glu Ile Leu Ser Gln Asn Val His Ile Pro
65                  70                  75                  80

Val Phe Asp Asp Ile Asp Phe Ser Ile Asn Ile Asn Asp Ser Phe Leu
                85                  90                  95

Ala Ile Ser Val Cys Ser Asn Thr Val Asn Thr Asn Gly Val Lys His
            100                 105                 110

Gln Gly His Leu Lys Val Leu Ser Leu Ala Gln Leu His Pro Phe Glu
        115                 120                 125

Pro Val Met Ser Arg Ser Glu Ile Ala Ser Arg Phe Arg Leu Gln Glu
    130                 135                 140

Glu Asp Ile Ile Pro Asp Asp Lys Tyr Ile Ser Ala Ala Asn Lys Gly
145                 150                 155                 160

Ser Leu Ser Cys Val Lys Glu His Thr Tyr Lys Val Glu Met Ser His
                165                 170                 175

Asn Gln Ala Leu Gly Lys Val Asn Val Leu Ser Pro Asn Arg Asn Val
            180                 185                 190

His Glu Trp Leu Tyr Ser Phe Lys Pro Asn Phe Asn Gln Ile Glu Ser
        195                 200                 205

Asn Asn Arg Thr Val Asn Ser Leu Ala Val Lys Ser Leu Leu Met Ala
    210                 215                 220

Thr Glu Asn Asn Ile Met Pro Asn Ser Gln Ala Phe Val Lys Ala Ser
225                 230                 235                 240

Thr Asp Ser His Phe Lys Leu Ser Leu Trp Leu Arg Ile Pro Lys Val
                245                 250                 255

Leu Lys Gln Ile Ala Ile Gln Lys Leu Phe Lys Phe Ala Gly Asp Glu
```

```
                260                 265                 270

Thr Gly Lys Ser Phe Tyr Leu Ser Ile Ala Cys Ile Pro Asn His Asn
        275                 280                 285

Ser Val Glu Thr Ala Leu Asn Val Thr Val Ile Cys Arg His Gln Leu
    290                 295                 300

Pro Ile Pro Lys Ser Lys Ala Pro Phe Glu Leu Ser Met Ile Phe Ser
305                 310                 315                 320

Asp Leu Lys Glu Pro Tyr Asn Thr Val His Asp Pro Ser Tyr Pro Gln
                325                 330                 335

Arg Ile Val His Ala Leu Leu Glu Thr His Thr Ser Phe Ala Gln Val
            340                 345                 350

Leu Cys Asn Lys Leu Gln Glu Asp Val Ile Ile Tyr Thr Ile Asn Ser
        355                 360                 365

Pro Glu Leu Thr Pro Ala Lys Leu Asp Leu Gly Glu Arg Thr Leu Asn
    370                 375                 380

Tyr Ser Glu Asp Ala Ser Lys Lys Lys Tyr Phe Leu Ser Lys Thr Leu
385                 390                 395                 400

Glu Cys Leu Pro Val Asn Val Gln Thr Met Ser Tyr Leu Asp Ser Ile
                405                 410                 415

Gln Ile Pro Ser Trp Lys Ile Asp Phe Ala Arg Gly Glu Ile Arg Ile
            420                 425                 430

Ser Pro Gln Ser Thr Pro Ile Ala Arg Ser Leu Leu Lys Leu Asp Leu
        435                 440                 445

Ser Lys Ile Lys Glu Lys Lys Ser Leu Thr Trp Glu Thr Ser Ser Tyr
    450                 455                 460

Asp Leu Glu
465
```

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 258 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```
Met Ser Lys Val Lys Leu Thr Lys Glu Asn Ile Val Ser Leu Leu Thr
1               5                  10                  15

Gln Ser Ala Asp Val Glu Phe Glu Glu Asp Gln Asn Gln Val Ala Phe
            20                  25                  30

Asn Phe Lys Thr Phe Cys Gln Glu Asn Leu Asp Leu Ile Lys Lys Met
        35                  40                  45

Ser Ile Thr Ser Cys Leu Thr Phe Leu Lys Asn Arg Gln Gly Ile Met
    50                  55                  60

Lys Val Val Asn Gln Ser Asp Phe Thr Phe Gly Lys Val Thr Ile Lys
65                  70                  75                  80

Lys Asn Ser Glu Arg Val Gly Ala Lys Asp Met Thr Phe Arg Arg Leu
                85                  90                  95

Asp Ser Met Ile Arg Val Lys Leu Ile Glu Glu Thr Ala Asn Asn Glu
            100                 105                 110

Asn Leu Ala Ile Ile Lys Ala Lys Ile Ala Ser His Pro Leu Val Gln
        115                 120                 125

Ala Tyr Gly Leu Pro Leu Ala Asp Ala Lys Ser Val Arg Leu Ala Ile
    130                 135                 140

Met Leu Gly Gly Ser Ile Pro Leu Ile Ala Ser Val Asp Ser Phe Glu
145                 150                 155                 160

Met Ile Ser Val Val Leu Ala Ile Tyr Gln Asp Ala Lys Tyr Lys Glu
                165                 170                 175

Leu Gly Ile Glu Pro Thr Lys Tyr Asn Thr Lys Glu Ala Leu Gly Lys
            180                 185                 190

Val Cys Thr Val Leu Lys Ser Lys Gly Phe Thr Met Asp Asp Ala Gln
        195                 200                 205

Ile Asn Lys Gly Lys Glu Tyr Ala Lys Ile Leu Ser Ser Cys Asn Pro
    210                 215                 220

Asn Ala Lys Gly Ser Ile Ala Met Asp Tyr Tyr Ser Asp Asn Leu Asp
225                 230                 235                 240

Lys Phe Tyr Glu Met Phe Gly Val Lys Lys Glu Ala Lys Ile Ala Gly
                245                 250                 255

Val Ala
```

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3049 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AGAGCAATTG GGTCATTTTT TATTCTAAAT CGAACCTCAA CTAGCAAATC TCAGAACTGT 60

AATAAGCACA AGAGCACAAG AGCCACAATG TCATCAGGTG TTTATGAATC GATCATTCAG 120

ACAAAGGCTT CAGTTTGGGG ATCGACAGCA TCTGGTAAGT CCATCGTGGA TTCTTACTGG 180

ATTTATGAGT TTCCAACTGG TTCTCCACTG GTTCAAACTC AGTTGTACTC TGATTCGAGG 240

AGCAAAAGTA GCTTCGGCTA CACTTCAAAA ATTGGTGATA TTCCTGCTGT AGAGGAGGAA 300

ATTTTATCTC AGAACGTTCA TATCCCAGTG TTTGATGATA TTGATTTCAG CATCAATATC 360

AATGATTCTT TCTTGGCAAT TTCTGTTTGT TCCAACACAG TTAACACCAA TGGAGTGAAG 420

CATCAGGGTC ATCTTAAAGT TCTTTCTCTT GCCCAATTGC ATCCCTTTGA ACCTGTGATG 480

AGCAGGTCAG AGATTGCTAG CAGATTCCGG CTCCAAGAAG AAGATATAAT TCCTGATGAC 540

AAATATATAT CTGCTGCTAA CAAGGGATCT CTCTCCTGTG TCAAAGAACA TACTTACAAA 600

GTCGAAATGA GCCACAATCA GGCTTTAGGC AAAGTGAATG TTCTTTCTCC TAACAGAAAT 660

GTTCATGAGT GGCTGTATAG TTTCAAACCA AATTTCAACC AGATCGAAAG TAATAACAGA 720

ACTGTAAATT CTCTTGCAGT CAAATCTTTG CTCATGGCTA CAGAAAACAA CATTATGCCT 780

AACTCTCAAG CTTTTGTTAA AGCTTCTACT GATTCTCATT TTAAGTTGAG CCTTTGGCTG 840

AGAATTCCAA AAGTTTTGAA GCAAATAGCC ATACAGAAGC TCTTCAAGTT TGCAGGAGAC 900

GAAACCGGTA AAAGTTTCTA TTTGTCTATT GCATGCATCC CAAATCACAA CAGTGTGGAA 960

ACAGCTTTAA ATGTCACTGT TATATGTAGA CATCAGCTTC CAATCCCTAA GTCCAAAGCT 1020

CCTTTTGAAT TATCAATGAT TTTCTCCGAT CTGAAAGAGC CTTACAACAC TGTGCATGAT 1080

CCTTCATATC CTCAAAGGAT TGTTCATGCT TTGCTTGAGA CTCACACTTC CTTTGCACAA 1140

GTTCTCTGCA ACAAGCTGCA AGAAGATGTG ATCATATATA CTATAAACAG CCCTGAACTA 1200

ACCCCAGCTA AGCTGGATCT AGGTGAAAGA ACCTTGAACT ACAGTGAAGA TGCTTCGAAG 1260

AAGAAGTATT TTCTTTCAAA AACACTCGAA TGCTTGCCAG TAAATGTGCA GACTATGTCT 1320

TATTTGGATA GCATCCAGAT TCCTTCATGG AAGATAGACT TTGCCAGAGG AGAGATCAGA 1380

ATCTCCCCTC AATCTACTCC TATTGCAAGA TCTTTGCTCA AGCTGGATTT GAGCAAGATC 1440

AAGGAAAAGA AGTCCTTGAC TTGGGAAACA TCCAGCTATG ATCTAGAATA AAAGTGGCTC 1500

ATACTACTCT AAGTAGTATT TGTCAACTTG CTTATCCTTT ATGTTGTTTA TTTCTTTTAA 1560

ATCTAAAGTA AGTTAGATTC AAGTAGTTTA GTATGCTATA GCATTATTAC AAAAAATACA 1620

AAAAAATACA AAAAAATACA AAAAATATAA AAAACCCAAA AAGATCCCAA AAGGGACGAT 1680

TTGGTTGATT TACTCTGTTT TAGGCTTATC TAAGCTGCTT TTGTTTGAGC AAAATAACAT 1740

TGTAACATGC AATAACTGGA ATTTAAAGTC CTAAAAGAAG TTTCAAAGGA CAGCTTAGCC 1800

AAAATTGGTT TTTGTTTTTG TTTTTTTGTT TTTTGTTTTT TTGTTTTATT TTTATTTTTA 1860

GTTTATTTTT TGTTTTTGTT ATTTTTATTT TTATTTTATT TTCTTTTATT TTATTTATAT 1920

ATATATCAAA CACAATCCAC ACAAATAATT TTAATTTCAA ACATTCTACT GATTTAACAC 1980

ACTTAGCCTG ACTTTATCAC ACTTAACACG CTTAGTTAGG CTTTAACACA CTGAACTGAA 2040

TTAAAACACA CTTAGTATTA TGCATCTCTT AATTAACACA CTTTAATAAT ATGCATCTCT 2100

GAATCAGCCT TAAAGAAGCT TTTATGCAAC ACCAGCAATC TTGGCCTCTT TCTTAACTCC 2160

AAACATTTCA TAGAATTTGT CAAGATTATC ACTGTAATAG TCCATAGCAA TGCTTCCCTT 2220

AGCATTGGGA TTGCAAGAAC TAAGTATCTT GGCATATTCT TTCCCTTTGT TTATCTGTGC 2280

ATCATCCATT GTAAATCCTT TGCTTTTAAG CACTGTGCAA ACCTTCCCCA GAGCTTCCTT 2340

AGTGTTGTAC TTAGTTGGTT CAATCCCTAA CTCCTTGTAC TTTGCATCTT GATATATGGC 2400

AAGAACAACA CTGATCATCT CGAAGCTGTC AACAGAAGCA ATGAGAGGGA TACTACCTCC 2460

AAGCATTATA GCAAGTCTCA CAGATTTTGC ATCTGCCAGA GGCAGCCCGT AAGCTTGGAC 2520

CAAAGGGTGG GAGGCAATTT TTGCTTTGAT AATAGCAAGA TTCTCATTGT TTGCAGTCTC 2580

TTCTATGAGC TTCACTCTTA TCATGCTATC AAGCCTCCTG AAAGTCATAT CCTTAGCTCC 2640

AACTCTTTCA GAATTTTTCT TTATCGTGAC CTTACCAAAA GTAAAATCAC TTTGGTTCAC 2700

AACTTTCATA ATGCCTTGGC GATTCTTCAA GAAAGTCAAA CATGAAGTGA TACTCATTTT 2760

CTTAATCAGG TCAAGATTTT CCTGACAGAA AGTCTTAAAG TTGAATGCGA CCTGGTTCTG 2820

GTCTTCTTCA AACTCAACAT CTGCAGATTG AGTTAAAAGA GAGACAATGT TTTCTTTTGT 2880

GAGCTTGACC TTAGACATGG TGGCAGTTTA GATCTAGACC TTTCTCGAGA GATAAGATTC 2940

AAGGTGAGAA AGTGCAACAC TGTAGACCGC GGTCGTTACT TATCCTGTTA ATGTGATGAT 3000

TTGTATTGCT GAGTATTAGG TTTTTGAATA AAATTGACAC AATTGCTCT 3049

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TTATGCAACA CCAGCAATCT TGGCCTCTTT CTTAACTCCA AACATTTCAT AGAATTTGTC 60

AAGATTATCA CTGTAATAGT CCATAGCAAT GCTTCCCTTA GCATTGGGAT TGCAAGAACT 120

AAGTATCTTG GCATATTCTT TCCCTTTGTT TATCTGTGCA TCATCCATTG TAAATCCTTT 180

GCTTTTAAGC ACTGTGCAAA CCTTCCCCAG AGCTTCCTTA GTGTTGTACT TAGTTGGTTC 240

AATCCCTAAC TCCTTGTACT TTGCATCTTG ATATATGGCA AGAACAACAC TGATCATCTC 300

GAAGCTGTCA ACAGAAGCAA TGAGAGGGAT ACTACCTCCA AGCATTATAG CAAGTCTCAC 360

AGATTTTGCA TCTGCCAGAG GCAGCCCGTA AGCTTGGACC AAAGGGTGGG AGGCAATTTT 420

TGCTTTGATA ATAGCAAGAT TCTCATTGTT TGCAGTCTCT TCTATGAGCT TCACTCTTAT 480

CATGCTATCA AGCCTCCTGA AAGTCATATC CTTAGCTCCA ACTCTTTCAG AATTTTTCTT 540

TATCGTGACC TTACCAAAAG TAAAATCACT TTGGTTCACA ACTTTCATAA TGCCTTGGCG 600

ATTCTTCAAG AAAGTCAAAC ATGAAGTGAT ACTCATTTTC TTAATCAGGT CAAGATTTTC 660

CTGACAGAAA GTCTTAAAGT TGAATGCGAC CTGGTTCTGG TCTTCTTCAA ACTCAACATC 720

TGCAGATTGA GTTAAAAGAG AGACAATGTT TTCTTTTGTG AGCTTGACCT TAGACAT 777

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTTCTGAGAT TTGCTAGT 18

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TTATATCTTC TTCTTGGA 18

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1401 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

ATGTCATCAG GTGTTTATGA ATCGATCATT CAGACAAAGG CTTCAGTTTG GGGATCGACA 60

GCATCTGGTA AGTCCATCGT GGATTCTTAC TGGATTTATG AGTTTCCAAC TGGTTCTCCA 120

CTGGTTCAAA CTCAGTTGTA CTCTGATTCG AGGAGCAAAA GTAGCTTCGG CTACACTTCA 180

AAAATTGGTG ATATTCCTGC TGTAGAGGAG GAAATTTTAT CTCAGAACGT TCATATCCCA 240

GTGTTTGATG ATATTGATTT CAGCATCAAT ATCAATGATT CTTTCTTGGC AATTTCTGTT 300

TGTTCCAACA CAGTTAACAC CAATGGAGTG AAGCATCAGG GTCATCTTAA AGTTCTTTCT 360

CTTGCCCAAT TGCATCCCTT TGAACCTGTG ATGAGCAGGT CAGAGATTGC TAGCAGATTC 420

CGGCTCCAAG AAGAAGATAT AATTCCTGAT GACAAATATA TATCTGCTGC TAACAAGGGA 480

TCTCTCTCCT GTGTCAAAGA ACATACTTAC AAAGTCGAAA TGAGCCACAA TCAGGCTTTA 540

GGCAAAGTGA ATGTTCTTTC TCCTAACAGA AATGTTCATG AGTGGCTGTA TAGTTTCAAA 600

CCAAATTTCA ACCAGATCGA AAGTAATAAC AGAACTGTAA ATTCTCTTGC AGTCAAATCT 660

TTGCTCATGG CTACAGAAAA CAACATTATG CCTAACTCTC AAGCTTTTGT TAAAGCTTCT 720

ACTGATTCTC ATTTTAAGTT GAGCCTTTGG CTGAGAATTC CAAAAGTTTT GAAGCAAATA 780

GCCATACAGA AGCTCTTCAA GTTTGCAGGA GACGAAACCG GTAAAAGTTT CTATTTGTCT 840

ATTGCATGCA TCCCAAATCA CAACAGTGTG GAAACAGCTT TAAATGTCAC TGTTATATGT 900

AGACATCAGC TTCCAATCCC TAAGTCCAAA GCTCCTTTTG AATTATCAAT GATTTTCTCC 960

GATCTGAAAG AGCCTTACAA CACTGTGCAT GATCCTTCAT ATCCTCAAAG GATTGTTCAT 1020

GCTTTGCTTG AGACTCACAC TTCCTTTGCA CAAGTTCTCT GCAACAAGCT GCAAGAAGAT 1080

GTGATCATAT ATACTATAAA CAGCCCTGAA CTAACCCCAG CTAAGCTGGA TCTAGGTGAA 1140

AGAACCTTGA ACTACAGTGA AGATGCTTCG AAGAAGAAGT ATTTTCTTTC AAAAACACTC 1200

GAATGCTTGC CAGTAAATGT GCAGACTATG TCTTATTTGG ATAGCATCCA GATTCCTTCA 1260

TGGAAGATAG ACTTTGCCAG AGGAGAGATC AGAATCTCCC CTCAATCTAC TCCTATTGCA 1320

AGATCTTTGC TCAAGCTGGA TTTGAGCAAG ATCAAGGAAA AGAAGTCCTT GACTTGGGAA 1380

ACATCCAGCT ATGATCTAGA A 1401

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 777 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGTCTAAGG TCAAGCTCAC AAAAGAAAAC ATTGTCTCTC TTTTAACTCA ATCTGCAGAT 60

GTTGAGTTTG AAGAAGACCA GAACCAGGTC GCATTCAACT TTAAGACTTT CTGTCAGGAA 120

AATCTTGACC TGATTAAGAA AATGAGTATC ACTTCATGTT TGACTTTCTT GAAGAATCGC 180

CAAGGCATTA TGAAAGTTGT GAACCAAAGT GATTTTACTT TTGGTAAGGT CACGATAAAG 240

AAAAATTCTG AAAGAGTTGG AGCTAAGGAT ATGACTTTCA GGAGGCTTGA TAGCATGATA 300

AGAGTGAAGC TCATAGAAGA GACTGCAAAC AATGAGAATC TTGCTATTAT CAAAGCAAAA 360

ATTGCCTCCC ACCCTTTGGT CCAAGCTTAC GGGCTGCCTC TGGCAGATGC AAAATCTGTG 420

AGACTTGCTA TAATGCTTGG AGGTAGTATC CCTCTCATTG CTTCTGTTGA CAGCTTCGAG 480

ATGATCAGTG TTGTTCTTGC CATATATCAA GATGCAAAGT ACAAGGAGTT AGGGATTGAA 540

CCAACTAAGT ACAACACTAA GGAAGCTCTG GGGAAGGTTT GCACAGTGCT TAAAAGCAAA 600

GGATTTACAA TGGATGATGC ACAGATAAAC AAAGGGAAAG AATATGCCAA GATACTTAGT 660

TCTTGCAATC CCAATGCTAA GGGAAGCATT GCTATGGACT ATTACAGTGA TAATCTTGAC 720

AAATTCTATG AAATGTTTGG AGTTAAGAAA GAGGCCAAGA TTGCTGGTGT TGCATAA 777

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TACTTATCTA GAACCATGGA CAAAGCAAAG ATTACCAAGG 40

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TACAGTGGAT CCATGGTTAT TTCAAATAAT TTATAAAAGC AC 42

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AGCATTGGAT CCATGGTTAA CACACTAAGC AAGCAC 36

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AGCTAATCTA GAACCATGGA TGACTCACTA AGGAAAGCAT TGTTGC 46

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CCCACTATCC TTCGCAAGAC CC 22

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

TACAGTGGAT CCATGGTTAA GGTAATCCAT AGGCTTGAC 39

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AGCTAACCAT GGTTAAGCTC ACTAAGGAAA GCATTGTTGC 40

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

AGCTAATCTA GAACCATGGA TGACTCACTA AGGAAAGCAT TGTTGC 46

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AGCATTGGAT CCATGGTTAA CACACTAAGC AAGCAC 36

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TACAGTTCTA GAACCATGGA TGATGCAAAG TCTGTGAGG 39

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 49 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

AGATTCTCTA GACCATGGTG ACTTGATGAG CAAAGTCTGT GAGGCTTGC 49